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vABSTRACT 
 
Biotechnological approaches have been applied to introduce resveratrol-synthase (RS) (aka. 
Stilbene synthase) into novel crops such as apple, kiwi, tomato and wheat. As with natural 
sources of resveratrol, genetically-modified plants, which constitutively express RS, 
accumulate resveratrol primarily in the form of piceid (RG). The chemopreventive activity 
of a RG-accumulating transgenic alfalfa (variety Regen SY) against colon cancer was 
assessed in an azoxymethane (AOM)-induced aberrant crypt foci (ACF) rodent model of 
carcinogenesis. Our initial studies revealed that the transgenic alfalfa (TA) at 20% in the diet 
by weight had no affect on the number, size or multiplicity of ACF in CF-1 mice after a 
five-week feeding trial.  However, the number of AOM-induced ACF was reduced in mice 
fed these diets supplemented with a ?-glucosidase enzyme relative to mice fed TA alone. To 
test that RG is not bioavailable to the colon, the colonic concentrations of resveratrol-
aglycone (Rag) and RG were measured following five-week administration of the diets. 
Rag, but not RG, was detected by liquid chromatography/mass spectrometry in the colons of 
mice fed transgenic alfalfa, but these concentrations tended to be lower in mice fed TA 
without L-galactosidase relative to mice fed these diets supplemented with enzyme. The use 
of a lactase inhibitor in transport studies conducted in everted, jejunal sacs from CF-1 mice 
suggested that RG was a substrate for lactase-phlorizin hydrolase and can be absorbed intact 
in the intestines, also. However, comparative studies with Rag suggest that the intestinal 
absorption of the Rag was much more efficient than that of RG. Rag could be detected in the 
plasma and the epithelia of the colon and small intestine of CF-1 mice intragastrically fed 25 
mg (111 MM) Rag/kg body weight 1-7 hours post-gavage, but neither Rag nor RG could be 
detected in mice fed an equal dose of piceid at these time points. Collectively, these data 
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suggest that the intestinal bioavailability of RG was much less than that of Rag. The findings 
of these studies raise doubt on the ability to achieve the purported health benefits of 
resveratrol through natural sources alone where resveratrol is present as RG. 
 
1CHAPTER 1: GENERAL INTRODUCTION 
Introduction 
 
Resveratrol (3,5,4’-trihydroxystilbene) is a polyphenolic phytochemical that is 
structurally and functionally related to flavonoid compounds, and is produced by a variety of 
plant species as a secondary metabolite (Fremont, 2000). A number of studies conducted in 
cell culture systems and animal models suggest that resveratrol may possess a multitude of 
health benefiting properties and may offer protection against diseases or conditions 
associated with oxidative damage, such as cardiovascular disease, neurodegenerative 
disorders, inflammation, aging and cancer (Aggarwal and Shishodia, 2005; book).  
 Research interest in resveratrol as a chemopreventive and therapeutic agent stems from a 
landmark report published in the journal Science in 1997. In the quest to identify natural 
plant constituents that may have anti-cancer properties, John Pezzuto’s research team at the 
University of Illinois at Chicago isolated a compound from the Peruvian legume Cassia 
quinquangulata that had apparent activity against cellular events associated with the 
initiation, promotion and progression stages of carcinogenesis (Jang et al, 1997). The 
compound, identified as resveratrol, was reported to be the most promising natural, anti-
cancer agent of the hundreds that were screened by the Illinois center. Interest in resveratrol 
in the scientific community and the general public has exploded since the revelations of this 
initial report. As a measure of the research effort that have been dedicated to further 
exploring the bioactivity of resveratrol, the number of Pubmed citations for ‘resveratrol’ 
have climbed from a total of 59 in 1997 to over 1,600 as of October 2006.  
 In recent years, studies have reported that resveratrol may be active against various site-
specific cancer, including those of the skin, prostate, breast, lung, liver, intestine and colon 
2(Aziz et al, 2003; review). Numerous biological activities have been ascribed to resveratrol, 
which may explain its chemopreventive properties. Resveratrol, in addition to possessing 
anti-oxidant properties, has been shown to inhibit cellular signaling pathways associated 
with cell survival, block the progression of the cell cycle at various points and induce 
programmed cell death (apoptosis) (Dong, 2002; review; Perviaz, 2004; review; Ulrich et al, 
2005; review).  
 Although resveratrol has been identified in over 70 plant genera, few of these species are 
consumed by humans (Pervaiz, 2003). In fact, the richest identified dietary sources of 
resveratrol remain grapes; grape-associated products, such as red wine and grape juice; and 
peanuts (Burns et al, 2002). With the exception of red wine, resveratrol is found 
predominantly conjugated to a glucose moiety (trans- or cis-resveratrol-glucoside) in a 
structure known generically as piceid (Gu et al, 1999; Vitrac et al, 2002; Rodriguez-Delgado 
et al, 2002; Gao et al, 2002). Only in rare cases does the concentration of free, resveratrol-
aglycone exceed 15 mg/ml in wine. Piceid concentrations can reach levels of 50 mg/ml in 
wines, but typically are much lower than this. In grapes and peanuts, total resveratrol 
concentrations rarely exceed 10 Mg/g fresh weight and 2 Mg/g fresh weight, respectively, 
with most of this being in the form of piceid (Burns et al, 2002).   
 There is growing interest in genetically-modifying crops to produce resveratrol for 
agronomical purposes. A number of crops, including apple (Sparvoli et al, 1994), (Ruhman 
et al, 2006), rice (Stark-Lorensen, et al, 1997), wheat and barley (Leckland et al, 1998), 
tomato (Thomzik, 1997), kiwi (Kubayash et al, 2000), alfalfa (Hipskand and Paiva, 2000) 
and rapeseed (Husken et al, 2005) have been genetically modified to express resveratrol-
synthase. Most of these crops have expressed resistance against a variety of plant pathogens 
3and, in addition to offering producer-oriented benefits, through increased crops yields, could 
offer a variety of health benefits to final users. Thus, metabolic-engineering strategies could 
be explored as a means to increase the availability of resveratrol-rich foods.  
 As with natural resveratrol-rich sources, crops genetically modified to express 
resveratrol-synthase accumulate resveratrol, almost exclusively, in the form of piceid 
(resveratrol-glucoside). Little is known about the bioactivity or bioavailability of piceid, 
since most of the resveratrol research has focused on the parent aglycone compound due to 
the commercial unavailability of the glucoside. The limited data available suggests that 
piceid may be bioavailable (Lv et al, 2006), and as with other phenolic-glucosides, may be a 
substrate for lactase-phorizin hydrolase, an extracellular enzyme in the small intestines that 
posseses glucosidase activity (Henry-Vitrac et al, 2006). However, other studies indicate 
that piceid may not be as biologically available or active as resveratrol-aglycone (Henry et 
al, 2005); (Kimura and Okuda, 2000). 
 The studies outlined in this thesis examined the potential chemopreventive activity of a 
transgenic alfalfa that accumulates piceid (Hipskand and Paiva, 2000) at the site of the 
colon, using the azoxymethane-induced aberrant crypt foci model of carcinogenesis in CF-1 
mice. Aberrant crypt foci are colonic lesions that are widely considered to be preneoplastic, 
since they are induced by a variety of known colon carcinogens and are highly correlated to 
risk of colon cancer development in humans (Corpet and Tache, 2002). Previous studies 
have demonstrated that trans-resveratrol-aglycone inhibits the number and size of AOM 
(Tessitore et al, 1997) and 1,-2-dimethylhydrazine (DMH)-induced ACF as well as the 
number of DMH-induced tumors in rodents (Sengottuvelan et al, 2006a; Sengottuvelan et al, 
2006b; Sengottuvelan et al, 2006c).  
4Studies assessing the health benefits of genetically modified crops are rare in the literature. 
A recent example involved the assessment of the influence of a transgenic tomato that 
accumulates high concentrations of flavonols on cardiovascular health (Rein et al, 2006). In 
this study, the transgenic tomato fruit peel was shown to significantly reduce basal plasma 
human c-reactive protein levels in human c-reactive protein transgenic mice relative to the 
non-transgenic tomato peel.   These results demonstrate that the transgenic tomato could 
provide a strategy to combat cardiovascular disease by providing a rich dietary source of 
flavonoids. 
 Genetically modified crops could provide the vehicle to deliver nutraceuticals, such as 
resveratrol, to a broad population at low costs. In regards to cancer prevention, the 
administration of a sustainable level of a protective agent over an extended time to a 
susceptible population via the diet may be a practical and effective intervention strategy, 
because the onset and progression of cancer occur in multiple stages over many years. 
Studies in rodent models can provide the initial data to verify the efficacy, in addition to 
safety, of a GM crop prior to its further development and eventual incorporation into the 
human diet.    
Dissertation Organization 
 
This dissertation examines the efficacy of transgenic, piceid-accumulating alfalfa against 
colon cancer in an azoxymethane-induced aberrant crypt foci (ACF) rodent model of 
carcinogenesis. The initial studies with the alfalfa suggested that piceid from the transgenic 
alfalfa may not be bioavailable. The remaining studies of this dissertation test the hypothesis 
that piceid is not available, and the addition of ?-glucosidase to transgenic-alfalfa as well as 
5the subsequent liberation of resveratrol-aglycone from piceid is necessary to induce the 
protective activity of this genetically modified crop in the colon.  
 The first paper entitled “Transgenic alfalfa that accumulates piceid (trans-resveratrol-3-
O-?-D-glucopyranoside) requires the presence of ?-glucosidase to inhibit the formation of 
Aberrant Crypt Foci in the colon of CF-1 mice” tests the hypothesis that the transgenic 
alfalfa would be effective in inhibiting the formation of ACF lesions in CF-1 mice. 
However, these studies reveal that the supplementation of transgenic alfalfa with exogenous 
?-glucosidase was necessary in order to achieve a significant reduction in ACF number, 
indicating that piceid may not be bioavailable. Angela Au, a former Research Associate in 
Dr. Diane Birt’s lab, contributed most of the data for this paper. The data presented in Table 
2 of Chapter 2 was conducted in three replicates. Two of these replicates (67% of the mice) 
were completed by Angela; I was responsible for the third replicate (32% of the mice). For 
the follow-up studies, comparing the effect of the ?-glucosidase supplementation, Angela 
conducted the first replicate (labeled as Study 1 on Table 3 of Chapter 2). For Angela’s 
studies, Dr. Nancy Paiva at the Samuel Roberts Noble Foundation in Oklahoma was 
responsible for the transformation and analysis of the alfalfa. For my studies, cuttings from 
the plants were shipped to Iowa where they were grown outdoors. Dr. Charlie Brummer, a 
former professor in the Agronomy Deparment at Iowa State University who is now at the 
University of Georgia in Athens, was involved in helping us grow the plants. I analyzed 
these plants for piceid accumulation to verify that we were getting values similar to what Dr. 
Paiva reported in her analysis. I gathered the data, conducted 100% of the data analysis, and 
wrote the manuscript for this collective work. This paper is currently undergoing a final 
review for publication in the journal Nutrition and Cancer.  
6The second paper, “Importance of hydrolysis of piceid to resveratrol-aglycone for 
inhibition of azoxymethane-induced aberrant crypt foci in CF-1 mice fed piceid-
accumulating transgenic alfalfa”, tests the hypothesis that the added ?-glucosidase activity 
liberated the more bioavailable resveratrol-aglycone from piceid. This study demonstrates 
that piceid is deglycosylated to a small extent in the gastrointestinal tract and may be a 
substrate for lactase in the small intestine, as evidenced by the identification of resveratrol-
aglycone in the colon of mice fed transgenic alfalfa and transport studies conducted in an ex-
vivo jejunal system using a lactase-specific inhibitor. However, the colon bioavailabilty of 
resveratrol-aglycone appears greater than piceid. The supplementation of transgenic alfalfa 
diets with ?-glucosidase appeared to augment resveratrol-glucoside colon bioavailability to 
levels achieved in mice fed diets with authentic resveratrol-aglycone as illustrated by the 
similar colon concentrations achieved in both of these groups. Moreover, increased colon 
bioavailability of resveratrol-aglycone coincided with significant reductions in colonic ACF 
lesions in these treatment groups compared to relevant controls. For this chapter, I was 
responsible for 100% of the data collection, data analysis and writing the manscript. 
Furthermore, I fully developed the concept and experimental approach for the ex-vivo 
jejunal studies. The plants featured in this study were grown in a greenhouse at Iowa State 
University under Dr. Brummer’s supervision. However, I was responsible for the plant 
crosses, propogation, harvesting and analysis.  
 The research papers are preceded by a general introduction and a literature review and 
followed by a general conclusion. The studies cited in the literature review and general 
conclusion are listed in alphabetical order according to the author’s name at the end of the 
chapter.  
7Literature Review 
 
Colon Cancer 
 Colorectal cancer is the term used for any cancer that originates in the colon or rectum of 
the gastrointestinal tract (American Cancer Society, 2006). Over 95% of colorectal cancers 
are adenocarcinomas; other colorectal cancers such as lymphomas and squamous cell 
carcinomas are not as common and not as well characterized (Cuffy et al, 2006). Therefore 
the research discussed in this review will focus only on studies examining cancers that 
originate in the colorectal epithelium. It is debatable whether colon and rectal cancers should 
be considered as a single entity. Although both cancers share many attributes, there is 
evidence that the etiologies of the two may differ somewhat (Frattini et al, 2004). When 
possible, this review primarily focuses on cancers originating from the colon. 
Epidemiology of Colon Cancer 
 Colon cancer is one of the most common human malignancies in economically 
developed societies worldwide as it is the second leading cause of cancer-related deaths in 
developed countries and the leading cause of cancer-related deaths when smoking-related 
cancers are excluded (Parkin et al, 2005). The highest incidence rates of colon cancer, based 
on 2002 data, are in North America, Western Europe and Japan, whereas the lowest rates 
occur in Africa, Asia and Central America (Parkin et al, 2005).  The incidence of and 
mortality rate for colon and rectal cancer are geographically similar although country 
differences between rates are more pronounced with colon than rectal cancer.  
 The incidence and mortality rate of colorectal cancer has decreased gradually throughout 
the last decade in the United States, but colorectal cancer still remains the third most 
8common cancer found in men and women living in the U.S. (American Cancer Society, 
2006). The American Cancer Society estimates that about 106,680 new cases of colon 
cancer and 41,930 cases of rectal cancer will be diagnosed in the United States in 2006 
(American Cancer Society, 2006). Colon and rectal cancer will account for approximately 
55,000 deaths in 2006, affecting males and females equally, based on American Cancer 
Society estimates.  
Laboratory rodent models of colon cancer   
Epidemiological studies may provide the empirical justification to further investigate the 
anti-cancer properties of a dietary constituent.  Since it is frequently not ethical or practical, 
due to time limitations and costs, to assess the potency and mechanism of the action of 
potential chemopreventive or therapeutic agents in humans, initial studies are often 
performed in rodent models of colon carcinogenesis.  
 Spontaneous epithelial tumors of the colon are very rare in experimental animals 
(Rangaajan and Weinberg, 2003). To induce colon tumors, laboratory rodent strains are 
injected with carcinogens, which most commonly consists of dimethylhydrazine (DMH) 
derivatives. Dimethylhydrazine is metabolized to azoxymethane (AOM) and 
methylazoxymethane in rodents (Macejova and Brtko, 2001). AOM is injected directly into 
the circulation of rodents and is usually preferred over DMH because it is more potent and is 
more stable in chemical solutions (Papanikolaou et al, 1995). Endoscopically visible colon 
tumors can be detected as early as 15 weeks in rats injected with AOM (Reddy, 2004). 
AOM treatment induces tumors predominantly in the distal region of the colon, and roughly 
70% of these tumors are adenocarcinomas (Reddy, 2004).  
9Since tumor studies are very costly and time consuming, shorter-term experiments are 
usually carried out using purported precancerous colonic lesions as biomarkers to screen 
dietary constituents or synthetic compounds for any pro- or anti- colon cancer activity. 
Currently, the most utilized and accepted pre-cancer markers for the colon are aberrant crypt 
foci (ACF). ACF are abnormally large crypts that are relatively easy to identify under a light 
microscope (Bird, 1995). They are defined as being elevated crypts that are at least two to 
three times larger than normal crypts and have a thick epithelial lining that can be stained 
darker than normal crypts with methylene blue.  ACFs are widely regarded as preneoplastic 
lesions because they are induced by all colon carcinogens, including AOM, in a dose-
dependant manner. They also predict tumor outcome in several rodent studies and correlate 
with cancer risk in humans (Corpet and Tache, 2002). Furthermore, ACFs in humans have a 
morphology similar to those examined in rodents.  
 Some studies have reported conflicting results between ACF number and tumor 
development. For example, hundreds of lesions are induced by AOM in rats, yet the number 
of tumors that eventually form are relatively few (Mori et al, 2004). Additionally, some 
chemopreventive agents, such as genistein and 2-(carboxyphenyl) retinamide, effectively 
suppress ACF induction by AOM, but do not suppress and may even facilitate the 
development of colon cancer (Zheng et al, 1999; Gee et al, 2000). Based on these 
observations, it has also been proposed that ACF are heterogeneous in nature, with two 
types occurring: non-dysplastic and dysplastic ACF (Mori et al, 2004). It is estimated that 
roughly 5% of AOM-induced ACF in rats are dysplastic (Jen et al, 1994). The associated 
mutations for non-dysplastic and dysplastic lesions in rats also appear to be different. Most 
non-dysplastic ACF express a k-ras mutation, whereas dysplastic lesions harbor 
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adenomatous polyposis coli (APC) mutations (Takahashi and Wakebayeshi, 2004). 
However, this characteristic is not observed in mice, where k-ras mutations in AOM-treated 
animals appear rarely. As of the time of this writing, ACF in mice largely remain 
uncharacterized.  
 In recent years, additional biomarkers have been proposed to be possible dysplastic 
subsets of ACF (Mori et al, 2004). Abnormal activation of the APC/?-catenin/TCF/Lef 
pathway (Wnt pathway) is documented to be associated with decreased membrane levels of 
?-catenin accompanied by the accumulation of ?-catenin in the cytoplasm at the cellular 
level (Logan et al, 2004). The accumulation of the ?-catenin protein can be observed in 
certain ACF following histological examination. The resulting lesions have been coined “?-
catenin accumulating crypts (BCAC)” and may better represent preneoplasic lesions 
(Yamada, 2003). However, the tissue preparation necessary to score colons for such lesions 
is tedious, and it is not practical to view entire colons for these markers. In addition to 
BCAC, mucin-depleted foci (MDF) are purported preneoplastic lesions that may correlate 
better with tumor development than ACF (Mori et al, 2004). MDF are characterized by 
absent or scarce mucous production than can be easily identified microscopically along the 
entire mucosal surface of colons by tissues stained with high-iron diamine alcian blue. 
Alcian blue is a cationic dye that reversibly binds to the negatively-charged carbohydrate 
mucin.  Whole colon tissues can be stained with methylene blue and scored for ACF number 
and also de-stained with methanol and then re-stained with alcian blue to identify ACF that 
are MDF. Unlike ACF, the number of MDF in AOM-treated rats are very low and are in the 
magnitude of tumors induced by the same dosage of the carcinogen. Additionally, MDF are 
more likely to exhibit over-expression of ?-catenin than ACF (Femia et al, 2005). In fact, 
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MDF comprising more than 4 crypts may well correspond to BCAC. Currently, however, 
ACF are still widely accepted as the “gold standard”, short-term biomarker of colon cancer 
as BCAC and MDF have been featured in very few studies.  
 In addition to the carcinogen-induced colon lesions discussed above, transgenic rodent 
models have been identified which spontaneously develop gastrointestinal adenomas and 
have been used in studies examining the efficacy of potential chemopreventive agents 
(Green and Hudsen, 2005). In 1990, a mutant mouse, Min, was found to have multiple 
intestinal neoplasia caused by a truncated APC protein (Moser et al, 1990). These mice have 
since been used in a number of rodent cancer studies. However, the major drawback of this 
model is that mice that are heterozygous for the mutated APC gene develop tumors in the 
small intestine, not in the colon; mice that are homozygous for the mutant APC gene die in-
utero (Green and Hudsen, 2005). Moreover, most dietary treatment regimes followed in 
studies using these mice begin with mice that are 4-5 weeks old when tumors are already 
present, which represents a more advanced stage of cancer (Corpet and Tache, 2002). 
Neoplastic lesions are observed in utero in Min mice.  
Etiology of Human Colon Cancer  
Genetic factors 
 Cancer is a disease that initiates from the acquisition of mutations at the cellular level 
with the sum of the mutations resulting in cells that divide and invade surrounding tissues 
and organs. In colon cancer, mutations are known to occur via inherited germline mutations 
or are acquired secondarily following an environmental insult.  About 20-25% of colorectal 
cancers occur in familial (hereditary) patterns (de la Chappelle, 2004). The two best known 
and characterized conditions of nonsporadic colon cancer are Familial Adenomatous 
12
Polyposis (FAP) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC), also known as 
Lynch Syndrome. A germline mutation in the adenamatous polyposis coli (APC) tumor-
suppressor gene is the likely cause of APC, which is characterized by the development of 
thousands of adenomas throughout the colorectal region of an individual, beginning in late 
childhood or early adolescence. If left untreated, at least one adenoma will develop into an 
adenocarcinoma. Germline mutations in the mismatch repair genes MCH1, MSH2, MSH6 
and PNS2 are the purported cause of HNPCC. Unlike APC, HNPCC is not limited to 
colorectal cancer. In addition to colorectal cancer, individuals with HNPCC are predisposed 
to developing cancers of the endometrium, stomach, ovaries, small bowel, hepatobilliary 
epithelium, uroepithelium and the brain. The genetic syndromes APC and HNPCC, 
collectively, account for about 5% of all colon cancer cases.  
 Sporadic colorectal cancers account for the vast number of cases diagnosed each year 
(around 75%) (Hendon and DiPalma, 2005). Based on epidemiological data, approximately 
5 to 7 oncogene mutations are necessary before the cellular transformation of a normal cell 
to a cancerous cell occurs (Kinzler et al, 1996; Calabrese et al, 2005). If one or more of these 
mutations are present at birth as a germline mutation, fewer mutations are required for 
complete transformation. Vogelstein and colleagues have proposed a multi-step model based 
on clinical data for the specific genetic events that potentially account for the progression of 
colorectal colon cancers (Fearon and Vogelstein, 1990). This model offers an explanation of 
the observed normal mucosa to adenoma to carcinoma sequence of morphological events 
that can be observed in biopsies from patients at various stages of colorectal cancer. 
According to the Vogelstein model, a mutation in the APC gene initiates the neoplastic 
process. Tumor progression results from the mutation of other genes prior and after this 
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initial event, since a mutation of APC alone does not seem to lead to dysplastic growth. A 
mutation in k-Ras is likely to occur early, following mutations in APC. Ras is a component 
of the MAP kinase single transduction pathway and is involved in regulating the rate of 
cellular division. Tumors in 20% of all human cancers and 50% of colon cancers harbor ras 
mutations (Halaschek-Wiener et al, 2004). Mutations in genes associated with 
“housekeeping” or tumor suppressor roles, such as the mismatch repair genes and p53, seem 
to occur at later stages. The tumor suppressor p53 appears to function DNA repair by halting 
the progression of the cell cycle to allow various DNA repair enzymes a chance to fix any 
mutated sequences in DNA (Johnson and Walker, 1999). Overall, p53 is mutated in about 
half of all human cancers (Midgley and Kerr, 1999).  
Diet and Lifestyle factors  
 In a 1981 report, Doll and Peto estimated that 75-80% of all cancer deaths in the United 
States could be avoided by dietary modifications (Doll and Peto, 1981). Findings from 
migrant studies of populations moving from areas of low incidence of colorectal cancer to 
areas of high incidence reveal that environmental factors play a major role in the 
development of colorectal cancer. For instance, the incidence rate of colorectal cancer in 
U.S.-born Japanese men has been reported to be twice that of foreign-born Japanese men 
and 60% higher than Caucasian U.S.-born men (Flood et al, 2000). This same trend has been 
shown with Korean, Filipino and Chinese populations that immigrated to the U.S. (Gomez et 
al, 2003).  
 As with other site specific cancers, various dietary constituents and lifestyle behaviors 
have been implicated as being possible determinates in the risk of developing colon cancer. 
Several observational studies suggest that diets low in energy and high in certain 
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micronutrients such as vitamin D and selenium may be protective against colon neoplasia, 
while high red meat intake (especially well-done meat), high alcohol consumption, physical 
inactivity and cigarette smoking increasing the risk of colorectal cancer (Potter, 1996; 
Lipkin et al, 1999).  Certain subtypes of fat may be related to risk, as high intake of red meat 
has been linked with colon cancer risk in some studies, whereas no correlation has been 
observed between the consumption of other foods rich in fat, such as poultry, fish and dairy 
products (reviewed by Giovannucci and Goldin, 1997). However, it is very difficult to 
control for other dietary constituents that may skew results when examining the health 
benefits or adverse effects of dietary fat subtypes. 
 Fruits and vegetables have traditionally been thought to be protective against colon 
cancer. Case-control studies have largely supported a protective role of vegetables and fruits 
against colon cancer (World Cancer Research Fund, 1997). However, higher intakes of fruits 
and vegetables (more than 5 servings per day) were not associated with lower risk of colon 
cancer in a prospective study featuring 62,602 men and 70,554 females (McCullough et al, 
2003). Individuals who consumed less than 1.3 servings of fruits and vegetables per day 
where at a higher risk of developing colon cancer relative to individuals who consumed 
more than 5 servings of fruits and vegetables per day (p=0.06). In contrast to this study, the 
Nurses Health Prospective study, which included 71, 910 female and 37,725 male subjects, 
did not reveal a causal relationship between decreased fruit and vegetable intake and 
increased risk of cancer even though an inverse trend between fruit and vegetable 
consumption and risk of cardiovascular disease was observed (Hung et al, 2004).  
 Epidemiological data does suggest that increased intake of folate, a nutrient rich in plant-
based foods, may be protective against colon cancer, but intervention studies in humans are 
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inconclusive on this matter (Kim, 2003).  Vitamins C and E and ß-carotene, which are also 
abundant in plants, have purported anti-oxidant activity, but case-control studies in humans 
do not support a protective role of any of these constituents against colon cancer 
(Greensberg et al, 1994).  The link between colon cancer and dietary fiber, another 
component of fruits and vegetables that may contribute to protective activity, is 
controversial as most large prospective studies have indicated no protective effect. A 16 year 
follow-up of 88,757 women did not reveal an association between intake of dietary fiber and 
the risk of colon cancer, since the relative risk of colon cancer was 0.95 (95% confidence 
interval; 0.73 to 1.25) in individuals who consumed less than 10 g of fiber per day (Fuchs et 
al, 1999). Data analysis from the Alpha-Tochopherol Beta-carotene Prevention study of 27, 
111 male smokers did not show a significant difference in relative risk of colorectal cancer 
between individuals who consumed more than 34 g of fiber per day verses subjects that 
consumed less than 16 g per day (Pietine et al, 1999). An inverse association between 
consuming few fruits and vegetables (less than 1.5 servings per day) and risk of colorectal 
cancer was reported in a 10 year follow-up study of 61, 463 individuals, but no association 
was found with subjects who consumed less than 6 g of fiber per day (Terry et al, 2001).  In 
contrast to these studies, the large European Prospective Investigation of Cancer and 
Nutrition Study that examined a heterogeneous population from ten countries showed a 
reduction in colon cancer risk between groups in the highest fiber quintile (35 g per day) vs. 
the lowest quintile (15 g per day), after adjusting for folate (Bingham, 2006). Animal studies 
and case control experiments in humans suggest a protective role of soluble fiber, but do not 
support a protective role for insoluble fibers against colon cancer (reviewed by Pool-Zobel, 
2005). 
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Vegetables and fruits are also rich in non-nutrient bioactive compounds called 
phytochemicals (Acamovic et al, 2005). Phytochemicals encompass diverse classes of 
compounds, including flavonoids, flavones, phenols and polyphenols. These compounds 
may be produced in plants for the purpose of attracting or repelling harmful organisms and 
providing protection against UV light and abiotic environmental stresses in addition to other 
unknown functions (Liu, 2004).  
 A few plant polyphenolic compounds have been isolated and have been shown to 
possess potent antioxidant and potential chemopreventive and therapeutic activities 
(Waladhani et al, 1998, review; Sun et al, 2002, review; Chu et al, 2002, review). 
Compounds, including phenolic acids, flavonoids, catechins, anthocyanins and stilbenes, 
have been reported to induce cell differentiation and apoptosis, inhibit cell proliferation by 
regulating genes involved in this process or by initiating cell cycle arrest, modulate the 
activities of enzymes involved in the detoxification of xenobiotics,regulate hormonal fluxes 
and elicit anti-bacterial or anti-viral activity (Waladhani et al, 1998, review; Sun et al, 2002, 
review; Chu et al, 2002, review).  
 Dietary sources of potential health-benefiting phytochemicals vary greatly depending on 
the class of compounds. For example, flavonols such as quercetin and anthocyanins, which 
provide the pigmentation of fruits and flowers, are found in a wide variety of edible plant 
species (Manach et al, 2004). On the other hand, the stilbene compounds are found in very 
few food sources and in very low concentrations (Scalbert and Williamson, 2000). The 
concentration of polyphenolic phytochemicals can vary within a particular plant species due 
to ripeness, time of harvest and environmental factors such as processing and storage 
(Manach et al, 2004). Most epidemiological studies do not differentiate daily intake of fruits 
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and vegetables based on storage or processing conditions (i.e., fresh vs. frozen) or in what 
manner foods were processed (Scalbert and Williamson, 2000). Frozen vegetables may have 
lower phenolic concentrations and antioxidant capacity relative to fresh vegetables (Ninfali 
and Bacchiocca, 2003) and, since phytochemicals are not evenly distributed throughout a 
plant, food fractionation that can occur during processing can result in the loss or 
enhancement of phytochemicals (Burda et al, 1990). Furthermore, very little is currently 
known about the phytochemical composition of specific foods (Brat et al, 2006). It is 
possible that the inconsistent findings between prospective and case-control studies in 
regards to the potential anti-cancer activity of fruits and vegetables in the colon could be the 
result of the limitations in estimating daily intake of phytochemicals. 
Resveratrol  
 One of the most studied polyphenolic compounds in recent years is resveratrol – a 
phytochemical that is produced by a few plant species in response to injury and external 
stresses such as UV light and fungal infection and is found in some natural and processed 
food and beverage products such as grapes, peanuts, red wine and grape juice (Fremont, 
2000). Research interest in resveratrol stems from epidemiological studies showing an 
inverse correlation between red wine consumption and incidence of cardiovascular disease 
(Renaud and de Lorgeril, 1992). Since resveratrol was identified as a consistent constituent 
in red wine, numerous  in vitro, in vivo and ex vivo experiments have been carried out and 
have demonstrated that this compound can trigger a wide array of biological activities. In 
addition to providing possible protection against cardiovascular disease, resveratrol may also 
have cancer chemopreventive and therapeutic benefits, and may protect against other 
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chronic diseases or conditions associated with oxidative damage, such as neurodegenerative 
disorders and aging (Aggarwal and Shishodia, 2005; book).  
Chemical Structure (s) 
 Resveratrol is a member of the stilbene class of polyphenolic compounds produced as 
secondary metabolites by plant species (Jeandet et al, 2002). All stilbenes have as their base 
structure two benzene rings connected by a carbon-carbon double-bond bridge. Resveratrol 
is the common term for 3,5,4’-trihydroxystilbene. Hence, resveratrol is a stilbene with three- 
hydroxyl moieties attached at the 3,5 and 4’ carbons on the stilbene- base structure. 
Resveratrol is an off-white powder with a melting point of 253 to 255°C, a molecular 
formula of C14H12O3 and a molecular weight of 228.25 g/mol (Fremont, 2000). Resveratrol 
exists in both trans and cis isomeric forms (Figure 1). Isomerization to the cis form is known 
to be induced by exposing the trans form of resveratrol to UV light (Fremont, 2000). The 
ultraviolet (UV) absorption maximum (Vmax) for the trans and cis isomers are 308 and 288 
nm, respectively, which allows for their detection and separation via high-performance 
liquid chromatography (HPLC). Since trans-3,5,4’ hydroxystilbene is the most extensively 
studied form of resveratrol, throughout this review the term “resveratrol” will be applied to 
refer specifically to the trans-3,5,4’ hydroxystilbene isomer.  
UV light
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In plants, resveratrol is found predominantly as a 3´-O-'-D-glucoside, also commonly 
known as piceid (Fremont, 2000). Other conjugated forms of resveratrol have been isolated 
from plants, including a 4´-O-'-D-glucoside and resveratrol with 1-2 methyl groups, a 
sulfate or a fatty acid (Pervaiz, 2003). However, these are very minor forms of resveratrol. It 
is believed that the addition of the glucose moiety to resveratrol protects it from enzymatic 
oxidation in nature, and thus extends the half-life and antioxidant capabilities of the 
compound in the plant cell (Regev-Shoshanini et al, 2003).  
Natural sources 
 To date, resveratrol has been identified in a limited number of plants (about 70 genera) 
(Pervaiz, 2003).  Resveratrol was first identified in 1940 as a constituent of the roots of 
white hellebore (Varatrum grandiflorum) and later, in 1963, as an active constituent of the 
Japanese and Chinese folk medicine Ko-jo-kon, which is the dried powdered root of 
Japanese knotweed Polygonum cuspidatum  (cited in Seeram et al, 2006). Resveratrol has 
also been documented in eucalyptus and spruce trees and has been identified in a few 
flowering plants, such as Veratrum grandiflorum and Veratrum formosanum (Pervaiz et al, 
2003).  
 Several methods have been used to extract resveratrol and related compounds from plant, 
foods and beverages. They include high-performance liquid chromatography (HPLC) 
(Goldberg et al, 1997), gas chromatography (Lin and Chen, 2001), gas chromatography-
mass spectrometry (Soleas et al, 2001) and capillary electrophoresis (Lin and Chin, 2001). 
As extraction methods and detection limits have improved, resveratrol and piceid have been 
identified in various foods and beverages (Table 1).  
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The first report of resveratrol detection in grapevines (Vitis vinifera) occurred in 1976 
(Langcake and Pryce, 1976).  
 
Table 1: Dietary and natural sources of resveratrol (from Bauer and Sinclair, 2006, with 
some modfications) 
 Trans-resveratrol 
concentration 
Comments 
Red wines  
0.1-14.3 mg l-1 
Cis-resveratrol, trans- and cis-piceid 
also present; usually at lower 
concentrations 
 
White wines <0.1-2.1 mg l-1 Cis-resveratrol, trans- and cis-piceid 
also present; usually at lower 
concentrations 
 
Grapes  
0.16-3.54 ug g-1 
Contents are similar for wine or 
table grapes, and black or white 
grapes, trans-picied predominant at 
concentrations of 1.5-7.3 ug g-1 
 
Red grape juices 0.50 mg l-1 Trans-piceid, cis-piceid and cis-
resveratrol found at concentrations 
of 3.38 mg l-1, 0.79 mg l-1 and 0.06 
mg l-1, respectively 
Blueberries Up to 32 ng g-1 
Peanuts 0.02-1.92 Mg g-1 
Itadori (Polygonum 
cuspidatum) tea 
 
0.68 mg l-1 
Trans-piceid found at concentration 
of 9.1 mg l-1 
Polygonum cuspidatum 
(herb root) 
 
0.524 mg g-1 
Trans-piceid found at concentrations 
of 1.65 mg g-1 
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In the years following this discovery, resveratrol has been intensely studied in grapes. In 
grapes and berries, resveratrol is mainly found in the skin, not in the flesh (Siemann and 
Creasy, 1992). As Table 1 shows, the resveratrol content of grapes can vary dramatically.  
 The concentration of resveratrol in grapes can depend on a variety of factors, including 
the type of grape, the climate in which the grape was grown and the time of harvest (Careri 
et al, 2003). Increasing irradiation of harvested grapes by ultraviolet B (UVB) or UVC light 
is also known to enhance yields of resveratrol (Cantos et al, 2000). Other berries, such as 
blueberries, cranberries and billberies, contain resveratrol, but only at trace amounts (less 
than 30 ng g-1) (Lyons et al, 2003).  Since the maceration process of red wine production is 
significantly longer than that of white wine, red wines consistently have much higher 
concentrations of resveratrol than white wines (Fremont, 2000).  
 In wine, cis and trans isomers of resveratrol are present in the free or glycosylated forms at 
significant but lower concentrations than the aglycone (Gu et al, 1999; Vitrac et al, 2002; 
Rodriguez-Delgado et al, 2002; Gao et al, 2002). Cis-resveratrol has not been reported in 
grape skins. It is assumed that the formation of the cis-isomer in wines occurs by the 
isomerization of the trans form on exposure to light and oxygen. Resveratrol has been 
predominantly identified in a glycosylated form (piceid) in plants and fruits where different 
isoforms of resveratrol have been assessed (Burns et al, 2002).  Polygonum cuspidatum 
remains one of the richest natural sources of resveratrol, which has been used for centuries 
to treat a number of ailments, including dermatitis, gonorrhea favus, athlete’s foot and 
hyperlipidemia (Shishodia and Aggarwal, 2006). However, the resveratrol found in 
Polygonum cuspidatum is almost exclusively in the form of piceid (Vastano et al, 2000).  
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In addition to the natural and processed sources mentioned, a variety of synthetic 
schemes have been reported for the production of purified resveratrol (Farina et al, 2006). 
Not surprisingly, various companies now sell resveratrol as a natural, unregulated 
supplement (Bagchi, 2000). 
Biological Activities of Resveratrol 
 Epidemiological evidence from many studies overwhelmingly supports the notion that 
light to moderate consumption of red wine is associated with a reduction in mortality due to 
cardiovascular disease (Renaud and Lorgeril, 1992). This relationship has been popularly 
coined “The French Paradox” or “The French Connection” because red wine consumption 
has been associated with the French who have a low incidence of cardiovascular disease 
although they consume a diet that is relatively high in saturated fat. Red wine is rich in a 
number of biologically active phytochemicals that could act individually or synergistically 
to provide cardiovascular benefits (German and Walzem, 2000).       
 Since its discovery in red wine in 1992 (Siemann and Creasy, 1992), resveratrol has been 
shown to possess a remarkable range of biological activities that reveal a possible role in 
protection against cardiovascular disease. Resveratrol has been shown to reduce the copper-
catalyzed oxidation of human low-density lipoproteins at a dose of 10 MM in an ex-vivo 
system (Frankel et al, 1993), induce vasorelaxation in human endothelial cells at a dose of 
30 MM (Li et al, 2000) and inhibit platelet aggregation and polymorphonuclear cell 
activation induced by collegen in-vitro in a dose range of 10-1000 MM (Wang et al, 2002; 
Rotondo et al, 1998). In addition to cardiovascular disease, resveratrol may be protective 
against other diseases and conditions associated with oxidative damage such as 
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neurodegenerative disorders (Han et al, 2006), inflammation (Surh, 2003) and cancer (Dong, 
2002; review; Perviaz, 2004;review; Ulrich et al, 2005; review).  
The first report on the possible bioactivity of resveratrol against chemical-induced 
carcinogenesis surfaced in 1997. In a landmark paper, Jang et al reported that resveratrol 
inhibited free-radical formation and incorporation of [3H] thymidine in promyelocytic 
leukemia (HL-60) cells, induced quinine reductase activity in cultured mouse hepatoma cells 
and, in a dose-dependant manner, inhibited DMBA-induced tumors in the mammary gland 
of female CD-1 mice (Jang et al, 1997). Collectively, these findings demonstrated that 
resveratrol can inhibit cellular events associated with each stage of carcinogenesis – 
initiation, promotion and progression. This report strongly suggested that resveratrol may be 
a potent chemopreventive and chemotherapeutic agent. In the years following the studies by 
Jang et al, many studies in cell culture systems and animal models have verified a 
chemopreventive or therapeutic role of resveratrol in various tissues including the prostate, 
breast, liver, digestive tract and lung (Aziz et al, 2003, review).  
 The activities of other isoforms of resveratrol are rarely discussed in the literature. By 
most indications, the cis isomer of resveratrol seems to be less active than the trans isomer. 
The trans isomer appears to inhibit cyclooxygenase (COX)-1 activity, COX-2 activity and 
the development of 7,12-dimethylbenz[a]anthracene-induced preneoplasic lesions in mouse 
mammary glands more effectively than the cis isomer (Pettit et al, 2002). Stivala et al 
reported that trans-resveratrol inhibited the proliferation of normal human fibroblasts and 
HT1080 cells, whereas cis-resveratrol had no significant effects on cell growth at the 
concentrations tested (Stivala et al, 2001). It was also shown in this study that trans-
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resveratrol, unlike cis-resveratrol, inhibits DNA biosynthesis in fibroblasts and inhibits the 
activity of B-type DNA polymerases L and [.
The bioactivity of piceid has been more rarely analyzed, probably because the purified 
compound was not commercially available until very recently. Using trolox, a water-soluble 
derivative of Vitamin E, Kerem et al. examined the potential anti-oxidant and L-glucosidase 
inhibitory activities of trans-resveratrol, piceid and a novel trans-stilbene (5,4’-
dihydroxystilbene-3-O-L-arabinopyranoside) (rumexoid), all of which were isolated from 
the roots of Rumex bucephalophorus (Kerem et al, 2006). The antioxidant capacity of 
resveratrol was slightly higher than that of piceid, 2.7 vs. 2.4, expressed as trolox equivalent 
antioxidant capacity. Rumexoid had the lowest antioxidant capacity (1.5 trolox equivalents). 
However, piceid did not significantly inhibit L-glucosidase activity at the concentrations 
tested (0.05-0.2 mM), unlike resveratrol and rumexoid (IC50 < 0.1 and < 0.5 mM, 
respectively).  
 Kimura and Okuda studied the effects of piceid on tumor growth and lung metastasis in 
Lewis lung carcinoma (LLC)-bearing mice (Kimura and Okuda, 2000). Piceid, which was 
isolated from the roots of Polygonum cuspidatum, did inhibit tumor growth in the right hind 
paw of mice injected with LLC cells, but at the very high dose of 300 mg (770 Mmol)/kg 
body weight which was administered orally twice daily for 32 days, starting 12 hours after 
tumor implantation. Piceid inhibited DNA synthesis in LLC cells at a concentration of 1,000 
uM, but not at lower concentrations (10 to 100 uM).  
 Seemingly, the activity of piceid has not been examined against other site-specific 
cancers, nor has the chemoprotective activity of piceid and resveratrol-aglycone been 
compared in a side-by-side study, since no other such studies could be located in the 
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literature when preparing this review. With only a few studies to consider, it is possible that 
piceid has some chemopreventive properties, but has less activity than trans-resveratrol. 
However, this is purely speculative at this point, because all of the studies examined used 
very high doses of piceid.  
Resveratrol and colon cancer  
Two carcinogen-treated animal models, azoxymethane and 1,2-dimethylhydrazine, have 
been used to assess the antitumor effects of resveratrol in the colon as a model reproducing 
the development of sporadic colorectal cancer in humans.  In addition, Min mice have been 
used as a model for familial adenomatous polyposis.  
 Tessitore et al. reported that resveratrol affected the formation of AOM-induced 
aberrant crypt foci in F344 rats administered with resveratrol at a dose of 200 ug (0.89 
Mmol)/kg body weight/day in the drinking water with 0.2% ethanol for 100 days beginning 
10 days before two AOM injections (15 mg/kg body weight) (Tessitore et al, 2000). In this 
study, resveratrol significantly reduced the number (25.7 ± 3.6 vs. 39.4 ± 3.3) and 
multiplicity (number of crypts/focus) (2.7 ± 0.3 vs. 4.9 ± 0.6) of aberrant crypt foci (ACF) in 
the colonic mucosa of the rats.  
 Recently, resveratrol was reported to inhibit full-blown colon carcinogenesis 
(Sengottuvelan et al, 2006a). In this study, resveratrol at a dose of 8 mg (36 Mmol)/kg body 
weight per day, intragastrically, in a 1% (w/v) carboxymethylcellulose/water solution 
reduced the incidence and size of 1,-2-dimethylhydrazine (DMH)-induced tumors in the 
colonic mucosa of Wistar rats after a 30-week treatment period. Rats were administered 
resveratrol either during the initiation (beginning one week before DMH injections until one 
week after final exposure to DMH), post-initiation (beginning two days after DMH 
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injections and lasting for the remaining 30 weeks of the study) or the entire phase of the 
study. Resveratrol was shown to be most effective in inhibiting the number of DMH-
induced tumors when it was administered throughout the duration of the study or during the 
post initiation phase. 
 Results of resveratrol chemoprevention studies in Min mice have been inconsistent. 
Resveratrol (12-16 mg (53-71 Mmol)/kg body weight) was administered in the drinking 
water over a seven week period to Min mice (Schnieder, 2001). The formation of intestinal 
tumors was reduced by 70% compared to mice that received drinking water with 0.4% 
ethanol, alone (Schnieder, 2001). On the other hand, resveratrol at daily doses lower than 90 
mg (400 Mmol)/kg body weight had no effect on tumor incidence in the small intestine of 
Min mice in other studies regardless of whether resveratrol was administered in 10% ethanol 
in water or via a solid diet vehicle (Ziegler et al, 2004; Sale et al, 2005). However, at the 
high dose of 240 mg (1 mmol)/kg body weight per diem, resveratrol did reduce the number 
of intestinal adenomas by 27% in one of these studies.  The results of Schneider et al. are 
perplexing as no feasible explanation can be offered to account for the differences in the 
final outcome of that study with the results of the studies of Ziegler et al and by Sale et al. 
All studies conducted in Min mice were initiated in mice that were 5-6 weeks of age, which 
probably represents a more advanced stage of cancer in this model compared to AOM- and 
DMH-treated rats. The discrepancy of results obtained with Min mice suggests that 
resveratrol may be more effective as a chemopreventive agent than as a therapeutic tool.  
Chemopreventive mechanisms of resveratrol 
 Biochemical pathways involved in cell-cycle regulation, apoptosis, angiogenesis and 
differentiation (Ragione et al, 1998; Della et al, 2002; Bruder et al, 2001; Nielson et al, 
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2000) have all been identified as being potential targets of resveratrol. The complexity and 
multiplicity of molecular targets of resveratrol in the intestine was illustrated in the study by 
Schneider et al, where the expression of 588 genes in the small intestine of Min mice 
administered with resveratrol was compared to control Min mice (Schneider et al, 2001). In 
that study, resveratrol was found to down-regulate genes that are directly associated with 
cell cycle progression or cellular proliferation (cyclins D1 and D2, DP-1 transcription factor 
and Y-box protein) and up-regulate genes involved in the recruitment and activation of 
immune cells (cytotoxic T lymphocyte Ag-4, leukemia inhibitory factor receptor and 
monocyte chemotactic protein 3) and in the inhibition of tumor progression. It is currently 
not known if the apparent chemopreventive properties of resveratrol are the result of its 
ability to affect the expression of a number of proteins in the cell or the result of 
resveratrol’s ability to influence specific pathways important in carcinogenesis.  
 The ability of resveratrol to prevent the initiation of carcinogenesis may, at least 
partially, be attributed to its antioxidant activity. DNA can undergo attack by different 
reactive oxygen species (ROS) generated during metabolic processes or physical activation 
of oxygen by irradiation (e.g. UVB in sunlight). Chemicals with antioxidant activities may 
prevent or delay the onset of cancer by blocking ROS generation. Resveratrol (75 MM) 
inhibited lipid peroxidation in RAW 264.7 macrophages exposed to OH] radicals (Leonard 
et al, 2003) and, at a dose of 25 Mg/ml (109 MM), induced an increase in glutathione 
reductase levels in a concentration-dependent manner in human lymphocytes activated H2O2
(Olas et al, 2004). 
 Resveratrol may also block the initiation of carcinogenesis through the inhibition of 
cyctochrome P450 monooxygenases CYP1A1 and CYP1B1 (Piver et al, 2003), which 
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catalyze the oxidation of xenobiotics. Reactive metabolites, which can form DNA adducts 
and cause mutations, are formed as by-products of these cytochrome P450 catalyzed 
reactions. Resveratrol down-regulates the expression of these enzymes by inhibiting the 
binding of the arylhydrocarbon receptor (AhR) to xenobiotic response elements (XRE) on 
DNA (Ciolino et al, 1998). On the other hand, resveratrol has been shown to induce 
expression of Phase II enzymes such as heme oxygenase I and quinone reductase, which are 
capable of detoxifying carcinogens (Heo et al, 2001).  
 In recent studies, Sengottuvelan et al. demonstrated that resveratrol at a daily dose of 8 
mg/kg body weight in the drinking water inhibited DMH-induced ACF and tumors after 30 
weeks through a process that may involve the induction of anti-oxidant enzymes, such as 
superoxide dismutase and catalase, in the colorectal mucosa (Sengottuvelan et al, 2006b) 
and reducing activity of enzymes involved in biotransformation in the colonic flora and 
mucosa (Sengottuvelan and Nalini, 2006c). In the later study, the fecal activity of ?-
glucuroniase, ?-glucosidase and ?-galactosidase were elevated in control-fed, DMH-injected 
rats. Resveratrol reduced the fecal and mucosal activities of these enzymes to levels 
observed in control rats that were not injected with DMH.  These enzymes may catalyze the 
hydrolysis of conjugated carcinogens, releasing the toxic versions of these compounds. In 
addition to this, resveratrol reduced the mucinase of the colonic flora. Mucinase hydrolyzes 
mucin, which provides a protective coating lining the intestinal luman wall, exposing the 
mucosa to potential carcinogens. Gut flora microflora ?-glucosidase and mucinase activity 
may be important pre-cancer events of the colon (Hambly et al, 1997).    
 Resveratrol has been shown to suppress proliferation in a number of immortalized cell 
lines (Aziz et al, review). Resveratrol, when administered to Wistar rats at a daily dose of 8 
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mg (36 Mmol)/kg body weight for 30 weeks, significantly reduced the number of 
argyrophilic nucleolar organizing region-associated proteins per nucleus in non-lesional 
colonic crypts by 30%, which suggests that resveratrol, at least in part, reduced the number 
of 1,-2-dimethylhydrazine (DMH)-tumors by reducing cellular proliferation (Sengottuvelan 
et al, 2005). The anti-proliferative activity of resveratrol could be attributed to its ability to 
reduce the activities of ribonucleotide reductase (Fontecave et al, 1998) and DNA 
polymerase activity (Locatelli et al, 2005). Resveratrol can also inhibit cellular proliferation 
by inducing cell cycle arrest. A number of studies have demonstrated that resveratrol 
induces cell cycle arrest in the G1/S phase in breast, prostate, colon, esophageal and 
leukemia cell lines (Hsieh et al, 1999 a and b; Joe et al, 2002; Kuwajerwala et al, 2002; Park 
et al, 2001). However, a G1/M phase arrest in HepG2 liver cancer cells (Kuo et al, 2002) 
and G2/M  phase arrest in SW480 human colon cells and WR-21 human salivary 
adenocarcinoma cells (Delmas et al, 2002; Young et al, 2006) have been reported. Some 
studies have also found that resveratrol-induced cell cycle arrest is reversible (Ragione et al, 
1998; Haider et al, 2003; Della et al, 2002).  
 Resveratrol also induced S-phase cell cycle arrest in Caco-2 human colon carcinoma 
cells treated with a dose of 25 MM for 16 and 24 hours in one study (Schneider et al, 2000) 
and at doses higher than 50 MM after 24 hours treatment in another study. In SW480 human 
colon cancer cell lines, resveratrol induced S-phase cell cycle arrest at a dose of 30 MM after 
24 hours treatment and at a lower dose of 10 MM following 48 and 72 hour treatments 
(Delmas et al, 2002).  The mechanism behind resveratrol’s ability to inhibit cell cycle 
progression at the S phase seems to be due to the up-regulation of p53, an oncosuppressor 
protein that activates the cyclin inhibitor p21 (Hsieh et al, 1999; Kim et al, 2003; Kim et al, 
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2004). Generally, up-regulation of p53 in resveratrol-treated cells is also accompanied by 
the accumulation of cyclins E and A, decreased levels of D-type cyclins and 
dephosphorylation and thus the activation of the tumor suppressor retinoblastoma protein 
(pRb) (Wolter et al, 2001; Adhami et al, 2001; Kim et al, 2003). In Caco-2 and SW480 cells, 
resveratrol induced the expression of cyclins A, B and E and reduced the expression of 
cyclin D. However, resveratrol at doses higher than 50 uM reversed S-phase arrest in Caco-2 
cells, possibly through a mechanism that involved reversed changes in the phosphorylation 
status of the retinoblastoma protein (Wolter et al, 2001).  
 Resveratrol may also induce apoptosis in cancerous cells by modulating the expression of 
proteins important in the apoptotic process. Mitochondrial-mediated apoptosis is facilitated 
by the proapoptitic Bcl-2 family proteins, such as Bax and Bid. Tessitore et al. reported that 
in resveratrol-treated rats, Bax expression was enhanced in the colonic mucosa of aberrant 
crypt foci, but not in the surrounding mucosa (Tessitore et al, 2000). It was further 
demonstrated in this study that p21 expression was lost in the normal mucosa of resveratrol-
treated rats, but was expressed in the normal mucosa of controls and in the ACF of both 
groups. However, resveratrol has also shown to induce apoptosis in both HCT116 cells with 
knockout Bax and in HCT 116 cells that expressed wild-type Bax (Mahyar-Roemer et al, 
2002). In HCT116 Bax -/- cells, apoptosis was reduced but not absent, which suggests that 
resveratrol can induce a Bax-mediated and a Bax-independent mitochondrial apoptosis in 
the colon.  
 Another mechanism whereby resveratrol may provide protective activity against 
carcinogensis could be through its ability to prevent the synthesis and/or activity of enzymes 
that are considered carcinogenic when over-expressed. Cyclooxygenases 1 and 2 catalyze 
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the first committed step of prostaglandin H2 from arachidonic acid. Prostaglandin H2, in turn, 
is converted to prostaglandin E2, which is a known inducer of angiogenesis and inhibitor of 
apoptosis (Mutoh et al, 2006). Cyclooxygenase-2 proteins are overexpressed in 80% of 
human colorectal cancers, whereas expression in normal tissue is negligible (Sinicrope, 
2004). Resveratrol (30 MM) was shown to reduce the activity of lipopolysaccharide-induced 
COX-2 in RAW 264.4 macrophages treated for 18 hours (Tsai et al, 1999) and in 184 
B3/HER mammary cells following 30 minutes treatment (Subbaramaiah et al, 1998) and 
reduce PGE2 levels in the intestine of Min mice fed 90 mg (394 Mmol) resveratrol/kg in the 
diet for 7 weeks (Ziegler et al, 2004). Resveratrol at 25 uM also decreased the activity of 
ornithine decarboxylase in Caco-2 cells (Schneider et al, 2000). Ornithine decarboxylase is a 
key enzyme in polyamine biosynthesis and is overexpressed in colorectal cancers (Nemoto 
et al, 2005).  
 In short, a variety of mechanisms may account for the chemopreventive activity of 
resveratrol. There is much that is still unknown and new advances in research technologies 
may provide the needed tools to fully realize the anticancer potential of resveratrol. 
Resveratrol may orchestrate changes at the cellular level that might be different depending 
on the tissue and/or chemical form and concentration of resveratrol. It is also possible that 
resveratrol may act synergistically with other polyphenolic compounds in plant-based foods 
to provide chemopreventive benefits. There is little doubt that this is a very active area of 
research and will continue to be so for the near future.  
 In our studies, azoxymethane was used to induce aberrant crypt foci lesions in the colon 
of CF-1 mice. Azoxymethane is converted to methylazoxymethane (MAM) by the 
hydroxylation of methyl groups catalyzed by CYP2E1 in the liver and extrahepatic organs 
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(Sohn et al, 2001). It is proposed that MAM is conjugated with glucuronic acid in the liver 
and is transferred to the intestine by the bile duct (Fiala, 1975; Fiala, 1977). Glucuronic acid 
conjugates can be hydrolyzed by bacterial ?-glucruonidases to free methylazoxymethane, 
which spontaneously breaks down to yield methyldiozionium ions that can methylate DNA.  
Subsequently, the methyldiozionium ions would act directly at the site of the colonic 
mucosa resulting in the formation of aberrant crypt lesions and eventually, tumors.  
 Since we were interested in determining the chemopreventive activity of resveratrol-
glucoside (piceid) in transgenic alfalfa, diets containing the alfalfa were administered to CF-
1 mice three days after final AOM injections, ensuring that any effect observed in the colon 
of these mice on ACF development was not the result of an inhibition of AOM metabolism 
in the liver, because resveratrol can inhibit the activity of CYP2E1. The mechanism of 
resveratrol-induced inhibition of ACF was not explored in our study, but the ones proposed 
above in other studies could explain the activity we observed and report on later in this 
dissertation.  
Bioavailability of resveratrol 
 Studies on the biological distribution of a proposed chemopreventive agent are necessary 
in order to examine the potential clinical value of that agent. Different research approaches 
have been applied in studying the bioavailability of resveratrol. Resveratrol bioavailablity 
has been examined in humans, laboratory rodents, ex-vivo intestinal preparations, and in 
human hepatic and colon human cell assays. Most of the bioavailability studies with 
resveratrol have been conducted using the trans-3,5,4’-hydroxystilbene isoform of 
resveratrol. Very few bioavailability studies have included piceid, and no studies could be 
located where other isoforms of resveratrol are examined.  
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Pharmakinetic studies reveal that resveratrol is rapidly absorbed following oral 
administration. Peak plasma levels of resveratrol (2-3 MM in mice and 1 MM in rabbits and 
rats) were reached within 5 minutes post-dose administration in animals fed 20 mg (88 
Mmol) trans-resveratrol/kg body weight (dissolved in 0.5 ml ethanol:saline 1:1) via gavage 
(Asensi et al, 2002). Plasma concentrations rapidly declined to levels below 0.1 MM in all 
animals after 60 minutes. Resveratrol reached a concentration of 42.8 ± 4.4 MM in the 
plasma of mice that received an i.p. injection of resveratrol at 88 Mmol/kg body weight, but 
had a short half life of 14.4 minutes.  Detected resveratrol levels in the brain, lung, liver and 
kidney were very low; all being under 1 nmol per gram of fresh tissue. When resveratrol was 
administered in the drinking water at 23 mg (100 Mmol)/l to mice for 10 days, plasma 
concentrations of resveratrol were much lower than achieved with gavage (0.075 ± 0.025 
MM). However, resveratrol inhibited the hepatic metastatic invasion of B16 melonoma cells 
that were injected into the spleen of mice prior to feeding the mice with resveratrol orally 
via gavage 88 Mmol/kg body weight, twice daily) or drinking water 100 Mmol/l). These 
findings illustrate that resveratrol may have very potent activity at specific tissues. 
 Peak plasma levels of resveratrol were reached rapidly in another study where Sprague-
Dawley rats were administered oral (50 mg (219 Mmol)/kg body weight in a solution of ?-
cyclodextrin) and intravenous (15 mg (66 Mmol)/kg body weight in 0.2% saline) doses of 
trans-resveratrol-aglycone (Marier et al, 2002). In this study, plasma was collected over a 
longer time (from 0-12 hours post dose administration). The plasma concentrations of 
resveratrol-aglycone rapidly declined during the first two hours after dose administration 
with a mean elimination half-life of 0.13 ± 0.02 hours after i.v. administration and 0.29 ± 0.1 
hours after oral administration. However, a sudden increase in plasma concentration 
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occurred 4 to 8 hours after drug administration, with a noted increase in glucuronide 
conjugates of resveratrol. Resveratrol-glucuronide plasma concentrations remained greater 
than 10 µM 8 hours out from the initial dose administration, whereas resveratrol-aglycone 
dropped off from a peak concentration of about 8 µM within minutes after treatment to 
levels below 1 µM after 2 hours. Enterohepatic recirculation of resveratrol was confirmed in 
a bile duct, rat linked model  where resveratrol-aglycone was administered to bile-donor rats 
whose bile ducts were surgically linked via catheters to the duodenum of bile-recipient rats. 
These studies indicated that resveratrol is rapidly absorbed and circulates to the liver where 
it undergoes phase-II metabolism before being reintroduced into the intestine via the bile 
duct.  
 Vitrac et al. reported the tissue distribution over time of 14C-trans-resveratrol-aglycone 
orally distributed to mice at a dose of 7.4 kbeqcuerels (0.2 Mcuries) 14C-trans-resveratrol-
aglycone (5 mg (22 Mmol)/kg body weight) by gastric intubation (Vitrac et al, 2002). The 
radioactivity in the blood 1.5 h post dose administration was low and did not increase 
throughout the 6 hour time-course of the experiment. However, earlier time points were not 
examined. Radioactivity was detected at high levels in the urine and bile at all time points. 
After 3 hours, radioactivity was detected in all organs and tissues detected, including the 
colon, brain, heart, liver, spleen, lung and testis. The highest levels were detected in the 
duodenum. To confirm that resveratrol accumulated in tissue, microutoradiography on the 
liver and kidney were performed.  14C-trans-Resveratrol-aglycone along with glucuronic 
acid and sulfonoconjugates were identified in these organs.  
 Recently, positron emission tomography was used to visualize the biodistribution of a 18F-
labelled resveratrol derivative, 3,5-dihydroxy-4’-[18F]-fluoro-trans-stilbene, in Wistar rats 
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injected intravenously with the compound (Gester et al, 2005). There was a rapid clearance 
of radioactivity from the blood, with levels at 5 minutes (0.15% of dose given) approaching 
the final concentrations measured after 60 minutes. The majority (37% of injected dose) of 
the radioactivity was detected in the urine of rats 60 minutes after they were injected with 
the isotope derivative at a single dose of 1.5 MBq [18F] in 0.5 ml saline with 2% ethanol. 
Extensive uptake of resveratrol in the liver and kidney was suggested by the high levels of 
radioactivity measured in these tissues (12.6% and 5.6%, respectively). High levels of 
radioactivity (31% of dose) were also retained in the intestine 60 minutes after treatments, 
indicating that resveratrol can accumulate in this tissue. 
 Circulatory appearance and disappearance as well as tissue distribution of tritium-
labeled resveratrol was assayed in Sprague-Dawley rats in a recent study (El-Mohsen et al, 
2006). In this study, resveratrol was administered by gastric gavage at a dose of 50 mg (219 
Mmol)/kg body weight in a mixture with 1.85 MBq [3H] to the rats. Biological samples were 
collected at 2 and 18 hours post-gavage, and tissue (brain, lungs, heart, liver and kidney) 
concentrations of resveratrol were determined using HPLC equipped with a diode array 
detector, whereas major metabolites of resveratrol were identified in the plasma and tissue 
using a mass spectrometer detector in tandem with fragmentation of trapped ions (MS/MS). 
Almost 90% of the resveratrol administered was absorbed in the rats over 18 hours post-
gavage after accounting for losses in the feces. Besides the gastrointestinal tract, which 
retained 76% of the radioactivity administered, the highest tissue levels of radioactivity 2 
hours post-gavage were obtained in the liver and kidney, which each contained less than 1% 
of the initial dose. Radioactivity in both the liver and kidney at 18 hours after treatment 
declined to 10 and 25% of the levels obtained at the 2 hour time point. However, the brain 
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retained 43% of the levels detected at 2-hours at the 18-hour time point, indicating that 
resveratrol may be retained in this tissue for a longer period. After 2 hours, resveratrol-
glucuronide was detected as the only form of resveratrol in the tissues and in the plasma. 
Plasma concentrations of resveratrol-glucuronide reached 7 MM at 2 hours and could not be 
detected at the 18 hour time point. At 18-hours, resveratrol-glucuronide remained the major 
metabolite detected in the liver, but resveratrol-aglycone was the major form of resveratrol 
measured in the liver, heart, lungs and brain. This later observation would suggest that these 
tissues possess ?-glucuronidase activity at significant levels. However, the concentrations of 
resveratrol-aglycone measured in these tissues at 18 hours was less than 0.2 nmol/g of tissue 
in all cases. Concentrations of resveratrol or identification of resveratrol metabolites in the 
colon or small intestine was apparently not determined in this study as these values were not 
reported.  
 The identification of phase-II metabolites of resveratrol in the plasma was the focus of a 
study in which male Wistar rats were fed daily doses of resveratrol-aglycone at 50 mg (219 
Mmol)/kg body weight or 300 mg (1.3 mmol)/kg body weight via the diet for 8 weeks 
(Wenzel et al, 2005). At the end of this treatment period, total resveratrol recovery in the 
urine and feces was 15% and 13%, respectively, in mice fed the 219 Mmol/kg body weight 
dose, and 54% and 17% in mice fed the higher dose. No phase-I metabolites of resveratrol 
were detected in the plasma, urine or feces but various sulfate conjugates (resveratrol-3-
sulfate, resveratrol-4-sulfate, resveratrol-3,5-disulfate, resveatrol-3.4-disulfate and 
resveratrol-3,5,4-trisulfate) as well as resveratrol-3-glucuronide were detected by high-
performance liquid chromatography–diode array detection (HPLC-DAD) in the biological 
samples tested. Free resveratrol was not detected in the plasma or kidneys.  
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Phase-II metabolites of resveratrol were also reported to be the major isoforms of 
resveratrol in the circulation of humans administered 14C-labeled trans-resveratrol (Walle et 
al, 2004). In this study, 0.1 mmole 14C-labeled trans-resveratrol was given to six healthy 
adult humans at a 25 mg oral dose. Peak plasma levels of resveratrol (491 ± 90 ng/ml _ 2
µM) were reached within 1 hour after administration. As observed in the rodent study by 
Marier et al (2002), a second spike in plasma resveratrol concentrations (1.3 ± 0.3 nmol/ml), 
occurred at 6 hours post dose administration. After this point, plasma resveratrol 
concentrations rapidly declined and could no longer be detected. Resveratrol plasma 
concentrations also rapidly declined 1 hour after a 1.5 mg intravenous administration of 
resveratrol. No second resveratrol peak was observed following i.v. administration of 
resveratrol, though. Most of the resveratrol following the oral and i.v. doses was recovered 
in the urine (53.4-84.9 % and 42.3-83.2%, respectively). Resveratrol recovery in the feces 
following both i.v. and oral doses was highly variable (0.3-38.1% and 0.6-22.7, 
respectively). Free resveratrol could not be detected in any of the plasma samples. Instead, 
resveratrol was recovered as glucuronic acid and sulfate conjugates.  
 To compare the bioavailability of three polyphenolic compound constituents of red wine 
and the influence of beverage matrices, healthy male, adult human subjects were 
administered trans-resveratrol (25 mg (110 Mmol)/kg body weight), catechin (25 mg (87 
Mmol)/kg body weight) or quercitin (10 mg (33 Mmol)/body weight) in vehicles consisting of 
white wine, grape juice or vegetable juice (Goldberg and Soleas, 2003). Blood and urine 
samples were collected at four intervals over the first four hours after consumption. The 
vehicle matrices had no effect on the serum profiles of resveratrol throughout the times 
analyzed. In each case, peak serum levels of resveratrol were reached at 30 minutes with 
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total resveratrol concentrations maxing at approximately 2 MM. The serum concentrations of 
free resveratrol in all cases were a small fraction of total concentrations (1.7 to 1.9%). 
Similarly, the absorption of catechin and quercitin were not affected by the liquid matrices. 
Resveratrol was the most efficiently absorbed compound of the three, judged by the peak 
serum concentration, area-under-the curve and urinary excretion during the 4- hour period 
(16-17% of dose consumed). These results suggest that alcohol does not enhance the 
absorption of resveratrol-aglycone.          
 Transport and uptake models have been established using whole liver and small intestine 
tissues as well as intestinal and heptatic cells. Rapid glucuronidation and sulfation of 
resveratrol following incubation with human liver microsomes have been documented (De 
Santi et al, 2000a; De Santi et al, 2000b). Both trans- and cis-resveratrol were subject to 
glucuronidation, which was region and stereoselective, and resulted in the formation of 3´-O 
and 4´-O glucuronides. This is in agreement with the human data showing that 3´-O- and 4´-
O- glucuronides are the major metabolites of resveratrol in the blood (Wang et al, 2004 and 
reviews above). 
 Using an isolated preparation of luminally and vascularly perfused rat small intestine, 
Andlauer et al. (2000) demonstrated that phase-II metabolism of resveratrol occurs in the 
small intestine. In this study, luminal media passing through the small intestinal preparations 
consisted of 28, 34 or 57 uM resveratrol. Following a 30 minute perfusion period, only 
20.5% of the resveratrol administered was recovered on the vascular side, as detected by 
HPLC/MS. The majority of the resveratrol absorbed was conjugated to yield resveratrol 
glucuronide (82% of resveratrol absorbed). Lesser amounts of resveratrol-aglycone (3.6%) 
and resveratrol sulfate (0.3%) were detected in the vascular effluent. Another group, using a 
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similar rat small intestine single-perfusion model, showed that the major metabolite detected 
on vascular side of the jejunm and ileum was the glucuronide conjugate of resveratrol 
(96.5% of the amount of resveratrol absorbed) following a 90- min period where resveratrol 
at a concentration of 200 MM was perfused through the lumen of the isolated intestinal 
sections (Kuhnle et al, 2000).  
 A cell-based assay using Caco-2 cell monolayers was used to study the transport of 
resveratrol (5-40 MM) in the intestines (Kaldas et al, 2003). When resveratrol was incubated 
with the cells at the lower concentration of 5 MM, apical efflux of resveratrol was favored.  
However, basolateral efflux of resveratrol was favored at higher doses of 20 and 40 MM. The 
transport rate of resveratrol doubled from doses 20 to 40 MM, with the recovery of 
resveratrol-3´-O-sulfate decreasing by more than two-fold at 40 MM, suggesting that the 
saturation of phase-II metabolism may, at least, partially explain the increase in basolateral 
transport of resveratrol at higher doses. The transport of resveratrol-3´-O-sulfate to the 
apical side of the cell monolayer system at lower resveratrol doses indicates that the 
multidrug-resistance protein may play a significant role in transporting intracellular 
resveratrol back out into the lumen following phase-II metabolism of absorbed resveratrol. 
In spite of this, the intracellular accumulation of resveratrol was extensive in Caco-2 cells, 
reaching as high as 40-fold compared to the surrounding buffers.  
 The Caco-2 monolayer system was used in another study to further probe the transport 
mechanism of resveratrol in the intestine (Li et al, 2003). The apical and basolateral efflux 
of resveratrol was similar in all concentrations examined (5-250 MM), indicating that 
resveratrol-aglycone is passively transported across the epithelium of the intestine. 
Furthermore, this study did not support a role for P-glycoprotein or the multi-drug resistance 
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associated proteins (MRP) in the apical transport of resveratrol as the addition of specific 
inhibitors to these proteins did not affect the transport of resveratrol across Caco-2 
monolayers. Resveratrol-3-glucuronide and resveratrol-3-sulfate were identified as the major 
metabolites of resveratrol in both the apical and basolateral fractions of a monolayer 
cultured with 200 uM resveratrol. 
 Resveratrol-3-o-glucuronide and resveratrol-3O-sulfate, along with resveratrol-4-o-
glucuronide were identified as metabolites produced in Caco-2 cells exposed to resveratrol 
in a monolayer system in another report (Maier-Salamon et al, 2006). In this study, Caco-2 
cells were treated with a variety of doses (10-200 uM). The apical to basolateral rate of 
resveratrol was 12 x 10-6 cms-1, which indicates that resveratrol is rapidly absorbed in these 
cells and supports the data gathered by the previous studies in humans and animals showing 
that resveratrol is rapidly absorbed within 30-60 minutes following oral administration. As 
with the study by Li et al (2003), the basolateral to apical rate for resveratrol was similar, but 
slightly less than the reverse rate, indicating that a basolateral efflux is marginally favored. 
However, the basolateral efflux of resveratrol was increased by 22% in cells treated with 10 
uM resveratrol and 5 MM cyclosporine, an inhibitor of the muti-drug resistance protein 
(MRP) and p-glycoprotein. The presence of 40 MM verapamil, a specific inhibitor of p-
glycoprotein, had no effect on resveratrol efflux, indicating that the MRP plays a role in the 
apical efflux of resveratrol, contradicting the findings of Li et al, but supporting the 
hypothesis generated by Kaldas et al (2003). The basolateral efflux of both resveratrol 
monoglucuronides vs. treatment concentration followed a classic Michaelis-Menton kinetics 
pattern as the efflux of these metabolites increased linearly at lower concentrations but 
reached a saturation point at higher doses. However, biotransformation of resveratrol to 
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resveratrol-3´-O-sulfate was strongly inhibited in cells treated with higher concentrations of 
resveratrol (200 MM). Remarkably, the intracellular concentrations of trans-resveratrol 
remained at about 61% of the applied dose across the treatments applied, with the 
concentrations ranging from 370 pmoles/cm2 of the cell layer at a dose of 10 uM to 37,200 
pmoles/cm2 at a dose of 200 MM.  
Bioavailability of piceid 
 In comparison to resveratrol-aglycone, much less is known about the bioavailability of 
piceid. The bioavailability of resveratrol via a grape extract, which consisted mostly of 
piceid, was examined in humans (Meng et al, 2004). Grape powder that contained 38 umol 
total resveratrol/kg dry weight was mixed into a juice (18% aqueous solution of grape 
preparation – juice contained 0.16 mg total resveratrol/ml) and administered to adult 
subjects at a single volume of 200, 400, 600 or 1200 ml (corresponding to 32-192 mg total 
resveratrol). Resveratrol could not be detected in the plasma or urine of subjects given 400 
or 600 ml of the grape juice. The cumulative excretion of resveratrol in the urine after 
drinking 1,200 ml of grape juice was only 5% of the dose administered. Furthermore, 
resveratrol was detected only following hydrolysis with ?-glucuronidase. Resveratrol-
aglycone was not detected in the plasma even at the higher doses examined. The resveratrol 
recovery in the urine was one-tenth of what was obtained in subjects administered pure 
resveratrol at a similar dose (1.95 mg per 65 kg weight). Since most of the resveratrol in the 
juice consisted of glucosides, this study suggested that the bioavailability of resveratrol-
glucosides is very limited compared to resveratrol-aglycone. 
 Recently, a group reported a new HPLC method to extract and measure piceid in 
biological tissues (Lv et al, 2006). This report featured a study were piceid was orally 
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administered to male Wistar rats at a dose of 50 mg (128 Mmol)/kg body weight in an 
aqueous vehicle consisting of 0.5% sodium carboxymethylcellose (it was not specified 
whether this was achieved using gavage or via drinking water). Plasma was collected 5 to 
240 minutes post dose administration. A separate study was conducted using the same dose 
of piceid in order to assess piceid levels in tissues following 10, 30 and 120 minutes post 
dose administration. All sample extracts were analyzed using HPLC with a diode array 
detector. Peak plasma concentrations of piceid (0.364 ± 0.151 Mg/ml, equivalent to 0.9 MM
piceid) were reached 20 minutes after treatment and gradually decreased to undetectable 
levels after 240 minutes. Piceid was detected in all of the tissues examined, but were at the 
highest levels in the stomach and small intestines. The levels in these tissues were over 0.3 
Mmol piceid/g tissue at 2 hours and declined to levels under 13 nmol/g after 18 hours. 
Besides the gastrointestinal tract, the highest concentrations of piceid were observed in the 
spleen and lung, with concentrations reaching around 25.6 nmol/g tissue after 10 minutes. 
Levels in the brain, liver, testis and kidney were around 5 nmol/g tissue at 10 minutes. After 
120 minutes, piceid levels declined to less than 2.5 nmol/g tissue in all of the samples 
examined. Collectively, these data imply that piceid is bioavailable, but is rapidly eliminated 
in rats. However, none of the biological samples were treated with ?-glucuronidase or 
sulfatase enzyme prior to analysis, which leaves open the possibility that piceid may be 
metabolized to other forms. Unfortunately, a side-by side comparison with resveratrol-
aglycone was not conducted.  
 Comparisons between piceid and resveratrol-aglycone intestinal transport have been 
made using the Caco-2 monolayer cell assay. Henry et al (2005) reported that resveratrol-
aglycone was absorbed across the apical membrane of Caco-2 cells more rapidly and in 
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higher amounts than trans-piceid. The recovered intercellular concentrations of resveratrol-
aglycone remained at least three times greater than that of piceid in Caco-2 cells exposed to 
equal molar concentrations of the two compounds (300 uM) in all time points examined (0-
30 minutes). The presence of phlorzin, an inhibitor of the sodium-glucose cotransporter-1 
(SGLT-1), did not affect the absorption of resveratrol-aglycone across the Caco-2 
monolayers, which further supports the data suggesting that resveratrol-aglycone is 
passively absorbed in the intestine. The active transporter SGLT-1, however, does seem to 
play an important role in the intestinal absorption of piceid as the addition of phlorizin 
inhibited the cellular uptake of piceid in Caco-2 cells. 
 Lactase phlorizin hydrolase (LPH), an enzyme located at the brush border membrane of 
the small intestine that is responsible for lactose hydrolysis, can deglycosylate certain 
flavonoid 3´- and 4´-glucosides, such as quercitin-3’-glucoside and quercitin-4´-glucoside 
(Day et al, 2001; Sesink et al, 2002) and may play an important role in the small intestinal 
absorption of other polyphenolic-glucosides. Since LPH is located outside of the epithelial 
cells along the enterocyte membrane, the deglycosylation of glycosylated compounds can 
occur in the lumen before the compound is absorbed across the enterocyte membrane. In 
addition to LPH, other ?-glucosidase enzymes have been identified in the small intestine 
cytosol and can hydrolyze glycosylated flavonoids to their respective aglycones (Day et al, 
2001). However, in order for any polyphenolic-glucoside to be a potential substrate for 
cytosolic-?-glucosidases, the compound would have to be initiallytransported across the 
enterocyte membrane of the intestine. 
 The role of LPH in the intestinal metabolism of piceid was explored in a recent study by 
Henry –Vitrac et al (2006). The transport permeability coefficient of 100 MM piceid across 
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Caco-2 monolayers was 10.5 X 10-6 ± 0.1 cm/s for the apical to basolateral direction and 
15.3 x 10-6 ± 6.6 cm/s in the basolateral to apical direction. The basolateral to apical rate was 
significantly greater than the reverse rate, but the rate for the apical to basolateral flux 
measured in this system predicts that piceid should be efficiently absorbed in the 
gastrointestinal tract. In Caco-2 cells that were seeded to 6-well plates and treated with 100 
uM piceid, evidence of piceid deglycosylation was obtained as the intracellular 
concentration of trans-resveratrol-aglycone measured increased in a time-dependent, linear 
fashion to a maximum concentration of 4.5 ± 0.1 pmol/cm2 after 24 hours oftreatment. To 
determine if the recovery of the aglycone was the result of a catalyzed event by LPH or 
cytosolic-?-glucosidases (CBG), the intestinal mucosa of Wistar rats was scrapted and 
extracted to obtain fractions that contain LPH or CBG. Resveratrol-aglycone was detected 
following piceid incubation with both extracts. The recovery of resveratrol-aglycone was 
inhibited by 93% in cells incubated with LPH and by 69% in cells with CBG by 2 mM D-
gluconolactone, an inhibitor of both cytosolyc and membrane-bound ?-glucosidases, which 
reveals that piceid can be a substrate for both types of cellular ?-glucosidases. Resveratrol-3-
O and resveratrol-4-O-glucuronide were identified as the major resveratrol metabolites in 
Caco-2 cells. Treatment of cells with 50 uM of crysin, a known inducer of UDP-
glucuronosylftransferases of the 1A1 family (UGT1A1), resulted in an increase of both 
resveratrol-monoglucuronides.  
 In summary, the current collective data raise some interesting questions on the potential 
role of resveratrol-aglycone as a chemopreventive or therapeutic agent at target tissues 
beyond the gastrointestinal tract. The bioavailability studies indicate that resveratrol, 
following an oral dose, is rapidly adsorbed in the upper gastrointestinal tract where it 
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undergoes extensive phase-II metabolism before transferring to the systemic circulation. In 
the liver, resveratrol undergoes a second pass of phase-II metabolism and then is re-
circulated to a variety of tissues, including the heart, lung, brain, prostate and kidney. As 
reported above, there is some evidence that tissue accumulation of resveratrol occurs at 
these sites. However, the bioactivity of glucuronide or sulfate conjugates of resveratrol, 
which by all indications are the predominant forms of resveratrol reaching these tissues have 
not been examined. Furthermore, the role of ?-glucuronidases or sulfatases at these sites 
remain unknown in regards to resveratrol metabolism as some studies indicate that 
resveratrol can be found in the native aglycone form at these sites. 
 Sor far, no studies of the accumulation of resveratrol in the colon of an animal model 
following an oral dose were found in the literature. Although resveratrol seems to be 
absorbed mainly in the upper g.i. tract, some of the compound could remain in the intestinal 
lumen and reach the colon. One study reported that phenolic degradation products of 
resveratrol could not be detected in the urine or tissues of Sprague-Dawley rats administered 
50 mg/kg body weight of [3H] trans-resveratrol 2 or 18 hours post-gavage following 
LC/MS-MS analysis of tissue (El-Mohsen et al, 2006). Since resveratrol glucuronide and 
sulfate metabolites could be examined in the biological samples, this would suggest that 
resveratrol-aglycone is not degraded to other compounds, but this has not been confirmed in 
humans. Studies in Caco-2 cells and radiotracer readings in the gastrointestinal tract of 
rodents administered radiolabeled versions of resveratrol suggest the possibility that 
resveratrol may accumulate in the colonic enterocytes once absorbed. The bioavailability 
studies in rodents also suggest that resveratrol-glucuronide or sulfate metabolites can be 
reintroduced into the intestinal lumen via the liver from the bile duct. In the colon, ?-
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glucuronidase and sulfatase activity expressed by the gut microflora could hydrolyze the 
conjugated metabolites (Aura et al, 2002), releasing free resveratrol-aglycone at the site of 
the colon.  
 With piceid, the picture is much less clear. The bioavailability studies indicate that piceid 
can be absorbed in the upper g.i. tract via an active process that may involve the SGLT1 or 
may be deglycosylated by LPH and then passively absorbed as resveratrol. It is not known if 
this occurs in humans or animals, since this has not been demonstrated in either yet. The one 
study by Lv et al (2006) indicates that piceid may reach the circulation intact, but the plasma 
concentrations of the compound were very low, and little is known about the biological 
activity of piceid relative to resveratrol-aglycone. Also, it is not known if the metabolic fate 
of the absorbed piceid is the same as resveratrol-aglycone. Bilary excretion may be a major 
pathway for resveratrol-aglycone following phase-II metabolism in the liver, which would 
provide an alternative pathway to the colon (Marier et al, 2002). This could be the same with 
piceid. Alternatively, renal excretion may be the terminal fate of piceid absorbed in the 
small intestine. Piceid that passes through the small intestine, unabsorbed or metabolized, 
would reach the colon where it could be absorbed or be a substrate for microbial ?-
glucosidases.  
 One of the goals of this research was to examine the colon bioavailability of piceid in diet 
preparations containing piceid-accumulating transgenic alfalfa with and without ?-
glucosidase activity. Additionally, we determined whether piceid is a substrate for LPH in 
the small intestine by comparing the recovery of piceid in the mucosal and serosal tissues of 
isolated, everted intestinal mouse sacs incubated in piceid in the presence and absence of a 
lactase-specific inhibitor. To our knowledge, our studies are the first to examine the role of 
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LPH in the intestinal absorption of piceid and compare its absorption with that of 
resveratrol-aglycone in-vivo. Our studies are also unique in that we link the colon 
bioavailability of piceid and resveratrol-aglycone to the inhibition of azoxymethane-induced 
aberrant crypt foci in this tissue.   
Genetic-engineering strategies to increase resveratrol availability in plant-based foods 
 Given the limited number of identified natural and processed consumable sources of 
resveratrol and the low levels of resveratrol in these sources, it is unlikely that desired 
biological endpoints could be achieved from normal dietary consumption of resveratrol 
alone. Instead, strategies will have to be employed to either increase yields of resveratrol in 
present sources, introduce resveratrol into additional plants, or concentrate resveratrol into 
an extracted or purified, marketable product. Genetic engineering strategies could be 
developed to achieve each of these goals. The second and remaining portion of this review 
will focus on the potential promise and limitations of using transgenic approaches to enrich 
the availability of resveratrol and related compounds in dietary sources to address human 
health concerns.  
Definition of “genetically-modified” and advantage over traditional breeding 
 The terms “genetically-enhanced, genetically-engineered, genetically-modified” and 
“transgenic” collectively describe an organism that is generated using recombinant DNA 
technology (Celec et al, 2005). Genetic diversification in plants has been achieved for 
thousands of years through traditional breeding practices (Diamond, 2002). However, 
genetic engineering technology offers the advantage over traditional plant breeding 
approaches in that the generation of useful phenotypes is not limited by the gene pool of 
existing plant germplasms. Additionally, there is growing concern that traditional plant 
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breeding practices may have resulted in the selection of crops with improved yields at the 
expense of decreased nutritional quality (Morris and Sands, 2006). In the last decade and a 
half, advances in molecular biology have made it possible to selectively introduce novel 
genes into crops from a virtually unlimited number of sources. As the result of this, new 
crops with disease-, pesticide- and insect- resistant traits; increased tolerance to 
environmental stress; and enhanced nutritional composition have been developed (Singh et 
al, 2006; review).  
Plant transformation techniques 
 Currently, two methods are widely used to genetically transform plants (Tourte, 2005). 
One method involves the use of the bacterium Agrobacterium tumefaciens, which can insert 
a plasmid into wounded plants. Laboratory strains of A. tumefaciens employ a binary 
plasmid that encodes several genes required for the transfer of the plasmid into the plant 
cells and engineered expression cassettes that can contain genes from virtually any source 
imaginable. The second method widely used is the biolistic method, which involves 
propelling microprojectiles, usually of tungsten or gold, coated with DNA into targeted plant 
cells. Traditionally, the Agrobacterium method has been applied to the transformation of 
dicotyledonous plant species, whereas the biolistic method has been employed for 
monocotyledonons species. However, in recent years, Agrobacterium-mediated techniques 
have been established for the transformation of cereals and rice, crops that were once 
deemed impossible to transform with this method.  
Scope of GM market 
 The estimated global area planted with genetically-modified crops for 2005 was 90 
million hectares, equivalent to 222 million acres, grown by 8.5 million farmers in one of 21 
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countries, up from 17 countries reported in 2004 (http://www.iaaa.org). Since the 
commercial introduction of GM crops in 1996, the average growth in area has been more 
than 10% per year (Dunwell, 2005).  
 Of the global area planted, about 99% of GM crops are grown in six countries: the United 
States, Argentina, Canada, Brazil, China and South Africa (Dunwell, 2005). The United 
States, by far, leads all nations in the production of commercial GM crops. In 2005, 123 
million acres of land in the U.S. was utilized for GM crop production. The leading GM 
crops are currently soybean, corn, cotton and canola. Based on the prevalence of soybean 
and corn in the U.S. food system, the Grocery Manufacturers of America estimates that 70% 
to 85% of processed foods in the U.S. contain one or more ingredients derived from GM 
plants (Bren, 2003). Thus, it is highly likely that every adult residing in the U. S. has 
consumed at least one GM product in their lifetime.  
 Plant-transforming technologies have improved in efficacy since the first GM crop 
became commercially available in the U.S. in 1994, and applications have been developed to 
extend the technology to a number of plant species (Celec et al, 2005). Genetically-modified 
crops that express tolerance to herbicides, insect-resistance or both of these traits stacked 
represent the GM market today and account for the vast majority of acres devoted to GM 
crops in the world (Dunwell, 2005). There is strong evidence that these crops have had a 
positive impact on the environment and have significantly resulted in profits for farmers 
who have adapted their use. In 2000, it was reported that farmers in the United States who 
grew transgenic cotton used 2.4 million fewer gallons of fuel and 93 million fewer gallons 
of water (Falck-Zepeda et al, 2000). It is estimated that the total economic benefits to 
farmers in the U.S. who plant GM crops are around $1.5 billion per year. A recent report 
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suggests that biotech crops have reduced the environment footprint associated with pesticide 
use by 14% from the years 1996-2004  (Brookes and Barfoot, 2005). The economic benefits 
of GM crops are now being felt worldwide. South African and Chinese farmers growing 
transgenic insect-resistant cotton, for instance, achieve yield increases of more than 20% and 
cost savings of nearly 30% (Entine, 2006). 
GM crop production to address nutrition and health discrepancies  
 Plants synthesize and accumulate a wide array of nutrients and other compounds that have 
health-promoting properties. A diverse, well-balanced plant-based diet, in theory, can supply 
all of the currently identified essential nutrients at all stages of the life cycle; the exceptions 
being vitamins B12 and D (Grusak and Della Penna, 1999). However, in practice, very few 
individual plants supply the daily recommended intakes of any micronutrient in a reasonable 
serving, and the bioavailability of some micronutrients is very limited in plant-based foods. 
Furthermore, many people do not consume a diet diverse enough to obtain the full range of 
health-benefiting attributes that can be gained from these foods. In many developing 
countries, people spend 70% of their income on food, with the majority of the energy 
requirments being supplied in the form of staple crops such as rice, wheat and maize, which 
have traditionally been poor sources of some macronutrients and many micronutrients 
(Bouis et al, 2003). To augment the consumption of various plant-derived nutrients and 
nutraceuticals by people around the world, biotechnology is being applied to enhance the 
nutritional composition of crops (Bouis et al, 2003; Yan and Kerr, 2002; Grusak and Della 
Penna, 1999). Examples of these crops include rice which accumulates ?-carotene, a 
precursor of vitamin A (Ye et al, 2000); phytase (Holm et al, 2002) and ferritin-rich rice 
(Lucca et al, 2001) with improved biological bioavailabilty of iron; a soybean with a higher 
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percentage of oleic acid and decreased levels of polyunsaturated fatty acids (Kinney and 
Kowlton, 1998), canola which produces omega-3 fatty acids (James et al, 2003), a potato 
with increased biosynthesis of lysine (Seveneir et al, 2002), tomato with elevated 
biosynthesis of ?-carotene (Romer et al, 2000) and soybean with increased levels of L-
tocopherol (Cahoon et al, 2003).  
 Many compounds have been identified in plants that may have health promoting or 
disease preventing properties beyond the mere provision of basic nutrition (Lampe, 2003), 
(Tsuda et al, 2004) and (Baliga et al, 2005). Some of the phytochemical compounds 
produced as secondary metabolites by plants may be of value for health as well as 
agronomical purposes, because their presence can improve crop yields and provide health 
beneficial properties to humans (Verpoorte et al, 2000; Rao and Ravishanker, 2002; Caspell 
and Christou, 2004). A number of phytochemical polyphenols are isolated from plants and 
are already commercially available as chemicals for use as drugs, dyes, flavors, fragrances 
and insecticides (Verpoorte et al, 2000). Some of these compounds, such as the flavonoids, 
play an important role in the plant’s defense against UV-B light exposure and pathogens, 
pollen development and fertility, and flower and fruit color development (Woo et al, 2005). 
These attributes have been exploited in some plants through genetic-engineering strategies 
to produce plants with greater growth yields and desirable physical traits.  From a nutritional 
point of view, flavonoids are of particular interest since many of these compounds have been 
suggested to protect against oxidative stress, coronary heart disease, certain cancers and age-
related diseases (Harborne and Williams, 2000). Examples of GM plants that have been 
introduced include alfalfa that produces genistein glucoside (Deavours and Dixon, 2005) 
and greater yields of anthocyanins and proanthocyanidins (Ray et al, 2003), tobacco that 
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expresses a phenylalanine ammonia-lyase gene from the Chinese herb Astragalus 
membranaceus and accumulates higher levels of quercetin (Lui et al, 2006), and tomato 
which expresses maize transcription factor LC and C1 genes and produces flavonoids in the 
fruit flesh in addition to the peel (Bovy et al, 2002). One of the most remarkable successes in 
recent years has been the production of a tomato which overexpresses petunia chalcone 
isomerase and exhibits an 80-fold increase in the content of flavonoids in the fruit peel 
(Muir et al, 2001). In a recent study, Rein et al. assessed the potential benefits of this 
transgenic tomato on cardiovascular health using human C-reactive protein transgenic mice 
(CRPtg) as test subjects (Rein et al, 2006).  The transgenic tomatoes used in this study 
accumulated high levels of quercetn-3-rutinoside (12120 ± 760 mg/kg dry peel) and 
kampferol-rutinoside (1985 ± 118 mg/kg dry peel) among other flavonols and flavones. The 
peel of the transgenic tomato was incorporated into a standard rodent diet at a concentration 
of 4 g peel/kg of diet and fed to CRPtg mice which for 7 weeks. Both wild type and 
transgenic tomato peel reduced basal plasma human c-reactive protein levels in the mice by 
43 and 56%, respectively. However, the reduction with the transgenic tomato was 
significantly higher than that with the wild-type tomato peel. 
 It is important to emphasize that none of the crops mentioned in this section are approved 
for commercial use and are currently at various stages of field trials. Scientific research is 
still needed to confirm the potential benefits and hazards of these crops. 
Genetically-engineering plants for resveratrol accumulation 
 Stilbene compounds, such as resveratrol, are flavonoid-type phytoalexins formed on the 
phenylalanine/polymate pathway (Jeandet et al, 2002). The terminal enzyme involved in 
resveratrol synthesis, stilbene synthase (StS) (a.k.a. resveratrol-synthase), catalyzes the 
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decarbocylative condensation of a p-coumaroyl residue from p-coumaroyl-CoA with three 
C2 subunits from maloynyl-CoA (Ruhmann et al, 2006). P-coumaroyl-CoA and maloynyl-
CoA are shared precursors for other polyphenolic compounds in the flavanoid biosynthesis 
pathway that are synthesized in a series of reactions initiating with one catalyzed by 
chalcone-synthase. Stilbene synthase and chalcone synthase (CHS) belong to the polyketide 
synthase (PKS) superfamily since they catalyze common condensation reactions of p-
coumaroyl CoA/cinnamoyl-CoA and three units from malonyl-CoA (Jeandet et al, 2002). 
Chromsomal DNA sequences show that StS enzymes from different plants share 70% 
identity to each other and many CHS enzymes, suggesting that StS evolved from CHS 
during plant evolution (Tropf et al, 1994). Stilbene-synthase and CHS catalyze different 
cyclization reactions to produce resveratrol and naringenin-chalcone, respectively, from the 
same precursors of p-coumaroyl CoA and three molecules of malonyl-CoA.  Naringenin-
chalcone is a precursor of various classes of flavonoid compounds, including flavones, 
flavonols, catechins, deoxyflavonoids and anthrocyanins (Schijlen et al, 2004).  
 Expression of StS is induced in plants by fungal infection and abiotic stimuli such as UV 
light and ozone (Jeandet et al, 2002). The exception seems to be in grape seedlings where 
StS is constitutively expressed (Sparvoli et al, 1994). As mentioned earlier, resveratrol is 
found in a variety of plant species, but in a limited number of varieties consumed by 
humans. The introduction of resveratrol into novel plants through genetic-engineering is 
theoretically an attractive plan since resveratrol is a proposed phytoalexin and has many 
purported health benefits (reviewed earlier). Therefore, such crops should offer both 
producer-oriented and consumer-oriented benefits. Furthermore, the introduction of a single 
gene is sufficient to synthesize resveratrol in plants, unlike the scenario faced with other 
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flavanoid compounds, where multiple genetic insertions may be required (Jeandet et al, 
2002).  
 To date, StS has been ectopically expressed in tobacco (Hain et al, 1993), rice (Stark 
Lorenzen et al, 1997),barley and wheat (Leckland et al, 1998), tomatoes (Thomzik, 1997), 
kiwi (Kobayashi et al, 2000), apple (Sparvoli et al, 1994; Ruhmann et al, 2006), white 
poplar (Giorcelli et al, 2004), arabidopsis (Yu et al, 2006) and rapeseed ( Husken et al, 
2005). Agrobacterium-mediated, biolistic and protoplastic techniques have all been 
employed in transforming crops to express StS from either grapevine or peanut sources.  In 
all experiments, the expression of single StS genes was optimized by using heterologous 
promoters and enhancer elements. The introduction of StS has resulted in plants that express 
resistance to a variety of pathogens, including Pyriculeria oryzoa in rice (Stark Lorenzen et 
al, 1997), Botrytis cinerea in wheat and barley (Leckland et al, 1998), Dhytophthora 
infestans in tomato (Thomzik, 1997) and Oidrum tuckeri in wheat (Leckland et al, 1998). In 
kiwi and white poplar, transformed plants did not express disease resistance against the 
pathogens examined, which are the exceptions to RS-transformed plants reported in the 
literature (Kobayashi et al, 2000; Giorcelli et al, 2004).  
 In the cases where the presence of resveratrol or derivatives thereof were examined in 
transformed plants using either HPLC units equipped with a diode array or mass 
spectrometer detector, resveratrol was demonstrated to accumulate almost exclusively in the 
form of trans-resveratrol-3-glucoside (piceid), suggesting that endogenous modification of 
resveratrol by a glycosyltransferase occurs. In arabidopsis, piceid was predominately 
identified in the cis- confirmation (Yu et al, 2006), whereas both trans-piceid and trans-
resveratrol-aglycone were identified in transformed tomato (Thomzik, 1997).  
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The accumulation of piceid has been reported to vary widely between plant species and 
cultivars genetically-modified to overexpress StS. Transgenic plant lines have been reported 
to accumulate as much as 400 ug piceid/g fresh weight of piceid, as in the case of tobacco 
(Fischer et al, 1997). In some plants, such as wheat and barely, piceid concentrations were 
very low in plants that contained only one copy of the StS gene, whereas higher yields and 
greater disease resistance was obtained in plants expressing multiple copies of the gene 
(Leckland et al, 1998). However, piceid could not be detected in a transformed apple 
cultivar which expressed 6 copies StS, indicating that gene silencing can occur in some 
plants with multiple copies of StS (Ruhmann et al, 2006). Piceid accumulation can also be 
restricted to certain tissues and, in many cases, appears to be age-dependent. In the kiwi 
plant, piceid accumulation was much higher in younger leaves (182 ug piceid/ g dry leaf 
weight) than in older leaves (20 ug/g dry weight) (Kobayashi et al, 2000). In apple, piceid 
accumulation varied between cultivars (Ruhmann et al, 2006). Piceid accumulated in both 
the ripe and unripe fruit of the transformed “Holsteir Cox” line of apple but was detected 
only in the unripe, green fruit of the ‘Elsteir’ cultivar. Flavonol levels were slightly 
decreased in the transgenic fruits that accumulated piceid; the levels of other polyphenolic 
compounds analyzed did not seem to be affected by the introduction of the StS transgene.  
 Phytochemical analysis of transformed StS-expressing plants has rarely been carried out, 
but the data that exist strongly suggest that substrate competition between flavonoid and 
resveratrol biosynthesis can occur. In apple, overexpression of StS and the consequent 
accumulation of piceid was accompanied by lower levels of flavonols (Ruhmann et al, 
2006). Overexpression of StS in tobacco resulted in male sterility and plants that produced 
faint pink flower petals, as opposed to the dark pink color observable in non-transgenic, 
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control tobacco plants (Fischer et al, 1997). This report suggested that the diminished flower 
pigmentation and male sterility was not the result of endogenous suppression of chalcone-
synthase, but rather due to competition for 4-coumaroyl CoA and malonyl CoA substrates 
between resveratrol and flavaonol biosynthesis, since certain flavonols play an important 
role in plant pigmentation and sterility. Decreased fertility and altered growth patterns have 
been described in other plants transformed to accumulate specific flavonoids (Schijlen et al, 
2004; review). Metabolic flux competition between endogenous pathways and ectopically 
introduced pathways can potentially pose a barrier in introducing a novel compound into 
plants. For example, substrate competition with the phenylpropanoid pathway leading to the 
accumulation of anthocyanins  was proposed  as the culprit in the failure to achieve high 
levels of isoflavonoids in transformed isoflavone-synthase-expressing, non-leguminous 
plant species (Yu et al, 2000). Consequently, the introduction of key enzymes involved in 
isoflavone synthasis into novel species has been met with little success beyond soybean 
plants and bacteria (McCue and Shetty, 2004; review).  
 Collectively, the contradictory results of these studies suggest that the introduction of StS 
into plants can lead to high accumulation of piceid and significant pathogen control, but the 
end result is not predictable and depends on the plant species and, in some cases, on plant 
age. It is conceivable that metabolic flux changes in flavanoid biosynthesis resulting from 
the overexpression of StS is the cause of the discrepancy in pathogen protection noted in 
certain transformed plants, because the introduction of RS into some plants may alter 
changes in defense systems involving other flavanoid compounds. However, this is purely 
speculative since the mechanism (s) behind the purported phyoalexin capabilities of 
resveratrol has not been entirely elucidated (Hammershcmidt, 1999). Studies with GM 
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plants reveal that one of the major considerations in developing a natural food product to 
produce higher yields of resveratrol is endogenous modification of resveratrol in the plant. 
Metabolic engineering of other plant species have also resulted in the accumulation of a 
glycosylated or methylated version of the flavonoid compound (Deavours and Dixon, 2005). 
Not much is known about the modifying enzymes and corresponding genes responsible for 
these endogenous modifications in plants.  
Transgenic piceid-accumulating alfalfa 
 The transgenic alfalfa used in our studies was originally produced to protect the plants 
against root rot caused by the fungal pathogen Phoma medicaginis. The original alfalfa 
plants (Medicago sativa variety Regen SY) were transformed with a peanut (Arachis 
hypogaea) cDNA encoding resveratrol-synthase under the transcriptional regulation of the 
enhanced cauliflower mosaic virus 35S promoter (Hipskand and Paiva, 2000). As with most 
of the plants genetically-modified to synthesize resveratrol, the transformed alfalfa plants 
demonstrated resistance against a notable plant pathogen (Phoma medicaginis). And, as with 
other plants that over-express RS, resveratrol accumulated as trans-resveratrol-3-O-
glucoside (piceid) in the transformed alfalfa plants, as confirmed by high-pressure liquid 
chromatography (HPLC) and 1H and 13C-nuclear magnetic resonance (NMR) analysis. 
Piceid was detected at the highest concentrations in the youngest leaves (expressed as 0.5-20 
µg resveratrol-equivalents/g fresh tissue, due to the lack of appropriate piceid standards 
available at the time of the study). Roots contained only trace amounts of piceid (<0.2 µg 
resveratrol equivalents/ g fresh tissue) as well as sprouts (Paiva, personal communication). 
Roots and sprouts accumulate high levels of flavanoids and isoflavones. However, the low 
concentrations of piceid in these tissues were not attributed to compentition between the 
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flavonoid and stilbene biosynthesis pathway, since chalcone-synthase mRNA levels were 
higher in these tissues relative to RS mRNA levels. 
 Alfalfa is a highly utilized crop because of its productivity and high feed value. It is a 
very rich source of protein (which constitutes 15-22% of the plant), vitamins and minerals 
(North American Alfalfa Improvement Conference (NAAIC), 2005). Alfalfa also contains 
numerous secondary metabolites such as saponins, flavonoids, tannins, carotenoids and 
tocols (Stochmal et al, 2001). Some of the major flavonoids identified in alfalfa include 
glycosides of apigenin, lutelin, tricin and chrysoeriol (Stochmal et al, 2001 a and b). Alfalfa 
is primarily used as a forage crop and is the fourth most widely grown crop in the United 
States behind corn, wheat and soybeans (NAAIC, 2005). In addition to its use in animal 
feeds, alfalfa is consumed by humans in the form of sprouts and occasionally as a tea or 
juice. Alfalfa offers many characteristics that make it an ideal crop for biotechnology 
applications. Its vegetative growth can be maintained for years; clonal propagation through 
stem cuttings can make batch-to-batch reproducibility of protein expression in the plant a 
highly feasible task; and modern varieties are capable of expressing high amounts of protein 
(D’Aoust et al, 2004).   
 We were interested in determining if the transgenic, piceid-accumulating alfalfa could 
provide any additional health benefits beyond those that can be obtained from normal, non-
transgenic alfalfa. Specifically, we analyzed the bioactivity of the transgenic alfalfa in the 
colon against AOM-induced carcinogenesis in CF-1 mice as resveratrol has purported 
chemopreventive properties in the colon (reviewed earlier) and the Birt laboratory is 
experienced in working with this rodent model of colon carcinogenesis (Au et al, 2006). 
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The initial studies with transgenic alfalfa, as discussed in more detail in chapter 2, 
revealed that piceid may not be bioavailable. The primary focus of this thesis was to test the 
hypothesis that piceid from the transgenic alfalfa is not bioavailable and that additional 
strategies are required to liberate the more bioavailable, native resveratrol-aglycone 
compound from piceid making the transgenic alfalfa more bioactive against the formation of 
AOM-induced ACF lesions in the colon of CF-1 mice. The strategies employed in the 
studies included supplementing diets containing the alfalfa with exogenous ?-glucosidase 
enzymes. The hypothesis was tested by examining the effect that these dietary preparations 
had on the formation of AOM-induced ACF in the colon of CF-1 mice and the resulting 
colonic and plasma concentrations of resveratrol following the administration of these diets 
in 5-week periods. The mechanism of the intestinal bioavailability of piceid was assessed by 
examining the substrate suitability of piceid for lactase phorizin hydrolase in the small 
intestine. 
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Abstract 
 
Plants have been genetically enhanced to produce a number of products for agricultural, 
industrial and pharmaceutical purposes. This technology could potentially be applied to 
providing chemoprevention strategies to the general population. Resveratrol (3,5,4’ – 
trihydroxystilbene) is a compound that has been shown to have protective activity against a 
number of cancers and could be an ideal candidate for such an application. Alfalfa that was 
genetically modified to express resveratrol-synthase was used as a model in applying 
biotechnological approaches to cancer prevention. The transgenic alfalfa, which accumulates 
resveratrol as a glucoside (piceid = trans-resveratrol-3-O-?-D-glucopyranoside) (152 ± 17.5 
µg piceid/g dry weight), was incorporated into a standard mouse diet at 20% of the diet by 
weight and fed for 5 weeks to  6-week old, female CF-1 mice (N=17-30) that were injected 
with a single dose of azoxymethane (5 mg/kg body weight). While the addition of 
resveratrol-aglycone (20 mg/kg diet) to the basal diet reduced the number of aberrant crypt 
foci/mouse, the transgenic alfalfa did not inhibit the number, size or multiplicity of aberrant 
crypt foci in the colon of the CF-1 mice relative to control alfalfa which does not accumulate 
resveratrol-glucoside. However, diets containing transgenic alfalfa with an exogenous ?-
glucosidase (860 U/kg diet) did significantly inhibit the number of aberrant crypt foci in the 
distal 2 cm of the colon of the mice relative to mice fed diets containing the transgenic 
alfalfa without the enzyme (p<0.05; Fisher’s Combination of p-values). The ?-glucosidase 
alone appeared to have no effect on the inhibition of aberrant crypt foci. These results 
suggest that piceid in transgenic piceid-accumulating alfalfa was not bioavailable.  
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Introduction 
 Colorectal cancer is the third most common cause of cancer-related illness in adults 
living in the United States (1). Data from case-control studies have suggested that diets rich 
in fruits and vegetables are protective against colon cancer (2), although findings from 
recent prospective studies reveal that this correlation may not indicate a causal relationship 
(3,4). Plants produce an array of phytochemicals as secondary metabolites for defense 
purposes (5). Several of these compounds have been shown to have cancer-preventing 
activity in laboratory studies (6). However, the concentration or bioavailability of these 
health-beneficial constituents is often very low in edible plants (7), which may partially 
explain the inconsistency between epidemiological and recent prospective studies. In recent 
years, there has been increased interest in developing strategies to grow crops for health-
promoting purposes (8). Genetic-engineering approaches have been successfully employed 
to increase the yield or introduce polyphenolic compounds into plant crops (9). A successful 
chemoprevention strategy could involve genetically modifying crops to increase the 
availability of some of these bioactive constituents.  
 One of the most studied phytochemicals in recent years has been resveratrol (3,5,4’-
trihydroxystilbene). Resveratrol is a phytoalexin synthesized in a variety of plant species in 
response to external stresses such as injury, UV irradiation and fungal infection (10). In the 
human diet, resveratrol was found in highest concentrations in red wine, grapes and peanuts 
(11,12). Epidemiological studies have shown an inverse correlation between the intake of 
red wine and the incidence of cardiovascular disease (13). It is proposed that resveratrol is  
partly responsible for the health benefit acquired from red wine.  
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Interest in resveratrol as a chemopreventive or therapeutic agent stems from an earlier 
report that showed that resveratrol inhibited cellular events associated with all stages of 
carcinogenesis - tumor initiation, promotion and progression (14). Since then, resveratrol 
has been shown to have growth inhibitory activity in a variety of human cancer cell lines 
and in animal models of carcinogenesis (15 and references therein).  
 A transgenic alfalfa that accumulates resveratrol (152 ± 17.5 Mg resveratrol-glucoside /g 
dry weight) was developed to protect alfalfa against root rot (16). Alfalfa normally does not 
express resveratrol-synthase (RS) and, therefore, does not produce resveratrol. In the 
transgenic alfalfa, RS catalyzes the synthesis of resveratrol from the metabolic precursors p-
coumaroyl CoA and malonyl CoA. Resveratrol in these plants is accumulated as trans-
resveratrol-3-O-?-D-glucopyranoside (also known as piceid (RG)). 
 The aim of the present study was to investigate the potential effects of the alfalfa that was 
genetically-modified to express RS on colon carcinogenesis in the mouse model of 
azoxymethane (AOM)-induced carcinogenesis using aberrant crypt foci (ACF) as short-term 
markers. ACF are putative preneoplastic lesions that directly correlate to risk of colon 
cancer and tumor size in humans (17). Resveratrol was previously reported to inhibit the 
number and multiplicity (aberrant crypts per focus) of AOM-induced ACF in the colorectal 
mucosa of F344 rats (18). Mucin-depleted foci (MDF) and ?-catenin accumulated crypts 
(BCAC) are subsets of ACF that have been identified on the bases of morphological and 
biochemical changes, respectively (19). Both MDF and BCAC are purported precancerous 
lesions but are currently not well characterized. Since ACF are widely accepted biomarkers 
for assessing the chemopreventive potential of agents in the colon, for our initial studies of 
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the transgenic resveratrol-accumulating alfalfa, we elected to use classic ACF lesions to 
assay the potential potency of this crop against colon cancer.   
 We report here that transgenic alfalfa that accumulates RG in combination with an 
exogenous ?-glucosidase inhibited the number of ACF in the distal colon of CF-1 mice. This 
apparent protective effect against AOM-induced ACF was not observed with the transgenic 
alfalfa or the ?-glucosidase alone. These results suggest that RG is not bioavailable and that 
the modification of polyphenolic-glucosides by endogenous enzymes may be needed to 
realize the potential health benefits of this transgenic crop. 
Materials and Methods 
Reagents and Chemicals: 
 Trans-resveratrol-aglycone (Rag) was purchased from the Toronto Research Institute 
(Ontario, Canada). The purity of the resveratrol was estimated to be > 98% by the 
manufacturer. L-galactosidase from Aspirgillus niger was purchased from the National 
Enzyme Company (Forsyth, MO). High-performance liquid chromatography (HPLC) grade 
acetone and acetonitrile were purchased from Fisher Scientific (Liberty Lane Hampton, 
NH). All diet ingredients were purchased from Harland Tekland (Madison, WI). All other 
reagents were purchased from Sigma-Aldrich (St. Louis, MO). 
Transgenic Alfalfa: 
 A single alfalfa (Medicago sativa) genotype from the Regen SY germplasm (20) was 
transformed with resveratrol-synthase (RS) cDNA from peanut (Arachis hypogaena) and 
analyzed for the presence and expression of RS and the accumulation of the RG metabolite 
at the Samuel Roberts Noble Foundation in Oklahoma as previously described (16). Clones 
of the transformed plant as well as untransformed control clones of the same genotype were 
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grown at the Samuel Roberts Noble Foundation in Oklahoma and shipped to Iowa following 
drying and grinding as described below. They were planted in the field at Ames, IA in 
adjacent plots, last harvested in October 2004. When plants reached the late bud or early 
flower stage, they were harvested by clipping aboveground biomass at 5 cm. Biomass was 
subsequently washed with water and dried in a forage drying oven at 55°C. The dried plant 
material was coarsely ground in a Wiley mill and the re-ground to a powder in a UDY mill 
with a 1mm exit filter. 
Mice and Diets: 
 CF-1 mice (6 weeks old) were obtained from the Charles Rivers laboratory (Wilmington, 
MA) and housed individually in stainless steel wire-mesh cages in a temperature controlled 
room with a 12-hour light:dark cycle. After one week of acclimatization, the mice received 
one intraperitoneal injection of AOM (5 mg/kg body weight) or saline. Three days after the 
injections, the mice were randomized and assigned to experimental diets, which they were 
fed ad-libitum, for 5 weeks (N=3-10/group in 3 replicates). Mice were assigned to one of 
four diets: 1). A basal diet (BD) based on the standard diet recommended by the American 
Society for Nutritional Sciences, report for mature rats (AIN-93) (21), 2). BD with control 
alfalfa (CA), 3). BD with transgenic alfalfa (TA) and 4). BD with Rag.  
 Diets were prepared by mixing all dry ingredients with water (25% by dry weight of 
diet). Diets were then rolled out, cut into thin strips and dried at room temperature. Alfalfa 
was added at 20% by dry weight into the diets in partial replacement of dextrin (60% of 
dextrin added to control diets) (Table 1). The TA that was added to the diets contained 152 
± 17.5 µg RG /g dry weight, thus these diets contained 30.5 ± 3.5 mg RG/kg diet. Trans-
Resveratrol-aglycone (Rag) was added to the diets in equal molar concentration (20 mg/kg 
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diet) to the RG by dry weight of the diet. In subsequent experiments, ?-glucosidase was 
added to diets at 860 U/kg of dry diet. Since purified -glucosidase was not commercially 
feasible at the time of this study, L-galactosidase, which was verified to have 12.5 ± 0.5 U ?-
glucosidase activity/mg, was used as a source of glucosidase activity. The amount of L-
galactosidase (2600 L-galactosidase U/kg of diet) added to diets was determined by 
extrapolating the recommended human dose of Beano to mice on a daily energy basis 
(equal to 0.675 L-galactosidase U /Kcal in humans).  
Resveratrol-glucoside identification in diets by HPLC analysis 
To confirm the stability and uniform distribution of RG and Rag in diets, 2 g of crushed 
diet sample was extracted in 50 ml of a 90% methanol/10% water (v/v) solution at room 
temperature for 2 days under minimal light exposure. The samples were centrifuged at 1000 
x g and the supernatants were evaporated and reconstituted in 1 ml methanol. The extracts 
were filtered and 10 Ml of each extract was injected into a C18 column (2.1*150mm; Alltech 
Altima). Compounds were separated using a 45-minute gradient from 20-60% of acetontrile 
in water with a flow rate of 0.3 ml/min. Eluding peaks were monitored at V=308 and 280 nm 
with a UV diode array detector (Beckman Instruments, Fullerton, CA). The spectra of peaks 
at 308 nm were compared to those of a trans-resveratrol-glucoside standard (Apin 
Chemicals, UK). 
Analysis of ß-glucosidase activity in diets 
 To estimate the ?-glucosidase activity of L-galactosidase, the procedures described by 
King (22) were followed with some modifications. Briefly, various concentrations of L-
galactosidase (250-2500 ng/ml) were incubated with 1 mM of 4-methylumbelliferyl-?-D-
glucoside for 30 minutes at 37°C. The reaction was stopped using sodium citrate, and the 
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florescence of the final product (4-methylumbeliferone) was measured using a Sequoia 
Turner Model 450 fluoromoter set at gain 1 with 360 nm excitation and 450 nm emission. 
 To measure ?-glucosidase activity in the diets, 0.2 g of diet sample was crushed in a 0.1 
M citric acid/0.2 M sodium phosphate buffer (pH=5.0). The suspension was vortexed and 50 
Ml was added to 450 Ml of 1 mM 4-methylumbelliferyl-?-glucoside and incubated for 30 
minutes at 37°C. The reaction was stopped by the addition of 1.5 M sodium citrate. The ?-
glucosidase activity of assayed samples was quantified by comparing the fluorescent 
readings of the final reaction to the concentration vs. the fluorescence curve of a 4-
methylumbeliferone standard.  
Analysis of Aberrant Crypt Foci 
 After feeding the experimental diets for five weeks, mice were killed by decapitation. 
The colon and rectum were collected from each mouse and rinsed thoroughly with 
phosphate buffer saline (PBS). The colon and rectums were dissected longitudinally and 
fixed flat in 10% buffered formalin (pH 7.5) for 24 hours. The samples were stained with 
0.2% methylene blue for 10 minutes and the ACF/colon were scored for each mouse at 10-
fold magnification as described by Bird (23). ACF number, size, multiplicity (number of 
AC/focus) and distribution were recorded in 2 cm increments, starting at the rectum in a 
blinded fashion. The sizes of ACF were scored with an eyepiece graticule.  
Statistical Analysis 
 The data presented in this paper were analyzed using SAS software (SAS Institute) and 
are expressed as means ± SE. The first experiment was conducted in three replicates ,and the 
significance of the differences between ACF means, changes in body weight (final weight-
initial weight) and food consumption (g/food/day) were assessed by performing a two-way 
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analysis of variance (ANOVA). Specific differences between groups were analyzed using a 
student’s t-test as the post-hoc test. Because the availability of alfalfa at harvest times was 
limited due to the weak growth performance of both the non-transformed and transformed 
alfalfa lines, follow-up comparisons of diets with and without L-galactosidase were 
conducted in multiple studies following different harvests. In these follow-up studies, group 
means within experiments were analyzed using a one-way ANOVA followed by a student’s 
t-test for specific comparisons. Treatment comparisons between follow-up experiments were 
made using Fisher’s procedure for combining p-values (24). All statistical tests performed 
on the data were two-sided, and a value of P<0.05 was considered statistically significant. 
Results 
D-glucosidase activity of E-galactosidase 
 The relationship between the amount of 4-methylumbelliferone (4-MU) formed vs. L-
galactosidase concentration was linear in the concentration range of 125-2,000 ng 
enzyme/ml following incubation with the substrate 4-methylumbelliferone-?-D-glucoside(4-
MUG) for 30 minutes at 37°C (Figure 1). The standard curve plot for the relationship 
between fluorescence vs. the amount of 4-MU was linear, in the range of 0.003-0.05 Mmoles 
of 4-MU (Figure 1, insert). This plot was used to convert fluorescent readings to 4-MU 
produced in the ?-glucosidase-catalyzed deglycosylation of 4-MUG. Based on this 
assessment, the ?-glucosidase activity of L-galactosidase was estimated to be 12.5 ± 0.5 ?-
glucosidase U (Mmoles 4-MU liberated from 4-MUG) mg enzyme-1 min-1. To test the 
reliability of our assay, a ?-glucosidase enzyme (Sigma Aldrich, G0395 more) with a 
reported activity of 2.1 ?-glucosidase U mg enzyme-1 min-1 was measured as well. The 
measured fluorescence of the ?-glucosidase enzyme was linear in the concentration range of 
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200-4000 ng/ml (figure 2) with an estimated activity of 1.9 ± 0.03 ?-glucosidase U mg 
enzyme-1 min-1.
Effect of diets on body weight and food consumption 
 The mice gradually gained weight throughout the duration of the experiment but, as table 
2 demonstrates, the change in body weight [(final weight (29.6 ± 2.4 g) – initial weight (26.4 
± 2.1 g)] between treatment groups was not significantly (mean gain= 3.2 ± 1.6 g, p=0.5). 
Food intake (g/mouse/day) did not differ between treatments in the first experiment (4.0 ± 
0.4 g/day/mouse, p-value=0.23). Also, there was no difference in change in body weight or 
in food intake in mice fed diets supplemented with L-galactosidase compared to mice that 
were fed diets that did not contain the enzyme in the follow-up experiments (data not 
shown). 
Effect of treatments on formation of aberrant crypt foci in experiment 1 
 The number of aberrant crypts was scored for different regions of the colon as defined by 
2 cm increments starting at the most distal end adjacent to the rectum. Aberrant crypts 
formed mainly in the distal 2 cm of the colon. The number of ACF in the most distal 2 cm of 
the colon was significantly lower in mice fed basal diets supplemented with Rag relative to 
the other diets (p-value < 0.05) (table 2). However, the number of ACF in the distal colon of 
mice fed TA was not significantly different from mice fed CA (p=0.5). Additionally, the 
number of ACF in the colon of mice fed CA with Rag (means= 2.5 ± 1.8 and 5.8 ± 1.5 in 
two replicates N= 5 and 9) was not significantly reduced compared to mice fed CA diets 
without Rag (means= 4.8 ± 2.5 and 8.8 ± 1.7 in two replicates N=10 each, p= 0.5 for first 
replicate comparison and p=0.2 for second replicate comparison).     
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There was no significant difference in the multiplicity (mean of all treatments= 1.4 ± 0.4 
AC/focus, p=0.3) of ACF or number of ACF in the middle 2 cm (mean of all treatments=2.4 
± 2.5, p= 0.3) and proximal 1 cm (mean of all treatments=0.3 ± 0.7, p=0.1) of the colon in 
the CF-1 mice. There was also no significant difference in the size of ACF (mean=2.0 x 10-2  
± 0.7 x 10-2 mm2, p=0.4), although this was assessed in only two of the three replicates. ACF 
were detected in 8% (4/50) of mice injected with saline and were not confined to any single 
treatment. 
 The amount of alfalfa added to the diets (20% by dry weight) was derived from previous 
studies in our lab showing that the number of AOM-induced ACF lesions in the colon of 
CF-1 mice fed diets containing resveratrol concentrations as low as 20 mg Rag/kg of diet 
(equivalent to the number of moles of piceid in diets containing 20% of the transgenic 
alfalfa) were significantly reduced (data not shown). Resveratrol at higher concentrations 
(40- 100 mg Rag/kg diet) significantly inhibited the number of ACF lesions formed, but the 
differences between these groups were not significant. Furthermore, we were concerned that 
supplementing alfalfa beyond 20% by dry weight would compromise the nutritional 
integrity of the diets.  
Effect of treatments with '-glucosidase on formation of aberrant crypt foci in follow-up 
experiments. 
As with the first experiment, the incidence of ACF was mainly limited to the distal 2 cm 
of the colon in all follow-up studies. The number of ACF in the entire colon and distal 
region of the colon was significantly reduced in the mice fed diets containing TA with L-
galactosidase compared to the number of ACF in mice fed diets containing TA without 
exogenous L-galactosidase (Table 3).  The difference in the number of ACF in the entire 
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colon or distal 2 cm of the colon was not significant between the BD and the BD containing 
L-galactosidase nor was the number of ACF different between diets containing 20% CA and 
diets containing the CA with L-galactosidase. ACF number did not differ between 
treatments with or without L-galactosidase in the middle or proximal region of the colon in 
any of these studies (data not shown). Size of ACF was assessed in only one replicate for 
each treatment in follow-up studies. As with the first study, there was no significant 
difference in ACF size (mean= 2.7 x 10-2 ± 0.6 x 10-2 mm2 , p=0.8) or multiplicity (mean= 
1.4 ± 0.5; p=0.2) between treatments in the follow-up studies.  
Discussion 
 The principal finding of this study was that TA that accumulates RG in combination with 
an exogenous ?-glucosidase was effective in inhibiting the formation of ACF in the distal 
colon of CF-1 mice. Neither of these treatments alone was effective in reducing ACF. The 
number of ACF was reduced by an average of 32% and 87% in mice fed the TA with the 
exogenous glucosidase relative to mice fed the TA alone in two replicates where these 
groups were included together. ACF number was reduced by 52% in mice fed diets with 
purified Rag that was added in equal molar concentrations to that of the RG in TA. The 
protective effect of the TA in combination with ?-glucosidase was not due to the presence of 
other plant metabolites present in alfalfa since CA supplemented at 20% by dry weight into 
the diet did not inhibit ACF development in the colon of CF-1 mice regardless of whether or 
not ?-glucosidase was added. These results imply that RG may not be bioavailable and 
modification of secondary metabolites by endogenous enzymes in the plant is an important 
consideration when assessing the potential health-benefits of a crop genetically-enhanced to 
produce high levels of these compounds. To our knowledge this is the first in-vivo 
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demonstration of the potential health benefits of a genetically modified crop against a 
biomarker of cancer.  
 Resveratrol is found in low and variable amounts in relatively few sources in the human 
diet. Resveratrol content is very low in peanuts (< 1µg/g wt) and grapes (< 10 µg/g fresh 
wt), which are two major dietary sources of resveratrol (12, 25). Furthermore, the majority 
of resveratrol found in grapes is in the form of cis- or trans-piceid with the aglycone 
comprising only a small fraction of the detectible levels of resveratrol (< 0.6 Mg Rag/g fresh 
wt). In the human diet, resveratrol is found in highest concentrations in red wine. However, 
analysis of different red wines revealed that trans-resveratrol-aglycone content of wines can 
vary (0.1 – 14 mg/L) depending upon the cultivar of grape used,  the climate in which the 
grapes were grown, and the maceration process followed (12, 26, 27, 28). Trans-piceid has 
also been identified at appreciable levels in red wine, in some cases as high as 50.8 mg/L. 
Genetic-engineering strategies could provide a means to increase the dietary availability of 
resveratrol to humans through additional food options.  
 In addition to alfalfa, several other plants have been genetically modified to express 
resveratrol-synthase for agronomical purposes, including tobacco (29), rice (30), barley 
(31), kiwi (32), and apple (33). Resveratrol was reported to accumulate as a glucoside in all 
of these plants when the presence of the resveratrol was assessed. 
 The present study suggested that RG was not as bioavailable or as bioactive as Rag for 
ACF prevention, since the addition of an exogenous ?-glucosidase to TA was required to 
achieve a reduction in AOM-induced ACF in the colorectal mucosa of CF-1 mice. TA alone 
was not protective against AOM-induced ACF. We hypothesize that the supplemented 
glucosidase catalyzed the liberation of the more bioavailable aglycone moiety from RG in 
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diets containing the TA. Diets which contained the exogenous glucosidase with CA did not 
reduce the number of ACF in the colon of CF-1 mice, suggesting that the protective effect of 
the glucosidase was associated with the RG in the transgenic alfalfa. This was a surprising 
observation as alfalfa contains numerous secondary metabolites (34, 35). The total 
concentration of flavonoids in alfalfa has been shown to range from 0.24 to 0.78% in dry 
matter with the majority of identified compounds being glycosides of apigenin, luteolin and 
tricin (34). The TA used in our study contained, on average, 0.015% RG by dry weight. It is 
possible that most of the natural-occurring polyphenols in alfalfa are not bioactive or some 
of the more active compounds are not present in very high concentrations. 
 Few studies have reported on the bioactivity or bioavailability of RG. RG was shown to 
inhibit platelet aggregation (36) and inhibit thymine incorporation into DNA in Lewis lung 
carcinoma cells (37). However, the effective dose in the later study was 100 MM (IC > 1000 
MM), bringing into question the potential bioactivity of RG. In the Kimura et al study (37), 
RG inhibited tumor growth in the paw of C57BL/6 mice that were transplanted with Lewis 
lung carcinoma cells, although his protective activity was achieved by the administration of 
very high doses of RG at 300 mg kg-1 daily for 32 days. Lower doses were not reported in 
this study. Assays conducted in Caco-2 monolayer systems reveal that the sodium-glucose 
co-transporter (38) and lactase phorizin hydrolase (39) may play an important role in the 
absorption and deglycosylation of RG in the intestine. In the former study, the uptake of Rag 
in Caco-2 cells was more rapid than RG with the intercellular concentrations of Rag 
remaining at least 4 times higher than RG at all time points examined in Caco-2 cells that 
were treated with 150 MM of each compound (38). In a recent study, RG was detected in a 
variety of tissues, including the brain, heart, liver and lungs in Wistar rats within 20 minutes 
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of the rats receiving a single, oral dose of piceid (50 mg/kg body weight) suspended in a 5% 
sodium carboxymethylcellulose solution (40). Plasma concentrations of RG reached a peak 
concentration of 0.9 ± 0.4 MM at 20 minutes post-dose administration. Unfortunately, side-
by-side comparisons with Rag where not featured in this study. To our knowledge, the colon 
bioavailability of piceid has not yet been examined. 
 Rag was shown to inhibit chemically induced ACF in rodents in at least two other 
studies. Rag at daily doses of 200 µg kg-1 body weight via 10% ethanol in drinking water 
reduced the number, multiplicity and size of AOM-induced ACF in the colorectal mucosa of 
F344 rats (18).  In a more recent study, Sengottuvelan et al showed that Rag (8 mg kg-1 body 
weight p.o., daily) reduced the number, multiplicity and size of ACF in rats injected weekly 
with 1,2-dimethylhydrazine (DMH) (20 mg kg-1 body weight for 15 weeks) (41). This group 
has also reported that Rag reduced the number of DMH-induced colonic tumors in rats 
regardless of whether Rag was administered before or following DMH injections (41, 42). In 
contrast, reports of resveratrol treatment on tumor incidence in C57BL/6J APCMin mice with 
genetic colon cancers caused by mutant adenomotosis polyposis coli (APC) have been 
inconsistent (43, 44). Studies with Rag have been conducted in Min mice between the ages 
of 4-5 weeks, which may represent a more advanced stage of cancer since preneoplastic 
lesions begin to develop in the small intestine of these mice in utero (45) and may indicate 
that resveratrol may be more valueable as a preventive rather than a therapeutic agent in the 
colon. A number of biological activities have been ascribed to resveratrol which may, at 
least partially, explain any anti-cancer properties that the chemical may possess. Resveratrol 
has been demonstrated to prevent free-radical formation and have anti-mutagenic activity; 
inhibit activity of cytochrome P450 enzymes; inhibit cyclooxygenase-2 catalyzed reactions; 
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induce phase-2 drug metabolism; induce cell cycle arrest and apoptosis (46 and references 
therein). Additional studies are warranted to determine resveratrol’s mechanism of action in 
the colon.  
 In conclusion, we have demonstrated that transgenic alfalfa that accumulates resveratrol-
glucoside did not inhibit AOM-induced ACF in the colorectal mucosa of CF-1 mice, but the 
addition of an exogenous glucosidase enzyme to diet preparations containing the transgenic 
alfalfa seemed to be protective against AOM induction of ACF in the distal colon of CF-1 
mice. Our data suggests that future studies on the bioavailability and bioactivity of RG are 
essential in determining the therapeutic value of resveratrol as a nutraceutical. In addition, 
we have offered a strategy whereby other transgenic crops may be analyzed for their heath-
benefiting value.   
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Table 1: Comparison of Diets 
 
Basal Diets with alfalfa 
Casein (g/kg) 200 200 
Dextrin (g/kg) 499.5 299.5 
Alfalfa (g/kg) - 200  
Dextrose (g/kg) 150 150 
Fiber (g/kg) 50 50 
Mineral mix (g/kg) 35 35 
Choline (g/kg) 2.5 2.5 
Methionine (g/kg) 3.0 3.0 
Vitamin mix (g/kg) 10 10 
Corn oil (g/kg) 50 50 
Trans-resveratrol-aglycone was added to some basal and control alfalfa diets at 0.002% by 
dry weight which was equivalent to the number of moles of piceid present in diets 
containing the transgenic alfalfa which accumulates 170 Mg piceid/g wt of plant. In follow-
up studies, L-galactosidase was added at 860 ?-glucosidase U (2600 L-galactosidase U/kg) 
to basal, control alfalfa and transgenic alfalfa diets. 
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Table 2: Number of azoxymethane-induced Aberrant Crypt Foci and multiplicity (Average number of aberrant crypts per focus)
in the colon of CF- mice.
Region of colon (ACF/mouse)
Treatment N Gain in Body
Weight
(Initial Body
weight) (g)
(ANOVA p-
value=0.5)
Total
ACF/mouse
(ANOVA p-
value =0.09)
D (ANOVA
p-
value=.0023)
M (ANOVA
p-value
=0.3)
P (ANOVA p-
value =.11)
Multiplicity
(AC/focus)
(ANOVA p-
value=0.3)
Basal (BD) 25 2.8 ± 0.3
(26.9 ± 0.4)
8.4 ± 1.1 5.4 ± 0.7 2.8 ± 0.5 0.2 ± 0.2 1.5 ± 0.1
Control Alfalfa
(CA)
17 3.3 ± 0.5
(26.3 ± 0.5)
7.9 ± 1.3 4.3 ± 0.9 3.1 ± 0.6 0.5 ± 0.2 1.5 ± 0.1
Transgenic
Alfalfa (TA)
21 3.1 ± 0.4
(27.1 ± 0.5)
7.2 ± 1.2 5.1 ± 0.8 1.9 ± 0.6 0.4 ± 0.2 1.5 ± 0.1
BD +
resveratrol-
aglycone
30 3.4 ± 0.3
(25.8 ± 0.4)
4.4 ± 1.01 1.9 ± 0.62 2.2 ± 0.5 0.3 ± 0.1 1.3 ± 0.1
Values represent mean ± SE (2-way ANOVA with student’s t-test post-hoc analysis; SAS software). This experiment was
conducted in three replicates with between 3 and 10 mice per group. The regions of the colon are defined as follows: D= distal 2
cm, M= second 2cm from distal end, P=proximal 1 cm. 1 p<0.05 compared to BD and CA groups for total ACF. 2p<0.05
compared
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to BD, CA and TA treatments in the rectal region of the colon. ACF size was also assessed 
in some studies but no significant difference between treatments was observed in all of the 
studies where this parameter was examined (p>0.33 for all studies; one-way ANOVA with a 
student’s t-test as the post-hoc analysis; SAS software). Mice from each treatment were also 
injected with saline. Aberrant crypts were observed in 8% of saline treated mice (4/50), but 
were not confined to any single treatment.  
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Table 3: The addition of ?-glucosidase activity to Transgenic alfalfa diets reduced the number of ACF in the colon of CF- mice.
Without Enzyme With Enzyme
Treatment
Comparison
Study N Mean ± SE
(Total colon)
Mean ± SE
(Distal 2 cm)
N Mean ± SE
(Total colon)
Mean ± SE
(Distal 2 cm)
p-value*
(Total
colon)
p-value*
(Distal 2
cm)
1 10
BD
6.9 ± 1.5
BD
3.8 ± 0.9 10
BD+E
9.9 ± 1.5
BD+E
4.6 ± 0.9BD vs. BD+E
2 10 8.6 ± 1.3 5.9 ± 0.1 9 11.7 ± 1.4 6.6 ± 1.0
> 0.1
(0.2, 0.1)
0.7
(0.5, 0.6)
1 10
CA
3.3 ± 1.5
CA
1.5±0.93 10
CA+E
5.1 ± 1.5
CA+E
2.2 ± 0.93
CA vs. CA+E
2 4 10.3 ± 2.4 7.3 ± 1.6 4 8.0 ± 2.1 5.3±1.6
>0.3
(0.3, 0.5)
>0.5
(0.6, 0.4)
1 10
TA
3.0 ± 0.9
TA
1.9±0.8 10
TA+E
0.8 ± 0.9
TA+E
0.6 ± 0.4
TA vs. TA+ E
2 3 10.4 ± 2.4 8.7 ± 1.8 3 1.3 ± 2.4 1.0±1.8
< 0.01
(0.06,
<0.01)
<0.01
(0.1,
<0.005)
Values represent mean ± SE. Diets are defined as follows: BD= basal diet, CA=control alfalfa, TA=transgenic alfalfa, E= L-
galactosidase and R= resveratrol-aglycone. Diets with L-galactosidase contained 2600 L-galactosidase U/kg diet and 860 ?-
glucosidase U/kg diet. *Comparing no enzyme vs. enzyme treatments p-values were derived using Fisher’s combination of tests of
significance analysis. P-values for individual studies are listed in the parantheses under the combined p-values for each
comparison.
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Figure 1: ?-glucosidase activity of L-galactosidase (National Enzyme Company) and ?-
glucosidase (G0395, Sigma Aldrich). i-glucosidase activity was expressed as a function of 
4-methylumbelliferone formed after incubating the enzymes with the substrate 4-
methylumbelliferone- ?-glucoside for 30 minutes @ 37ºC. Values represent means ± SE 
(N=6). Linear parameters were as follows: (for L-galactosidase) slope= 2 x 10-5, y-intercept= 
0.0007 and R2=0.9993; (for ?-glucosidase) slope=3 X 10-6, y-intercept=--.0001 and 
R2=0.997. Fluorescent units (recorded at 360 nm excitation and 450 nm emission) were 
converted into Mmoles of 4-methylumbelliferone formed based on the relationship between 
fluorescence and concentration of 4-MU authentic standards (see insert). This relationship 
was linear in the concentration range of 0.003-0.05 umoles of 4-MU (linear parameters 
were:  slope= 34142, y-intercept = 136.89 and R2= 0.9683).  
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Abstract 
 
Based on our previous findings, we tested the hypothesis that piceid (resveratrol-glucoside, 
RG) is not bioavailable from transgenic alfalfa that accumulates RG. Transgenic alfalfa 
(TA) which contained 193 ± 18 Mg RG /g dry weight was incorporated into diets at 20% by 
dry weight and fed to female, 6-week old CF-1 mice for 5 weeks. The supplementation of 
860 ?-glucosidase U/kg diet to transgenic alfalfa and control diets with authentic RG 
reduced the number of azoxymethane (AOM)-induced aberrant crypt foci (ACF) in the 
colon of CF-1 mice fed these diets by 36%  and 41%, respectively, compared to transgenic 
alfalfa and RG, alone. The incidence of Rag detection was significantly less in the TA group 
relative to TA with E1 (60 vs. 100%, respectively, p<0.05). Colonic concentrations of 
resveratrol-aglycone (Rag) (< 0.5 nmol/g tissue) in mice fed TA with enzyme (0.22 ± 0.18 
nmol/g tissue) tended to be higher than in animals fed diets without the enzyme supplement 
(0.1 ± 0.08 nmol/g tissue) (p= 0.09). Rag could be detected in the colonic, small intestinal 
epithelial and plasma 1, 3 and 7 hours following intrgastric feeding of 25 mg resveratrol-
aglycone/kg body weight. However, neither RG or Rag could be detected in these tissues 
following the same time-course in mice intragastrically fed 25 mg RG/kg body weight. The 
use of N-(n-butyl)-deoxygalactonojirimycin (NB-DGJ), an inhibitor of lactase-phlorizin 
hydrolase (LPH), in transport studies with everted jejunal sacs from CF-1 mice (N=8) 
suggested that LPH is involved in the intestinal deglycosylation of RG. However, the 
concentration of Rag measured in intestinal mucosa of preparations incubated in 100 µM 
Rag was much greater than the amount of piceid and resveratrol-aglycone detected in the 
mucosa of intestinal sacs incubated in equal molar concentrations of RG. Collectively, our 
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studies suggest that the intestinal bioavailability of RG is much less than that of the Rag and 
that bioavailability was related to inhibition of AOM-induced ACF.  
Introduction 
 
In recent years, genetically-engineering strategies have been employed to produce plants 
with higher yields of constituents that may be beneficial to human health (Grusak MA and 
DellaPenna, 1999; Yan and Kerr, 2002; Bouis et al, 2003; Celec et al, 2005). The new 
products include plants with high concentrations of flavanoid phytochemicals (Muir et al, 
2001; Bovy et al, 2002; Schijlen et al, 2006; Sreevdya et al, 2006). Many of these 
compounds have been individually studied for their anti-oxidant and anti-inflammatory 
properties and may potentially offer a variety of health benefits (Prior, 2006). However, the 
efficacy of GM products designed to improve human health through increased yields of 
these plant metabolites are not well documented. 
 Resveratrol (trans-trihydroxystilbene) is a polyphenolic compound found in the diet in 
highest concentrations in red grapes, red wine and berries and in certain herbs such as 
Polygonum caspidatum (Ribeiro de Lima et al, 1999; Wang et al, 2002; Burns et al, 2002). 
Resveratrol is one of the constituents of red wine that has been purported to have protective 
activities against cardiovascular disease (reviewed by Demlas et al, 2005). In addition to 
cardiovascular disease, Rag may be protective against other diseases and conditions 
associated with oxidative damage such as neurodegenerative disorders (Han et al, 2006), 
inflammation (Martin et al, 2006) and cancer (Jiang et al, 1997). Rag was shown to inhibit 
cell growth and induce cell cycle arrest in SW480, HT29 (Liang et al, 2003) and Caco-2 
(Wolter et al, 2001) human colon cell lines and inhibit the formation of axoxymethane 
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(AOM)-induced aberrant crypt foci (ACF) (Tessitore et, 2000) and 1,-2-dimethylhydrazine-
induced tumors in rodents (Sengottuvelan et al, 2005). The later animal experiments indicate 
that Rag may be bioavailable to the colon. 
 Interest in applying recombinant DNA strategies to enrich new plant species with 
resveratrol has surfaced in recent years due to the purported phytoalexin activity and health 
benefits of resveratrol. Thus, resveratrol-rich crops may have both agronomical and 
consumer-oriented benefits. To date, stilbene synthase has been ectopically expressed in rice 
(Stark Lorenzen et al, 1997); barley and wheat (Leckland et al, 1998), tomatoes (Thomzik, 
1997), kiwi (Kobayashi et al, 2000), apple and arabidopsis (Yu et al, 2006). Resveratrol 
accumulated as trans- or cis-piceid (resveratrol-glucoside) (RG) in all of these plants where 
the presence of resveratrol was assessed. Likewise, resveratrol is found predominantly as a 
glucoside in natural sources (Baur and Sinclair, 2006). Interestingly, the bioactivity of 
resveratrol has largely been demonstrated with Rag, while the glucoside forms of resveratrol 
have received limited attention.  
 We were interested in examining the colon chemopreventive properties of transgenic 
alfalfa (TA) which accumulated RG (Hipskind and Paiva, 2000). Previously, we reported 
that the TA inhibited the formation of AOM-induced ACF in the colon of CF-1 mice only 
when diets containing the alfalfa were supplemented with an exogenous ?-glucosidase 
(Kineman et al, submitted). Our findings suggested that RG may not be bioavailable and 
liberation of the Rag via deglycosylation may be required before the potential benefits of 
resveratrol are realized from RG-rich sources. 
 Studies suggest that the intestinal absorption of polyphenols is dependant on the release of 
aglycones from glucoside conjugates by intestinal or microflora ?-glucosidases (Nemeth et 
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al, 2003). Lactase Phlorizin hydrolase (LPH) is an extra-cellular enzyme that has ?-
glucosidases activity and is located at the brush boarder of the intestinal epithelium. The 
lactase catalytic site of LPH has been shown to play an important role in the deglycosylation 
of some polyphenolic-glucosides, including quercetin-3’ and quercetin-4’-glucoside (Day et 
al, 2000 and Day et al, 2003), and other glucosides such as pyridoxine-5-?-D-glucoside 
(Mackey et al, 2002). Recently, a role for LPH in the intestinal cleavage of RG to 
resveratrol-aglycone was supported in Caco-2 cells (Henry-Vitrac et al, 2006).  
 The objective of this study was to explore a tactic to increase the anti-cancer activity of 
the TA through the addition of purified ?-glucosidase and to determine if bioavailability of 
RG with these diet preparations may explain the improved inhibition the formation of AOM-
induced ACF in the colon mucosa of CF-1 mice. We tested the hypothesis that RG is not 
bioavailable by measuring Rag and RG levels in the colon and plasma of CF-1 mice 
following administration of diet preparations containing the TA with and without the 
supplemented ?-glucosidase. Furthermore, we assessed the potential substrate suitability of 
RG for LPH, an endogenous glucosidase of the small intestine in a mouse everted-jejunal 
sac model. Our findings indicate that RG is a substrate for intestinal LPH, but that its 
colonic bioavailability may be much less than that of Rag.   
Materials and Methods 
 
Plant material and greenhouse conditions 
A single alfalfa (Medicago sativa cv. Cimarron) was transformed with resveratrol-
synthase (RS) cDNA from peanut (Arachis hypogaena) at Samuel Roberts Noble Foundation 
in Oklahoma as previously described for cv. Regen SY (Hipskand and Paiva, 2000). 
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Cuttings from the transformed plants were shipped to Iowa State University where they were 
grown in a greenhouse at 25°C with a 16 hour light cycle. Transformed plants were crossed 
to alfalfa cultivar Pioneer 5246 and seeds from the crossed pods were collected and grown in 
the greenhouse. Plants were propagated through stem cutting by planting stem internodes 
that were trimmed free of mature leaves. Rooted cuttings were grown in 3.5 x 3.5 inch plots 
under greenhouse conditions.  
PCR analysis of Transgenic alfalfa lines 
 Genomic DNA was extracted from 0.1 g of alfalfa green leaf tissue as previously 
described (Doyle and Doyle, 1989). To identify plant crosses, plants were screened for the 
kanamycin resistance gene (NPTII) that was included on the binary vector used in the 
transformation of the plants. The resveratrol-synthase (RS) gene was not directly assessed, 
since RS shares 70-80% homology with chalcone synthase at the DNA level (Tropf et al, 
1994).  
 Specific NPTII primers (5’ TCACTGAAGCGGGAAGGGACT 3’) and (5’ 
CATCGCCATGGGTCACGA 3’) were used for PCR. For the reaction, one microgram of 
genomic DNA was combined with 0.8 MM primers (final concentration), 0.2 MM dNTPs, x 
U of Taq polymerase (Promega, Madison, WI) in 1 X PCR buffer (Promega, Madison, WI) 
adjusted to a final volume of 25 ul. Thermocycler (Biorad, Hercules, CA) conditions were as 
follows: denature at 94° C for 2 min, anneal at 63°C for 1 min, elongate at 72°C for 1 min 
for a total of 30 reactions. Twenty-five Ml of PCR product was separated by agarose gel 
electrophoresis and visualized by ethidium-bromide staining under UV light.  
Identification of resveratrol-glucoside in plants 
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Stems and leaves from alfalfa were harvested, dried at 55°C in a forage drying oven and 
ground to a fine powder using a Wiley Laboratory mill with a 1 mm screen (Thomas 
Scientific, Swedesboro, NJ). To analyze dry material for RG accumulation, the procedures 
described by Hipskind et al (2002) were followed, with some modifications. RG was 
extracted from 2 g of powdered plant material in 90% methanol/10% water overnight at 
room temperature. Samples were centrifuged at 4000 x g and 10 ml of supernatant was dried 
using a rotary evaporator. The extract was then dissolved in 500 ul methanol, filtered using 
syringe filters (0.25 Mm PTFE, Altech) and 10 ul of samples was analyzed using reverse-
phase high-performance liquid chromatography (HPLC). A Beckman System Gold HPLC 
was used equipped with a 168 diode array detector and an Alltech Alltima 2.1 x 150 mm 
C18 column and Alltima C18 precolumn. The mobile phase consisted of milliQue (MQ) 
water (A) and 100% HPLC grade acetonitrile (Fisher) (B). Separation was carried out using 
a 45 minute linear gradient from 10-60% B at a flow rate of 0.3 ml/min. The column was 
equilibrated with 100% B 10 minutes prior to each analysis. UV spectra were recorded at 
308 nm (optimal for trans-RG and trans-Rag) and 280 nm (optimal for cis-RG and cis-Rag). 
The identification of RG and Rag in samples was confirmed by comparing UV spectra at 
308 nm to standards of both compounds. The recovery of a spiked RG standard was 99.8% 
(N=5).  
Diets 
 The control diet consisted of the standard diet recommended by the American Society for 
Nutritional Sciences report for mature rats (AIN-93) (Reeves et al, 1993).  Diets were 
prepared by mixing all dry ingredients with water (25% by dry weight of diet) into a slurry. 
Diets were then rolled out, cut into thin strips and dried at room temperature for two days. 
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Alfalfa was added at 20% by dry weight into the diets in partial replacement of dextrin (60% 
of dextrin added to control diets) as described previously (Kineman et al, submitted). The 
TA that was added to the diets contained 193± 18 Mg RG /g dry weight (100 Mmol RG/kg 
diet). Trans-Rag (Sigma-Aldrich, St. Louis, MO) and trans-RG (trans-resveratrol-3-
glucoside) (Apin Chemicals, UK)  weere added to the diets at a concentration of 100 
Mmols/kg diet, which was equivalent to the amount of RG measured in the transgenic alfalfa 
diets. L-galactosidase (E1) from almond (National Enzyme Company, Forsyth, MO) and ß –
glucosidase (E2) (G4511, Sigma Aldrich, St. Louis, MO) from almond were added to diets 
at 860 U/kg of diet (Kineman et al, submitted). Enzymes were added along with the water 
into the diets and mixed with the other ingredients. Diets were stored at -20°C and 
administered every two days. The stability and uniform distribution of RG and Rag in the 
diets during the 5-week duration of the studies was confirmed by HPLC analysis. The 
stability of ?-glucosidase activity in the diet over the 5-week period was confirmed by a 
methylumbelliferone ?-D-glucoside assay as previously described (Kineman et al, 
submitted). Additionally, the stability of ?-glucosidase activity in the diet was determined at 
a pH of 3, 5 and 7, to mimic the conditions of the stomach (pH=3) and small intestine 
(pH=7).  
Animals 
 CF-1 mice (6 weeks old) were obtained from the Charles Rivers laboratory (Wilmington, 
MA) and housed individually in stainless steel wire-mesh cages in a temperature controlled 
room with a 12-hour light:dark cycle.  Mice were fed control (basal) diet, ad-libitum, upon 
arrival. Body weights were recorded weekly and food consumption was monitored every 
two days.  
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Animal experiments: 
1). Aberrant Crypt foci (ACF) Study 
 To induce ACF, the mice were intraperintonially injected with a single dose of 
azoxymethane (5 mg/kg body weight) (Midwest Research Institute, Kansas City, MO) or 
0.1% saline. Three days after the injections, the mice were randomized and assigned to one 
of the following 12 experimental diets:  1) control diet, 2) control diet with RG, 3) control 
diet with Rag, 4) control diet with non-transgenic alfalfa (CA), 5) control diet with TA, 6-
10) diets 1-5 supplemented with  ?-glucosidase enzyme (E2) and 11-12) diets 4 and 5 
supplemented with an alpha-galactosidase enzyme (E1). The mice were fed these diets ad-
libitum for 5 weeks.  
 Following the five week experimental period, mice were killed by decapitation. Whole 
trunk blood was collected into heparin-coated tubes and immediately placed on ice and 
shielded from light exposure. Colons were excised from the mice and rinsed thoroughly with 
ice-cold 0.1 % saline to remove luminal contents. The colons were then dissected 
longitudinally and fixed flat in 10% buffered formalin (pH 7.5) for 24 hours. The samples 
were stained with 0.2% methylene blue (Sigma Aldrich, St. Louis, MO) in 0.1% saline for 
10 minutes and the ACF/colon were scored for each mouse at 10 fold magnification using 
the criteria defined by Bird (1995). ACF number, size, multiplicity (number of AC/focus) 
and distribution were recorded in 2 cm increments, starting at the rectum in a blinded 
fashion. Sizes of ACF were scored with an eyepiece graticule.  
2). Colon and plasma concentrations of piceid and resveratrol-aglycone in mice fed diets 
from ACF study 
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CF-1 mice were fed the following diets for five weeks: 1) control diet, 2) control diet 
with Rag, 2) control alfalfa (CA), 3) CA with E1, 4) transgenic alfalfa (TA) and 5) TA with 
E1. All food was removed from cages 4 hours prior to killing all the mice by decapitation. 
Whole trunk blood was collected into heparin-coated tubes and immediately placed on ice. 
Colons were excised from the mice and rinsed thoroughly with ice-cold saline and snap 
frozen in liquid nitrogen.  
Analysis of plasma and tissue samples for resveratrol 
 Plasma was isolated from whole blood by centrifugation at 500 x g for 15 minutes. 
Aliquots (50 Ml) of plasma containing 20 uM flavone (2-phenyl-4H-1-benzopyran-4-one) 
(Sigma Aldrich, St. Louis, MO) as an internal standard were placed in Eppendorf tubes for 
enzyme digestion with 980 U ?-glucuronidase containing 9.1 U sulfatase (?-glucuronidase 
from Helix pomitia, Sigma Aldrich, G-0876) for 18 hours at 37°C. The reaction was 
terminated with an equal volume of 100% methanol. The samples were centrifuged at 
10,000 x g for 15 minutes and the supernatants were filtered. 
 Colons were weighed and then homogenized in 2 ml of 100% methanol using a Polytron 
homogenizer for 40 s. Flavone was added as an internal standard to each sample (20 uM 
final concentration). The samples were centrifuged at 4000 x g for 15 minutes. The 
supernatants were dried under nitrogen gas, reconstituted in 500 ul methanol and filtered 
prior to LC-MS analysis. Colon extracts were not digested with ?-glucuronidase/sulfatase 
prior to analysis, since results described below indicated that there was no difference in the 
amount of Rag detected in the colonic epithelial between digested and undigested samples.  
LC-MS analysis of plasma and colon extracts 
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In order to confirm the identity and amount of Rag and RG in the plasma and colon 
extracts, LC-MS analysis was carried out using a 1100 Series resverse-phase HPLC (Agilent 
Technologies) coupled to a mass selection trap SL detector (Agilent Technologies) equipped 
with a Turbo ionspray source with the capillary voltage set at 0.7 and heated to 350°C. 
Acquisition was performed in negative ion mode using the deprotonated molecule of trans-
Rag (m/z 227) and RG (m/z 389) as precursor ions. Compounds were separated using an 
Alltech Alltima 2.1 x 150 mm C18 column and Alltima C18 precolumn C18 column 
(Alltech). The solvent system consisted of a 16 minute linear gradient from 10-60% 
acetonitrile in 0.1% formic acid. At the end of the gradient the column was flushed with 
100% acetonitrile for 2 minutes. Eluted peaks were monitored at 308 nm and 280 nm prior 
to being introduced into the ionization chamber. Quantitative determination of Rag was 
based on an external standard. A calibration curve was conducted in the range of 30-4000 
pmol and was linear over the entire range with correlation coefficient value of 0.9973 (figure 
1). The recovery of the flavone internal standard was 94.7 ± 2%.  
3). Plasma, colonic and small intestinal epithelium concentrations of RG and Rag in mice 
fed high concentrations of both compounds 
 The colonic epithelium was measured for Rag and RG concentrations following the 
administration of high doses of each compound to mice, to determine the relative amounts of 
these compounds that can reach this tissue compared to the small intestinal epithelium and 
plasma, since this is the precise site where ACF form. Six-week old CF-1 were fed control 
diets for a one-week wash-out period. All food was removed from the cages 12 hours prior 
to administration of RG or Rag. Mice were intragastrically fed 25 mg/kg Rag or RG in 10% 
ethanol via gavage and killed 1, 3 or 7 hours post-dose administration by decapitation. 
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Colons were excised and luminal contents were flushed with 0.1 % saline. Trunk blood was 
collected into heparin-coated tubes and immediately placed in ice.  
 Colonic and small intestinal epithelial cells were isolated using the procedures described 
by Brasitus and Kereztes (1983) with minor modifications. Colons were rinsed with solution 
containing 0.015 M NaCl and 0.001 M dithiothreitol (DTT) and tied at one end. The colon 
sacs were filled with 10% fetal calf serum in 1.6% Joklik’s modified minimal essential 
medium, tied shut at the other end, and incubated @ 37°C for 12 minutes in 0.1% in a 25 ml 
flask.  Following the incubation period, the colons were removed from the water bath and 
the inner media drained. The colonic sacs were then filled with Weiser B solution (0.0015 M 
EDTA and 0.0005 M DTT in 0.1 M phosphate-buffer, pH=7.2) and incubated at 37° C for 
15 minutes while shaking. The Weiser B contents were collected into 15 ml centrifuge 
tubes. Flavone was added to each sample as an internal standard (final concentration = 20 
uM) and the samples were homogenized for 30 seconds. Methanol (4 X volume) was added 
to each sample and the samples were vortexed for 1 minute each and centrifuged at 4000 
rpm for 15 minutes. Supernatants were collected and methanol was evaporated off under 
nitrogen gas and redissolved in 500 Ml potassium phosphate buffer (5 mM, pH 6.7). 
Subsamples were digested with 980 U ?-glucuronidase and 9.1 U sulfatase (?-glucuronidase 
from Helix pomitia, Sigma Aldrich, G-0876) at 37°C for 24 hours.  Resveratrol was 
extracted from aqueous solution with equal volumes of ethyl acetate (3 x). The ethyl acetate 
fractions were pooled and dried under nitrogen gas. The extracts were reconstituted in 500 
µl methanol and filtered prior to reverse-phase HPLC analysis as described above. One-
hundred Ml of each plasma sample was processed and analyzed by HPLC as described 
above. The calibration curves of RG and Rag were made by injecting methanolic solutions 
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of each in a concentration range of 0.5 to 25 Mmol/L, which were linear with a correlation 
coefficient value of 0.9634 and 0.9965, respectfully. The detection limits of RG and Rag 
were determined to be 0.02 Mmol/L for each compound. The recovery of the flavone internal 
standard was 72 ± 2% for the colon and small intestinal extracts and 92 ± 5% for the plasma 
extracts. The relative standard deviation of 5 concentrations over 5 different times was 1.6-
2.5 for the RG and 1.8-3.9 for Rag.  
4). Role of lactase-phlorizine hydrolase in intestinal deglycosylation of piceid 
 The substrate suitability of RG for the lactase catalytic site of LPH was examined in the 
jejunum of CF-1 mice, since the highest activity of LPH in humans is found in this section 
of the small intestine (Skovbjerg et al, 1981). For these studies, everted, jejunal sacs from 
CF-1 mice were incubated with piceid in the presence or absence of N-(n-butyl)-
deoxygalactonojirimycin, a specific inhibitor of lactase (Andersson et al, 2000).  
Optimization of lactase inhibitor concentration 
 To indirectly assay the small intestines of CF-1 mice for lactase activity, the procedure 
outlined by Day et al (2003) were followed. Briefly, mice were killed by cervical dislocation 
prior to removal of their small intestine via abdominal incision. The jejunum was identified 
in each mouse, excised and rinsed with Krebs-Henselect bicarbonate buffer (115 mM NaCl, 
2.5 mM KCl, 2.5 mM MgSO4, 1.9 mM CaCl2 x 2H2O, 5.6 mM glucose, 1.4 mM NaH2PO4 x
2H2O and 25 mM NaHCO3 at pH=7.4). Approximately 2 cm sections were cut from the 
proximal jejunum, weighed and everted. One end of the everted intestine was ligatured and 
the intestine was filled with Krebs bicarbonate buffer using a bulb end needle attached to a 1 
ml disposable syringe at the other end of the intestine. The needle was removed and the 
intestine was ligatured to form a sac. The everted intestinal sacs were suspended in organ 
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baths at 37°C in 25 ml Erlenmeyer flasks containing incubation media (10 mls) as described 
below and continuously gassed with 95% O2/CO2.
Pre-weighed everted, intestinal sacs from CF-1 mice were incubated for 15 minutes @ 
37ºC in various concentrations (0-500 uM) of N-(n-butyl)-deoxygalactonojirimycin (NB-
DGJ) (EMB Biosciences, San Diego, CA) along with 14C-lactose (final concentration = 
4.63 kBq/mL) (GE Health Sciences) in Krebs bicarbonate buffer that was continuously 
gassed with 95% O2/ 5%CO2. The sacs were removed from the organic baths and the outer 
mucosa of the sacs was rinsed with Krebs bicarbonate buffer and blotted with filter paper to 
remove excess solution. The inner serosal solutions were drained into 20 ml glass 
scintillation vials with 9.5 mls of Hionic-fluor™ scintillation cocktail (PerkinElmer, 
Wellerley, MA). The tissues were placed in 20 ml glass vial and digested in 2 mls of 
Solvable™ tissue solubilizer (PerkinElmer) for 2 hours at 55°C. Hionic-fluor™ scintillation 
cocktail (8 mls) was added to the digested samples. The 14C isotope was measured in the 
tissue extracts using a 1900 TR TriCarb Packard Liquid Scintillation Analyzer. 
 The amount of 14C-glucose cleaved from the 14C-lactose and absorbed into the intestinal 
sacs was determined as a function of the measured radioactivity of the serosal solutions + 
tissue normalized to tissue weights.  
Transport studies using lactase inhibitor 
 Everted, jejunal sacs were incubated with piceid in the presence and absence of NB-DGJ 
to determine if RG is a substrate for LPH. Preweighed, everted intestinal sacs from CF-
1mice were incubated in 100 uM RG or 100 µM Rag in the presence or absence of 300 uM 
NB-DGJ in Krebs bicarbonate buffer as described above. The intestinal sacs were removed 
from the water bath following incubation at 37°C for 15 minutes and blotted once on filter 
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paper. The inner serosal solution was collected into 1.5 ml microcentrifuge tubes and 
vortexed with an equal volume of 1 mM ascorbic acid in methanol containing 20 uM 
flavone (Sigma-Aldrich) as an internal standard. The extracts were centrifuged at 16,000 x g 
and the supernatants were dried under vacuum using a rotary evaporator. The extracts were 
reconstituted in 500 ml methanol and filtered using a syringe filter prior to HPLC analysis.  
 The mucosa was scrapped from the intestinal sacs using two microscope slides. The 
mucosal collections were then transferred to 2 ml microcentrifuge tubes that contained 2 mls 
1 mM ascorbic acid in methanol along with 20 uM flavone. The mucosal samples were 
homogenized for 30 seconds (Polytron) and centrifuged at 4,000 x g for 15 minutes. 
Supernatents were collected and dried under nitrogen gas. Extracts were reconstituted in 500 
µl methanol. Subsamples of all serosal and mucosal extracts were dried and subjected to 
enzyme hydrolysis with 980 U ?-glucuronidase and 9.1 U sulfatase (?-glucuronidase from 
Helix pomitia, Sigma Aldrich, G-0876) for 2 hours @ 37°C. Enzymatic reactions were 
stopped by the addition of equal volumes of methanol. The samples were centrifuged at 
16,000 x g, dried under vacuum and reconstituted in 250 ml methanol prior to analysis. All 
samples were analyzed using reverse-phase HPLC as described above. The recovery of the 
flavone internal standard from the serosal solution and mucosal extracts was 90 ± 1%.  
Statistical Analysis  
 All values reported are expressed as means ± standard error of the mean. Changes in body 
weights (final weight-initial weight) and ACF number, multiplicity and size were analyzed 
using one-way analysis of variance test (ANOVA) with a t-test as a post-hoc analysis for 
individual treatment comparisons. Daily food consumption was analyzed using a 2-way 
ANOVA for enzyme vs. alfalfa and treatment comparisons were made using a t-test. 
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Treatment comparisons for incidence of Rag detection in colonic extracts were made using a 
Fisher’s Exact test. A chi-square test was used to detect significant difference in the 
incidence of Rag detection in the colons of mice between treatments. All other treatment 
comparisons were achieved by performing a 1-way ANOVA followed by a Tukey-Kramer 
post-hoc test. In the experiment conducted with the jejunal intestinal sacs, treatment 
comparisons were made across each sac section (mucosa and serosal solution). All statistical 
analyses were performed using SAS software (SAS Institute) and P < 0.05 was considered to 
be significant.  
Results 
 
PCR and HPLC analysis of transgenic alfalfa plants 
 PCR analysis of genomic DNA from fresh leaves confirmed the presence of the 
kanamycin gene in 43% (26/61) of attempted plant crosses made between transgenic 
Cimarron with non-transgenic Pioneer 5246. Plants with this gene were used as the TA for 
the studies reported here. The 99-4 transgenic parent plants produced a similar band whereas 
no fragment was amplified in the 5246 nontransformed parent plants (data not shown). The 
HPLC-UV chromatograms of leaf and stem extracts from plants which were positive for the 
kanamycin gene were found to contain an additional broad peak which coeluted with an 
authentic RG standard (Figure 2). The UV spectrum of the peak, which demonstrated a 
maximum absorbance at 308 nm, closely matched the spectrum of the RG standard (Figure 
2, insert). The quantitative HPLC analysis of dry, ground plant material demonstrated that 
RG levels were 193 ± 17.58 Mg RG/g dry weight (N=10) in the transgenic plants.  
Diet Analysis 
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Diets were analyzed prior to and following five weeks storage at -20°C. RG, but not 
Rag, was identified in all TA diets supplemented with L-galactosidase or ?-glucosidase. The 
amount of Rag in the BD+Rag diets following 5 week storage at -20°C was 84 ± 23 nmol 
Rag/kg diet (N=5), 84% of the amount added to the diets at the beginning of the study. The 
recovery of RG in TA diets following 5 weeks was 88% (N=10) (88 ± 21 nmol RG/kg diet).  
 The recovery of ?-glucosidase activity in the diets supplemented with E1 and E2 
following five weeks storage was 85% (731 ± 77 ?-glucosidase U/kg diet) (N=10). The ?-
glucosidase activity of BD supplemented with E1 was also determined following incubation 
for 30 minutes at pH 3 and 7 to determine if the enzyme can remain stable under various 
conditions of the gastrointestinal tract. At pH 3, the activity of the BD with E1 was 267 ± 12 
U/kg diet (N=5) (31% recovery of the original activity) and at pH 7, the activity of the diet 
was 430 ± 65 U/kg diet (N=5) (50% recovery).  
Body weights and food consumption 
 The body weights of the mice did not differ between treatment groups at baseline (mean = 
24.4 ± 1.3 g; p= 0.6). The mice gradually gained weight throughout the five-week duration 
of the study with the average gain being 4.2 ± 1.6 g, which was not significantly different 
between treatments (p=0.4). The addition of E1 or E2 to the diets did not significantly 
influence food consumption (p=0.11) (Figure 3). However, mice fed diets containing alfalfa 
consumed more food per day compared to mice fed BD with or without enzyme 
supplementation (4.3±0.1 g/day compared to 3.8±0.1 and 3.7±0.1, respectively. p<0.001 for 
both comparisons).  Mice fed diets containing alfalfa with either E1 or E2 consumed, on 
average, 4.6 ± 0.1 g of food/day, which was significantly more than all of the other groups. 
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There was no difference in food intake between mice fed diets with CA verses TA (p=1.0, 
data not shown).  
Formation of Aberrant Crypt Foci in the colorectal mucosa  
 The total number of ACF in the entire colon was significantly reduced in mice fed diets 
containing alfalfa relative to mice fed basal diet following the five-week, post-initiation 
experimental period (Table 1). This reduction was observed with both CA and TA. 
However, the number of ACF lesions/colon were reduced by an additional 64% in mice fed 
TA supplemented with E1 relative to mice fed TA without the enzyme (p=0.02). A similar 
reduction was observed with the addition of E2 to the TA, but the difference was not as 
statistically significant (p=1.2).   
 The addition of authentic Rag at 0.002% in the BD by dry weight resulted in a 74% 
reduction in the total number of ACF/colon in mice fed these diets compared to mice 
administered BD, alone (p<0.0001). Interestingly, the addition of authentic RG to BD in 
equal molar concentrations to RG in combination with E2 resulted in a similar reduction in 
the number of ACF/colon relative to mice fed basal diet (p=.0005). Diets containing RG, 
alone, without E2 supplementation, did not reduce ACF number. Furthermore, there was no 
difference between ACF numbers in mice fed basal diet with or without E2 or between mice 
fed CA with or without either E1 or E2. There was also no difference between multiplicity, 
overall (mean= 1.6±0.5 aberrant crypts/focus) and size of ACF, overall (mean = 179 ± 57 
Mm) between treatments.  
 Aberrant crypt lesions were primarily concentrated in the distal 4 cm of the colon 
(differentiated in 2 cm portions as the distal and middle region during our analysis). Few 
ACF were observed in the proximal 1 cm of the colon examined. Similar trends in the 
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number of total ACF between treatment comparisons were observed for the number of ACF 
in the distal and middle portions of the colon. The addition of E1 to TA reduced the number 
of ACF lesions in the distal colon by 55% (p=0.06) and by 72% (p=0.09) in the middle 
portion of the colon. The addition of E2 to diets containing authentic RG in BD resulted in a 
reduction of ACF number in the distal portion of the colon (p=0.003), but not significantly 
in the middle portion.  
Colon and plasma concentrations of resveratrol following treatments 
 Rag could be detected at low levels (all under < 1 nmol/g tissue) in the colon of mice fed 
diets containing TA with or without E1 or BD with authentic Rag (Table 2). Liquid 
chromatography-MS/MS analysis confirmed the presence of Rag in the colon of CF-1 mice 
fed diets containing the TA (figure 4). Rag was identified by comparison with the retention 
time and the fragmentation pattern of the authentic standard.  
 As table 2 illustrates, tissue levels of Rag were similar in mice administered TA with E1 
and mice fed Rag. Rag was also detected in the colon of mice administered TA without 
enzyme. However, the colonic Rag concentrations in the mice fed TA, alone, was about half 
that measured in the mice fed TA with E1 (p=0.09). Furthermore, the incidence of Rag 
detection was significantly less in the TA group relative to TA with E1 (60 vs. 100%, 
respectively, p<0.05). The colon concentrations of Rag in mice fed TA without E1 was also 
lower than concentrations measured in the Rag group (p<0.05). Resveratrol-aglycone was 
not detected in the colons of mice fed control, non-TA or CA and BD. The presence of Rag 
could not be confirmed in the plasma extracts regardless of ?-glucuronidase/sulfatase 
enzyme digestion. RG could not be identified in any of the colon or plasma samples. 
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Resveratrol intestinal and colonic epithelial and plasma concentrations following gavage 
feeding 
 Rag could be detected in the colonic and intestinal epithelium cells of CF-1 mice fed a 
single 25 mg (110 Mmol)/kg body weight oral dose of Rag via gavage at all time points 
examined (Figure 5A and 5B).The amount of Rag detected in the small intestine was 
significantly higher in extracts treated with ?-glucuronidase/sulfatase (Rag + metabolites) 
relative to undigested extracts (figure 5A). In the small intestines, there was no difference in 
amount of Rag detected in ?-glucuronidase digested extracts throughout the time-course. In 
contrast, there was no significant difference between the concentration of Rag detected in 
colonic epithelial extracts digested with ?-glucuronidase and sulfatase vs. extracts analyzed 
without enzyme digestion (figure 5B). Colon epithelial concentrations of Rag were 
significantly higher 7 hours post-gavage relative to values obtained 1 hour following dose 
administration. Free, unconjugated Rag could not be detected in the plasma of mice 
administered Rag (figure 5C). The plasma concentration of glucuronide/sulfide metabolites 
of resveratrol were higher 7 hours post-gavage than at 3 hours in these mice.  
 In contrast to these findings, neither RG nor Rag was detected in the plasma or colon and 
small intestine epithelia of mice orally administered 25 mg (64 Mmol)/kg RG at the time 
points examined. 
Deglycosylation of piceid by lactase phlorizin hydrolase in small intestine 
 Everted-jejunum intestinal sacs from CF-1 mice were incubated with 14C-lactose and 0-
300 µM N-(n-butyl)-deoxygalactonojirimycin (NB-DGJ). The recovery of 14C-glucose in the 
tissue and serosal solution of the intestinal sacs was significantly reduced with 10MM
treatment of NB-DGJ (Figure 6) and was further reduced at a NB-DGJ dose of 300 MM. At 
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300 MM the recovery of 14C-glucose was 47% of what was achieved in the control group. 
Consequently, this dose was used in the follow-up study to examine the role of lactase in the 
deglycosylation of RG in the jejunum.  
 To determine if LPH is involved with the deglycosylation of RG in the intestine, everted 
intestinal sacs from CF-1 mice were incubated in 100 µM RG in the presence or absence of 
300 µM NB-DGJ. Following incubation in 100 MM RG for 15 minutes at 37°C, RG was 
detected in the mucosa and serosal solution of the jejunum (Table 3). Rag was only detected 
in the mucosa. In intestinal sacs incubated with 100 µM Rag, Rag was detected in the 
mucosa, but not the serosal solution. RG was not detected in any of the Rag treated samples. 
Subsamples of all mucosal and serosal extracts were digested with glucuronidase containing 
sulfatase to account for glucuronic acid or sulfate metabolites that may have formed. Rag 
was detected in all serosal solutions following enzyme treatment, indicating that complete 
phase-II metabolism of Rag had occurred (Figure 7). The concentration of resveratrol 
glucuronide/sulfate metabolites in the mucosa and serosal solution of intestinal sacs 
incubated with RG and NB-DGJ was significantly less than the concentrations detected in 
the mucosa and serosal solution of intestinal sacs in RG without NB-DGJ.  The presence of 
NB-DGJ did not affect the concentrations of Rag or resveratrol-metabolites in the mucosa 
and serosal solution of intestinal sacs incubated in Rag.  
 The concentration of Rag in the mucosa of samples incubated with 100 MM Rag without 
NB-DGJ was almost five times greater than the concentration of RG without NB-DGJ in the 
mucosa of samples incubated with 100 MM RG. There was a similar difference between the 
concentrations of resveratrol-metabolites in the mucosa between intestinal sacs incubated 
with Rag without NB-DGJ and RG without NB-DGJ. The amount of resveratrol glucuronic 
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acid/sulfide metabolites in the serosal solutions of intestinal sacs treated with Rag was 
approximately two times greater than the concentration of metabolites in RG-treated sacs. 
Discussion 
 
Studies have shown that Rag may have protective activity against colorectal cancer 
(Tessitore et al, 2000; Sengottuvelan, 2006a; Sengottuvelan, 2006b; Sengottuvelan, 2006c). 
Previously, we reported that TA that accumulates resveratrol as RG inhibited the number of 
AOM-induced ACF in CF-1 mice when supplemented with L-galactosidase (E1), but not 
without enzyme supplementation (Kineman et al, submitted). To our knowledge, no other 
studies have investigated the bioactivity of RG against colorectal cancer. Our hypothesis 
was that RG was not bioavailable and the glucosidase activity of the E1 liberated Rag from 
RG in the TA resulting in the reduction of ACF in the colon.  
 In the present study we show that the addition of E1 to the TA resulted in a 64% 
reduction in the number of AOM-induced ACF in CF-1 mice fed these diets compared to 
mice fed diets with TA alone. The addition of ?-glucosidase (E2) to TA resulted in a very 
similar reduction, suggesting that the glucosidase activity of E1 in combination with RG 
accumulation was responsible for the ACF reduction in these mice. Additionally, the 
supplementation of authentic RG to control diets had no influence on ACF number whereas 
the addition of E2 to these diets resulted in a 41% decrease in the number of ACF in mice 
who ate these diets compared to control-fed mice. This reduction was similar in magnitude 
to that achieved in mice administered control diets with Rag at equal molar concentrations to 
the RG contained in the these diets. These findings support the hypothesis that RG was not 
as bioavailable as Rag.  
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In contrast with our previous study (Kineman et al, submitted), alfalfa, independent of 
RG-accumulation, reduced the number of ACF in the colon of CF-1 mice in the study 
reported here. This was probably due to the different alfalfa cultivars used between the two 
studies. It is possible that the plants in the current study accumulate additional health-
promoting compounds, or the same chemicals, but in higher concentrations, than the plants 
used in our previous study. Alfalfa normally accumulates a number of secondary metabolites 
that may have health-promoting activity (Stochmal et al, 2000a; Stochmal et al, 2000b). It is 
possible that the phytochemical profiles of the two cultivars differ, but this was not 
examined in our studies. In spite of this, the addition of E2 to the TA further enhanced the 
protective activity against AOM-induced ACF in CF-1 mice in comparison with transgenic 
alfalfa alone. 
 Since ?-glucosidases occur ubiquitously in plants, being localized in the cell wall of 
dicot plants, such as alfalfa (Esen, 1993), we measured the endogenous ?-glucosidase 
activity contributed by the alfalfa. We also explored a strategy to induce the release of 
endogenous ?-glucosidases from the alfalfa through chopping fresh plants prior to 
processing the material through drying and milling. However, this did not have any affect on 
the endogenous ?-glucosidase activity of the plant material after processing (mean= 0.117 ± 
0.076 glucosidase U/g of dry material; p=0.8). Based on our measurements, alfalfa, when 
added at 20% in the diet, accounted for 23.4 ?-glucosidase U/kg of diet, whereas exogenous 
?-glucosidase was supplemented in the diets at 860 ?-glucosidase U/kg of diet. Thus, the 
alfalfa plants contribute some ?-glucosidase activity, but at a very minor level compared to 
the amount we supplemented in the diets. 
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We tested the hypothesis that piceid from the TA is not bioavailable by quantifying by 
LC/MS the amount of Rag present in the colon and plasma of the mice following the 5-week 
treatment period.  The amount of Rag found in the colon was below 0.5 nmol/g of tissue in 
all samples where it was identified. Rag was detected in the colon of mice fed TA without 
E1, which suggests that deglycosylation of RG does occur somewhere along the digestive 
tract. The concentration in these mice tended to be less than mice fed TA with E1 (p=0.09). 
Rag was also detected in fewer of these animals relative to the animals fed TA with E1 
(p<0.05, Fisher’s Exact Test). RG was not detected in any samples, indicating that it is not 
absorbed intact in the colon.   
 We hypothesize that the supplemented ?-glucosidase activity was effective in liberating 
Rag from RG in the diets during the process of digestion and not prior to this, since Rag was 
not detected in the TA diet preparations with supplemented E2. We were also able to verify 
that the enzymes can retain some ?-glucosidase activity at a pH of 3 and 7, which would 
indicate that the enzyme could be active under the pH conditions of the mouth, stomach and 
lower gastrointestinal tract.  
 Since the epithelium of the colon is the site where the majority of colorectal cancers 
originate, we compared the concentrations of Rag and RG that can reach this tissue 
following the administration of high doses of both compounds. At a dose of 25 mg trans-
Rag/kg body weight, Rag was detected at low levels (< 2 nmol/mg protein) in the colonic 
epithelium 1, 3 and 7 hours post-gavage in the CF-1 mice. Higher levels were observed in 
the small intestine epithelium following ?-glucuronidase/sulfatase treatment of these 
extracts, indicating that phase-II metabolism of the aglycone occurred at this site.  
Resveratrol was not detected in the aglycone form in the plasma.  Contrary to these findings, 
130                                                                                   
neither RG nor Rag could be detected in the plasma or epithelial of the colon or small 
intestine at the 1, 3 or 7 hour post-gavage time points of mice that were administered 25 mg 
RG/kg body weight. Lv et al (2006) recently reported that peak plasma levels of 
approximately 0.9 µM RG were reached within 20 minutes in Wistar rats orally 
administered 50 mg RG /kg body weight and rapidly declined within an hour. Unfortunately, 
comparisons with Rag were not made in that study. Our findings would suggest that the 
bioavailability of RG was much less than that of the Rag. Also, since neither RG nor Rag 
could be detected in samples at later time points in mice intragastrically fed a high dose of 
RG, this suggests that the systemic metabolism of RG may be different than that of the Rag.  
 Emerging evidence indicates that LPH may play an important role in the bioavailability 
of polyphenolic-glucosides (Day et al, 2000 and 2003; Nemeta et al, 2003). Since LPH is an 
extracellular enzyme located at the apical surface of the small intestine and has ?-
glucosidase activity, it could potentially catalyze the cleavage of glycosidic linkages in 
polyphenolic compounds resulting in the release of aglycone compounds that may be 
absorbed intact in the intestine or become available to the colon if unabsorbed in the upper 
gastrointestinal tract.  
 We further examined the role that LPH may play in the deglycosylation of RG in the 
intestines by conducting a transport study in everted, jejunal sacs from CF-1 mice using a 
lactase-specific inhibitor NB-DGJ. Our study suggested that LPH can deglycosylate RG to 
Rag, since the presence of NB-DGJ reduced the recovery of resveratrol-glucuronide/sulfate 
metabolites in the mucosa and serosal solution of the intestines. This data is in agreement 
with the observations made by Henry-Vitrac et al (2006) in Caco-2 cells, showing that 
deglycosylation was reduced in the presence of lactase-specific inhibitors. RG was also 
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detected in both the mucosal and serosal samples, indicating that it can be absorbed intact in 
the small intestines.  
 Our data revealed that Rag is either transported more efficiently across the intestinal wall 
or accumulates at higher concentrations in the mucosa compared to RG. The concentration 
of Rag detected in the mucosa of the intestinal sacs following incubation in 100 µM was 
almost 40-fold higher than the amount of Rag and almost 5-fold greater than the 
concentration of RG detected in the mucosa of sacs incubated in equal molar concentrations 
of RG. In a comparative study, Rag was shown to be transported at a higher rate and in 
greater amounts than RG into the human Caco-2 colorectal cells (Henry et al, 2005).  
 The resveratrol detected in the serosal solutions of intestinal sacs incubated in 100 µM 
Rag was exclusively in the form of glucuronic acid or sulfate metabolites. Glucuronic acid 
or sulfate metabolites were also a large fraction of the resveratrol detected in the mucosa 
samples in these intestinal sacs. These observations are in strong agreement with other 
studies showing that phase-II metabolism of Rag occurs in the small intestine (Andlauer et 
al, 2000; Kuhnle et al, 2000).  The concentration of glucuronide/sulfate metabolites of 
resveratrol in the serosal solutions of intestinal sacs incubated in Rag without NB-DGJ was 
approximately 50% greater than the concentration of metabolites detected in the serosal 
solution of intestinal preparations incubated in RG, without NB-DGJ, further indicating that 
the absorption of Rag in the intestine may be more efficient than that of RG. 
 RG that passes through the upper gastrointestinal tract (g.i.) undigested could be 
hydrolyzed in the lower g.i. tract by microflora ?-glucosidases. This has not been confirmed 
in any studies, to our knowledge. However, studies conducted in ileostomy patients indicate 
that the colon bioavailability of some polyphenol-glucosides may not be very high, since 
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these compounds are either largely absorbed or metabolized in the small intestine (Hollman 
et al, 1995; Kahle et al, 2006). Thus, the majority of ingested RG may be absorbed in the 
upper g.i. tract and does not reach the colon.  
 Bioavailability studies reveal that the gastrointestinal tract accumulates much higher 
amounts of Rag following oral administration of the compound relative to other tissues 
(Vitrac et al, 2002 and El-Mohsen et al, 2006). We were not able to detect Rag or RG in the 
plasma following the five-week treatments in the mice, which is in accordance with these 
studies and suggests that beyond the g.i. tract, the chemopreventive activity of resveratrol 
may not be achievable via physiologically relevant doses. However, few studies have 
attempted to link the bioavailability vs. bioactivity of resveratrol at a tissue following similar 
oral doses, so little is known about the potency of resveratrol in biological systems. Asesni 
et al (2002) reported that Rag following oral doses via gavage (20 mg/kg body weight daily) 
or the drinking water (25 mg/kg body weight) inhibited the hepatic metastatic invasion of 
B16 melanoma cells that were injected into the spleen of mice prior to the treatments. 
Following the 21 day study, Rag plasma levels were below 0.1 MM, which would suggest 
that in-vitro studies may not provide a real sense of the potency of Rag, since Rag 
concentrations below 5 MM rarely induce noticeable activity in cell culture systems (Gescher 
and Steward, 2003). In our studies, Rag, when administered at an approximate daily dose of 
3 mg/kg body weight to CF-1, resulted in the significant reduction in the number of ACF in 
colons that averaged 0.2 nmol Rag per gram of wet tissue after a five-week treatment period. 
The dose of Rag in our study is still relatively high, considering that the most resveratrol-
rich red wines contain about 15 mg Rag/L of wine. At this concentration, the mice in our 
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study received the equivalent of about 500 L of red wine/day, which raises some doubt on 
the feasibility of achieving clinically relevant doses of Rag via natural sources, alone.  
 In summary, our findings suggest that RG, the glucoside of Rag, may not be bioavailable 
to the colon. Although RG is a substrate for LPH in the intestine, the inability of TA or 
purifed RG to affect the number of AOM-induced ACF in CF-1 mice may be the result of 
the intact absorption of RG in the upper intestine and its subsequent rapid clearance from the 
systemic circulation or its limited metabolism in the colon. The addition of ?-glucosidase 
activity to TA appeared to be effective in reducing ACF lesions by liberating Rag from RG. 
Since RG is the predominant form of resveratrol in natural sources and in other genetically-
modified crops which over-express resveratrol-synthase, the human bioavailability of RG 
certainly warrants future investigation.  
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Table 1: Azoxymethane-induced Aberrant Crypt Foci number, multiplicity and size in CF-1 mice
D M P
Treatment Incidence Size (Mm)
(p=0.2)
Multiplicity
(AC/F)
(p=0.4)
Total ACF
(p<0.0001)
#ACF
(p<0.0001)
#ACF
(p=0.002)
#ACF
(p=0.28)
BD 9/20 198.9 ± 19.0 1.7 ± 0.1 6.3 ± 0.6A 3.5 ± 0.4A 2.5 ± 0.3A 0.3 ± 0.1
BD+E2 8/9 209.8 ± 20.0 1.7 ± 0.2 5.7 ± 0.9A 3.9 ± 0.6A 1.4 ± 0.5B 0.3 ± 0.2
BD+RG 8/10 166.3 ± 20.0 1.4 ± 0.1 5.5 ± 0.9A 3.7 ± 0.6 A 1.4 ± 0.4B 0.4 ± 0.2
BD+Rag 11/20 170.0 ± 17.1 1.5 ± 0.1 1.6 ± 0.6C 0.9 ± 0.4B 0.7 ± 0.3B,C 0.1 ± .01
BD+RG+E2 7/10 230.0 ± 21.4 2.0 ± 0.1 2.6 ± 0.8B,C 0.8 ± 0.5B 1.5 ± 0.4B 0.5 ± 0.1
CA 14/20 172.5 ± 20.0 1.6 ± 0.2 2.3 ± 0.6B,C 1.3 ± 0.4B 0.9 ± 0.3B,C 0.1 ± 0.1
CA+E1 15/20 192.3 ± 18.9 1.8 ± 0.2 2.3 ± 0.6B,C 1.7 ± 0.4B 0.5 ± 0.3B,C 0.1 ± 0.1
CA+E2 7/10 147.1 ± 21.4 1.4 ± 0.2 2.8 ± 0.9B,C 1.5 ± 0.6B 0.8 ± 0.4B,C 0.4 ± .01
CA+Rag 11/15 181.4 ± 17.1 1.5 ± 0.2 1.5 ± 0.7B,C 0.9 ± 0.5B 0.6 ± 0.4B,C 0.1 ± 0.1
TA 16/20 173.9 ± 20.0 1.7 ± 0.3 3.3 ± 0.6B 2.0 ± 0.4B 1.1 ± 0.3 B,C 0.3 ± 0.1
TA+E1 11/20 158.6 ± 20.0 1.4 ± 0.2 1.2 ± 0.6C 0.9 ± 0.4B 0.3 ± 0.3C 0.1 ± 0.1
TA+E2 6/10 148.3 ± 23.1 1.4 ± 0.2 1.7 ± 0.9B,C 1.1 ± 0.6B 0.4 ± 0.5B,C 0.2 ± 0.5
Values represent means ± SE (N=9-20). Treatments abbreviations are defined as follows: BD=basal diet, CA= control alfalfa,
TA=transgenic alfalfa, RG= piceid, Rag= resveratrol-aglycone, E1= L-galactosidase and E2= ?-glucosidase. ACF number,
multiplicity and size were assessed in three increments of the colon (distal most 2 cm (D), middle 2 cm (M) and proximal 1 cm
(P)). Treatments assigned different letters within a column are significantly different (p<0.05; 1-way ANOVA, SAS).
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Table 2: Concentration of resveratrol-aglycone (Rag) in colon of CF-1 following 5-week dietary 
treatments  
 
Treatment # where Rag was 
detected/total # assessed 
Concentration (nmol/g 
tissue) in mice where Rag 
was detected 
Basal diet (BD) 0/15 ND 
BD + resveratrol-aglycone 13/15 0.27 ± 0.14A
Control alfalfa (CA) 0/15 ND 
CA + L-galactosidase (E1) 0/15 ND 
Transgenic alfalfa (TA) 9/15† 0.10 ± 0.08B
TA + E1 15/15 0.22 ± 0.18A, B 
Values represent means ± SD (N=15). Female CF-1 mice were administered dietary 
treatments for 5 weeks. The transgenic alfalfa diets contained 100 ± 9 Mmols piceid/kg diet. 
Resveratrol-aglycone was supplemented to basal diet in equal molar concentrations (100 
Mmols/kg diet) to the piceid in the transgenic alfalfa diets. Colon extracts were analyzed by 
liquid-chromatography-MS for the presence and amounts of resveratrol-aglycone and piceid. 
Values with different letters are significantly different (p<0.05; Tukey-Kramer). † symbol 
indicates that the incidence of Rag detection in the colon of mice fed TA diets was 
significantly less than that of mice fed TA + E1 diets (p < 0.05; Chi-square test). Piceid was 
not detected in the colon extracts. ND indicates that resveratrol-aglycone was not detected.  
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Table 3: Deglycosylation of piceid by lactase-phlorizin hydrolase in jejunum of CF-1 mice.  
 
Concentration (nmol/g tissue) 
Treatment Tissue Form Detected -NB-DGJ +NB-DGJ 
RG (100 MM) Mucosa RG 17.94 ± 2.7X 17.2 ± 2.7 
Rag 2.3 ± 0.6 0.5 ± 0.2 
 Metabolites 15.3 ± 8.4A 4.8 ± 2.0B
Serosal solution RG 8.8 ± 2.0 13.3 ± 2.7 
 Rag ND ND 
 Metabolites 20.7 ± 3.0A, X 8.8 ± 2.8B
Rag (100 MM) Mucosa RG ND ND 
 Rag 88.1 ± 13.7Y 94.0 ± 14.7 
 Metabolites 38.7 ± 15.7 36.7 ± 11.1 
 Serosal solution RG ND ND 
 Rag ND ND 
 Metabolites 40.2 ± 6.9Y 35.0 ± 6.6 
Values represent means ± SE (N=8). Everted, jejunum sacs were incubated with 100 MM
trans-piceid or trans-resveratrol-aglycone (Rag) in the presence or absence of the lactase 
inhibitor N-(n-butyl)-deoxygalactonojirimycin (- or + NB-DGJ). Amount of piceid, Rag or 
glucuronide/sulfate metabolites of resveratrol (determined by measuring difference between 
Rag concentrations following digestion of extracts with ?-glucuronidase/sulfatase from 
concentration of Rag+piceid before enzyme digestion) was assessed in mucosa and serosal 
compartment of intestinal sacs following the 15 minute incubation at 37°C. Concentration 
comparisons made in a row (A vs. B superscripts) within each tissue are significantly 
different; comparisons made in the –NB-DGJ column (X vs. Y superscrits) with each tissue 
are significantly different  (p<0.05; Tukey-Kramer, SAS). ND indicates “not detected”.  
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Figure 1: Calibration curve for the LC-MS analysis of trans-resveratrol. Negative ion 
mass spectrometry was used with selected ion monitoring detection. The correlation 
coefficient was determined to be 0.9973 over the range of 3- 4000 pmol.  
Figure 2. HPLC chromatogram of transgenic alfalfa and control (non-transformed) 
alfalfa extracts. The reverse phase-HPLC chromatogram of methanol extracts of dried, 
powered alfalfa @ 308 nm. Extracts of alfalfa plants which were positive for the kanamycin 
gene revealed a peak with retention time at 13.1 minutes, consistent with an authentic piceid 
standard. The UV absorption spectra of the peak (insert) had a maximum UV absorbance of 
about 308 nm and matched that of the piceid standard (Apin Chemicals, UK).  
Figure 3. Average daily amount of food consumed. Values represent means ± SE (N=19-
60). +Enz refers to dietary treatments supplemented with 860 U ?-glucosidase / kg of diet 
(in the form of L-galactosidase or ?-glucosidase). + alfalfa indicates diets that contained 
either nontransgenic or transgenic alfalfa at 20% by dry weight. Dietary treatments assigned 
different letters signify groups that are significantly different (p<0.05; 2-way ANOVA, t-
test, SAS).  
Figure 4. LC/MS/MS spectrum of A). resveratrol-aglycone (Rag) standard and B). 
colon extract from mouse fed transgenic alfalfa with E-galactosidase (E1). Rag is 
identified by the retention time of the standard (16.1 minutes) and the fragmented ions m/z 
208, 182 and 112.9.  
Figure 5. Concentration of resveratrol-aglycone (Rag) in colonic and intestinal 
epithelium cells and  
plasma of CF-1 mice following intragastric feeding of Rag (25 mg/kg body weight). 
Values represent means ± SE (N=5). Treatments with different letters differ significantly 
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(p<0.05; Tukey-Kramer, SAS). Light bars indicate Rag (Rag detected without ?-
glucuronidase/sulfatase digestion). Resveratrol-aglycone was not observed in the plasma 
(panel C).  Dark bars indicate Rag + resveratrol metabolites (resveratrol-aglycone detected 
following ?-glucuronidase/sulfatase digestion). There was no significant difference between 
the amount of Rag detected in the colon extracts before and following ?-
glucuronidase/sulfatase digestion (panel B). On the other hand, free, unconjugated Rag 
could not be detected in the plasma samples.  
Figure 6. Inhibition of 14C-lactose deglycosylation by N-(n-butyl)-
deoxygalactonojirimycin (NB-DGJ) in jejunum of CF-1 mice. Excised everted, jejunum 
sacs were incubated in the presence of  4.63 kBq/ml 14C-lactose with various concentrations 
of the lactase inhibitor N-(n-butyl)-deoxygalactonojirimycin (NB-DGJ) for 15 minutes @ 
37°C. Values represent means ± SE (N= 5).  
Figure 7. HPLC Chromatograms of serosal extracts from intestinal sacs incubated 
with 100 uM resveratrol-aglycone. A). Untreated extract. B) Extract digested with ?-
glucronidase/sulfatase.  
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Figure 1 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 10 50 100 300
Conc. of NB-DGJ (uM)
14
C
-g
lu
co
se
(u
m
ol
gl
uc
os
e/
g
tis
su
e)
A
B
B,C
B,C
C
150                                                  
Figure 7.  
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CHAPTER 4: GENERAL CONCLUSIONS 
General Discussion 
 
Resveratrol may be one of the most versatile botanical phytochemicals known, possibly 
possessing a myriad of biological activities. Recent studies suggest that resveratrol may 
alleviate diabetic complications (Szkidelski, 2006), protect against Alzheimer’s disease 
(Riveire et al, 2006) and mimic the biochemical changes associated with calorie restriction 
(Baur et al, 2006). Unfortunately, the typical human diet is extremely limiting in resveratrol-
containing foods (Cassidy et al, 2000; Burns et al, 2002), making it doubtful that clinically-
relevant doses of resveratrol can be achieved through natural sources, alone. Metabolic 
engineering strategies in plants have been very successful in introducing disease resistance 
traits into new crops through the introduction of stilbene synthase genes and consequent 
biosynthesis of resveratrol in these crops (discussed in Literature review). This year alone, 
new reports emerged showing that resveratrol was introduced into apple (Ruhmann et al, 
2006), lettuce (Liu et al, 2006) and peas (Richter et al, 2006). These crops, if introduced 
onto the commercial market, could provide an increased, more diverse pool of resveratrol-
rich products as well as offer producers with more agronomical crop varieties. As with 
nontransgenic, natural sources of resveratrol, these crops accumulate resveratrol as piceid.  
 Our findings indicate that the bioavailability of piceid may be limited compared to 
resveratrol-aglycone, which raises questions on the feasibility of using GM products or 
natural products of resveratrol for chemopreventive or therapeutic purposes.  We 
demonstrated that piceid-accumulating alfalfa, alone, did not affect the number, multiplicity 
or size of azoxymethane-induced aberrant crypt foci in the colon of CF-1 mice whereas the 
supplementation of transgenic alfalfa with exogenous ?-glucosidase activity, via L-
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galactosidase or purified ?-glucosidase, did significantly reduce the number of AOM-
induced ACF in these mice. Furthermore, we demonstrated this trend with an authentic 
piceid in basal diet, indicating that the protective effect observed with the ?-glucosidase 
supplementation was not simply the result of piceid being liberated from the plant matrix. 
Liquid chromatography-mass spectrometry data of colonic extracts verified that the amount 
of resveratrol-aglycone that reached the colon of mice fed transgenic alfalfa with 
supplemented ?-glucosidase activity for 5 weeks was greater than the concentration in the 
colon of mice fed transgenic alfalfa, alone (p=0.09). Piceid could not be detected in the 
colon of any of these mice, which further supports our hypothesis that piceid was not 
bioavailable to the colon. Since resveratrol-aglycone could not be detected in the plasma 
following the 5-week treatments, our results further imply that the systemic distribution of 
resveratrol-aglycone may not be very high.  
 The metabolic fate of polyphenolic-glucosides following oral administration is a 
controversial topic and, until recently, subject to much speculation since few bioavailability 
studies have been conducted on these compounds. The traditional hypothesis was that these 
compounds were very unlikely to be absorbed intact in the gastrointestinal tract, due to their 
larger, bulkier structure and polarity (Walle, 2004). Comparative studies between 
polyphenolic-aglycones and their glucosides reveal that the small intestine may play a much 
more significant role in the bioavailability of polyphenolic-glucosides than previously 
realized (Nemeta et al, 2003). Studies in ileostomy patients showed that quercetin glucosides 
were almost completely hydrolyzed and absorbed as aglycones in the small intestine of 
humans (Walle et al, 2000). Day et al in a series of classical studies, demonstrated that the 
intestinal enzyme lactase-phlorizin hydrolase (LPH) was capable of hydrolyzing quercetin-
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glucosides (Day et al, 2000; Day et al, 2003), with quercetin-4-glucoside being a better 
substrate for LPH than quercetin-3-glucoside, indicating that the position of the glucose 
moiety on the parent compound may dictate the substrate suitability of the compound for 
LPH and, perhaps, the overall bioavailablity of the compound. LPH has since garnered 
special attention for its potential role in intestinal polyphenol metabolism, since it is located 
extracellularly along the brush boarder membrane of the intestine (Nemeta et al, 2003). 
Other intestinal ?-glucosidases seem to be located in the cytosol of epithelial cells. 
Therefore, in order for polyphenol glucosides to be substrates for cytosolic ?-glucosidases, 
they would initially have to be transported from the intestinal lumen across the lipid bi-layer 
membrane of the epithelial cells. Vitamin B-6 (Amanda et al, 2002; Mackay et al, 2004) as 
well as a variety of flavonoid and isoflavone compounds (Day et al, 2000; Day et al, 2003; 
Nemeta et al, 2003) have been shown to be possible substrates for LPH.  
 Our data demonstrate that piceid can be a substrate for LPH and be absorbed intact in the 
small intestines.  These observations are in agreement with studies conducted in Caco-2 
cells showing that piceid could be absorbed intact in addition to being deglycosylated by 
LPH (Henry et al, 2005; Henry-Vitrac et al, 2006). The sodium-glucoside cotransporter-1 
(SGLT1) may play a role in the active transport of piceid into the intestinal epithelial, as has 
been demonstrated in Caco-2 cells using inhibitors of SGLT1 (Henry et al, 2005). However, 
these studies also indicate that piceid that is absorbed in the cells can be deglycosylated by 
cytosolic ?-glucosidases (Henry-Vitrac et al, 2006). In contrast to this last finding and in 
agreement with our results, a recent study on the systemic distribution of piceid in Wistar 
rats showed that piceid was detected in the plasma and in various organs, such as the spleen, 
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lung, liver and brain in animals orally administered a high dose of piceid (50 mg/kg body 
weight) (Lv et al, 2006).  
 Our results suggest that the deglycosylation of piceid in transgenic alfalfa occurs 
somewhere along the digestive tract as revealed by the detection of resveratrol-aglycone in 
the colon of mice fed these diets. The human lower gastrointestinal tract contains about 1014 
bacteria of more than 500 distinct species (Klein et al, 2006). The colon microflora express 
?-glucosidase activity that can hydrolyze glucoside compounds which pass through the 
upper g.i. tract, unabsorbed or undigested. However, colonic metabolism of some 
polyphenolic compounds does not simply end with hydrolysis of the sugar bonds. The 
microflora of the colon can further degrade polyphenolic compounds into a variety of 
phenolic and carboxylic acid products (Gontheir et al, 2003; Rechner et al, 2004) as largely 
reported for flavonoids. The structure of flavonoids and position of glycosidic bonds may 
dictate whether a flavonoid-glycoside will be a further degraded by colonic bacteria (Simons 
et al, 2005). Our study in the everted, jejunal sacs suggested that the absorption of 
resveratrol-aglycone is higher than piceid in the small intestine; therefore, it would be 
expected that most of the piceid would pass through into the colon. However, the 
metabolism of piceid in the colon seems to be unknown. In rats administered tritium-labeled 
resveratrol, there was no evidence that resveratrol-aglycone was further degraded to other 
compounds in these animals (El-Mohsen et al, 2006). Also, in a study were the human fecal 
water content of polyphenols was assessed, resveratrol-aglycone could be detected at a mean 
concentration of 0.04 µM, indicating that resveratrol can reach the colon, intact, in humans 
(Jenner et al, 2005). However, this study consisted of only 5 healthy, adult subjects who 
were on a non-restrictive diet, so the amount of resveratrol or piceid consumed by the 
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individuals was not known. It would be expected that the piceid which reaches the colon 
would be deglysoylated by colon bacteria and then have the same metabolic fate as that of 
resveratrol-aglycone from the colon. Our studies suggest that resveratrol-aglycone can reach 
the colon, but it is not known if degradation of at least some of the compound occurs at this 
site. At this time, the biochemistry of resveratrol-aglycone and piceid in the colon remains a 
black box.  
 It is possible that the majority of the piceid consumed in the diet via the transgenic 
alfalfa was metabolized in the small intestine. In a recent study between 0-33% of 
polyphenols in apple juice administered orally to ileostomy patients reached the end of the 
small intestines after 2 hours (Kahle et al, 2006). The type of sugar moiety attached to the 
polyphenol seemed to dictate the colon bioavailability of that molecule as a smaller 
percentage of glucosides were recovered at the distal end of the small intestine relative to 
other conjugated compounds and aglycones. This would suggest that the majority of piceid 
could possibly be metabolized or absorbed in the upper gastrointestinal tract, with a small 
percentage of the oral dose ultimately reaching the colon. In addition to the small intestine 
and colon, recent data has indicated that deglycosylation of glucosides can occur in the 
mouth (Walle et al, 2005). Regardless of the possible mechanism involved, our studies 
suggest that piceid may be bioavailable to the colon as resveratrol-aglycone, but the amount 
of the aglycone that ultimately reaches the colon from an oral dose of piceid was less than 
the amount that accumulated at the colon from an equivalent oral dose of resveratrol-
aglycone.  
 In our studies, exogenous ?-glucosidase enzymes were supplemented into diets with 
transgenic alfalfa as a strategy to liberate resveratrol-aglycone from piceid in these diets. 
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Although the exogenous ?-glucosidase supplementation to piceid-accumulating transgenic 
alfalfa reduced the number of AOM-induced ACF in CF-1 mice, these studies would need to 
be followed up in a longer-term tumor experiment in order to provide a more complete 
assessment of the chemopreventive potential of this strategy. In a recent study, the number 
of AOM-induced ACF in F344 rats administered 10 g/kg body weight quercetin did not 
correlate with tumor development as quercetin decreased tumor incidence but had no affect 
on ACF development (Dihal et al, 2006). Rutin (quercetin-3-O-?-rutinoside) had no affect 
on tumor or ACF incidence. Plasma concentrations of 3-methyl-quercetin (the main 
metabolite of quercetin, identified) reached only 30% in rats administered 40 g rutin/kg 
body weight of what was observed in rats dosed with 10 g quercetin/kg body weight after 38 
weeks, illustrating that the difference in anti-tumor activities between the two compounds 
may be related to the low bioavailability of rutin.  
 In our case, there were challenges in producing enough alfalfa to carry out a thirty-week 
tumor study, since the availability of alfalfa was limited due to its poor growth performance 
in the field and greenhouse. The ACF identified in our last study were counterstained with 
alcian blue to differentiate lesions that were depleted in the carbohydrate mucin. Mucin-
depleted foci have been purported to be a subcategory of ACF that are more likely to be 
dysplastic and, thus, more likely to correlate with tumor development (Mori et al, 2005). 
MDF could only be identified in a few mice in that study and could not be fully assessed 
relative to dietary treatment due to the low statistical power.  
 Another limitation to our studies may be the use of the mouse model in examining the 
bioavailability of glucoside compounds. To our knowledge, it is not known how the 
intestinal activity of LPH in CF-1 mice compares with that of normal, healthy humans. It is 
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documented that the activity of LPH in Caco-2 cells is significantly less than lactose-
intolerant adults (Chantret et al, 1994), so interpretations on the bioavailability of piceid 
using this model may not be accurate. If the activity of LPH is significantly higher in 
humans than mice, then piceid may be largely deglycosylated in the small intestine by LPH 
and absorbed as the aglycone in humans and would therefore be expected to be metabolized 
and distributed the same as resveratrol-aglycone. Also, the colonic microflora population 
may substantially differ between CF-1 mice and normal humans.  
 The fecal and cecal contents of the CF-1 mice fed the diet treatments for five weeks 
could have been assessed for piceid and resveratrol-aglycone concentrations to more fully 
assess the intestinal absorption and colonic metabolism of the two compounds. If piceid was 
detected in the colonic and cecal contents of mice fed purified piceid or transgenic alfalfa 
alone, then that would have suggested that the low colon bioavailability of piceid was 
largely the result of its poor absorption at that tissue and its limited deglycoyslation by the 
gut microflora. On the other hand limited detection of piceid in these samples would indicate 
that piceid was degraded in the colon or was largely absorbed intact in the small intestine 
and was metabolized differently than resveratrol-aglycone. For instance, resveratrol-
aglycone can be redistributed to the intestine via the bile duct following phase-II conjugation 
in the liver (Marier et al, 2002). It is not known if piceid is hydrolyzed by liver ?-
glucosidases and further metabolized in a similar manner to resveratrol-aglycone.  
 The collective findings of our studies could spawn future investigations to address 
important questions on the bioavailablilty of piceid. For starters, the role of the sodium-
glucose co-transporter-1 (SGLT1) in the intestinal absorption of piceid could be examined 
using a similar approach to the one we employed using everted, jejunal sacs from mice to 
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study the involvement of lactase in the deglycosylation of piceid. It would also be interesting 
to see if the presence of other plant constituents (i.e. polyphenolic compounds) influences 
the intestinal absorption of piceid, due to substrate competition for LPH or SGLT1. These 
comparisons could be made using the everted, jejunal sacs and Caco-2 cells with alfalfa 
extracts and pure compounds.  
 The rat-linked model designed by Marier et al (2002), where the bile duct of one rat is 
surgically linked to the duodenum of a recipient rat, could be used to study the potential of 
enterohepatic recirculation of piceid. The enterohepatic reabsorption of piceid in this model 
would be confirmed by the appearance of piceid in the plasma of the bile recipient rat 
following the oral administration of piceid to the bile donor rat.    
 In order to fully assess the potential of piceid as a nutraceutical, bioavailability of piceid 
could be more fully explored in a human study. It would be interesting to compare the 
plasma kinetics of piceid that is administered both orally and intravenously to resveratrol-
aglycone introduced by the same routes at equivalent molar doses. Liquid 
chromatography/mass spectrometry analysis of plasma, urine and fecal samples could be 
used to identify resveratrol-metabolites and possible byproducts formed from the catabolism 
of resveratrol. The gut metabolism of piceid and resveratrol-aglycone could be more fully 
examined in humans by incubating both compounds in fecal samples to determine if piceid 
is a substrate for microflora ?-glucosidases and degradation of the free, aglycone occurs in 
the colon.  
 One of the more interesting observations made in our studies was the different affect that 
the two alfalfa cultivars had on the formation of ACF in the colon of CF-1 mice. The studies 
illustrated in chapter 2 of this dissertation were conducted using the Regen SY alfalfa 
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germplasm. These studies did not reveal that the alfalfa, alone, offered any protective 
activity against ACF formation. On the other hand, the germplasm utilized in the later 
studies, Pioneer 5246, which were reported on in chapter 3, did reduce ACF number. Regen 
SY was originally selected as a laboratory strain (Bingham, 1991). This cultivar proved to 
be a poor performer under both outdoor and greenhouse conditions. The plants used in 
chapter 3 studies were grown under greenhouse conditions, exclusively, with superior 
growth performance to Regen SY. Although, there were no noticeable phenotypic changes 
in the transformed Pioneer 5246 plants relative to the transformed Regen SY, with the 
exception of growth, it would be interesting to see if the plants used in the later studies 
expressed higher levels of flavonoid or flavonoid-related compounds relative to the Regen 
SY plants used in the earlier studies. Cell-culture experiments using extracts generated from 
the plants could be conducted with comparisons to purified piceid and resveratrol-aglycone 
to examine the anti-cancer properties of the plants and any added activity that may be 
attributed to other compounds present. 
 In addition to alfalfa, the variety of other crops developed to express stilbene- synthase 
could possibly demonstrate health-benefiting properties. Some of these other crops could 
offer a variety of foods that could be processed to hydrolyze piceid to resveratrol-aglycone 
in the final products. Efforts could also be directed into improving the piceid content of 
alfalfa sprouts, through the use of alternative promoters. However, this may be seriously 
challenged by the high expression of flavonoid compounds in these tissues and, thus, 
possible substrate competition between stilbene synthase and chalcone synthase.
Since low colon concentrations of resveratrol (<0.5 nmol/g wet tissue) were associated 
with a reduction of AOM-induced ACF in the mice of our study, resveratrol may be a very 
160                                                  
biologically potent compound. The extent of resveratrol’s activities may not be fully 
illustrated in cell-culture studies, since resveratrol-aglycone doses below 5-10 µM rarely 
result in observable biochemical or molecular changes in in-vitro studies (Gescher and 
Steward, 2003). Thus, there is a need for studies linking tissue concentrations achieved with 
lower doses in in-vivo studies to doses required to achieve equivalent intracellular 
concentrations in in-vivo studies. Furthermore, additional studies examining the biological 
activity and bioavailabilty of resveratrol at specific tissues need to be examined.  
 In conclusion, our studies suggest that the colon bioavailability of resveratrol-aglycone 
from piceid is very low and indicates that chemopreventive activity at the colon by piceid is 
very limited. Our studies support a role for LPH in the intestinal metabolism of piceid and, 
thus, add to the accumulating literature suggesting that enzymes and transporters important 
in carbohydrate metabolism may also play a very important role in the metabolism of plant 
polyphenolic compounds. Furthermore, we provide evidence that GM strategies to increase 
concentrations of resveratrol in plants may provide health benefits to humans; however this 
strategy may be challenged by the limited bioavailability of piceid.  
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